var title_f38_27_39344="Squamous cell carcinoma erythronychia";
var content_f38_27_39344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal erythronychia secondary to squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39344=[""].join("\n");
var outline_f38_27_39344=null;
var title_f38_27_39345="MRI large sellar mass";
var content_f38_27_39345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F87693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F87693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    MRI images of a large sellar mass after administration of gadolinium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 186px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) MRI image, taken after the administration of gadolinium, depicting a coronal view of a large sellar mass that was a gonadotroph adenoma. The arrow points to the mass. The arrowhead points to the optic chiasm elevated by the mass.",
"    <br>",
"     (B) MRI image, taken after the administration of gadolinium, depicting a sagittal view of&nbsp;the same&nbsp;large sellar mass that was a gonadotroph adenoma. The arrow points to the mass.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39345=[""].join("\n");
var outline_f38_27_39345=null;
var title_f38_27_39346="Patient information: Ovarian cysts (The Basics)";
var content_f38_27_39346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15670\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/8/5251\">",
"         Patient information: Endometriosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/1/11283\">",
"         Patient information: Ovarian cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/29/28115\">",
"         Patient information: Polycystic ovary syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/63/26611\">",
"         Patient information: Endometriosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/34/41507\">",
"         Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/32/22021\">",
"         Patient information: Hormonal methods of birth control (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/15/6386\">",
"         Patient information: Ovarian cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/20/2371\">",
"         Patient information: Ovarian cysts (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/46/30437\">",
"         Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ovarian cysts (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ovarian-cysts-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H565474936\">",
"      <span class=\"h1\">",
"       What are ovarian cysts?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ovarian cysts are little sacs of fluid that form on or in a woman&rsquo;s ovary. Each woman has two ovaries, one on each side of her belly. In women who are still having their monthly period, the ovaries release an egg about once a month (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"mobipreview.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Ovarian cysts can cause pain or a feeling of pressure in the belly. Or women might not feel them at all. Many women worry about cancer when they learn they have cysts. But most of the time, cysts are nothing to worry about.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H565474943\">",
"      <span class=\"h1\">",
"       What are the symptoms of ovarian cysts?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many women have no symptoms. When symptoms do happen, they can include pain or pressure in the lower belly on one side. The pain can be dull or sharp, and it can come and go.",
"     </p>",
"     <p>",
"      Sometimes, ovarian cysts break open or cause the ovary to twist. This can be a serious problem. Call your doctor right away or go to the emergency room if you feel intense pain in the lower belly on either side. For example, you should go to the emergency room if you have sudden pain that makes you double over or that makes it hard for you to walk. Along with the pain, you might also feel nauseous or throw up, or have light bleeding from your vagina.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H565474950\">",
"      <span class=\"h1\">",
"       What causes ovarian cysts?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are many possible causes of ovarian cysts. The most common causes include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Ovulation or pregnancy",
"        </strong>",
"        &ndash; When an egg is released from the ovary each month, it grows a sac, called a &ldquo;follicle.&rdquo; Sometimes, a follicle grows but does not release an egg and instead forms a cyst. Or, if a woman gets pregnant after the egg is released, a cyst can stay on the ovary for weeks or months. These kinds of cysts usually go away on their own.",
"       </li>",
"       <li>",
"        <strong>",
"         Dermoid cysts",
"        </strong>",
"        &ndash; These are a common type of cyst. They sometimes have teeth, hair, or fat in them. That might sound strange. Dermoid cysts are normally not harmful to your health, but your doctor might want to remove them with surgery.",
"       </li>",
"       <li>",
"        <strong>",
"         Polycystic ovary syndrome (also called PCOS)",
"        </strong>",
"        &ndash; Women with this condition grow many small cysts each month, instead of one big follicle. These cysts usually do not go away and the cysts themselves do not need to be treated or removed. But PCOS does sometimes require treatment for reasons unrelated to the cysts.",
"       </li>",
"       <li>",
"        <strong>",
"         Cancer",
"        </strong>",
"        &ndash; Cancer is the cause of ovarian cysts in less than 1 in 100 cases. Ovarian cancer is most likely to affect women who have stopped having their periods or who have a family history of ovarian cancer.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H565474957\">",
"      <span class=\"h1\">",
"       How big is an ovarian cyst?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some cysts can be 4 inches wide or wider. That&rsquo;s about the size of a large orange. Others are much smaller.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H565474964\">",
"      <span class=\"h1\">",
"       Is there a test for ovarian cysts?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Common tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Imaging tests &ndash; The most common kind is a pelvic ultrasound. This test uses sound waves to make a picture of your uterus and ovaries. The pictures can show if you have cysts. It can also show where they are and how big they are. Your doctor might also take pictures with an MRI or a CT scan.",
"       </li>",
"       <li>",
"        Blood tests to check for pregnancy or the possibility of cancer",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H565474971\">",
"      <span class=\"h1\">",
"       How are ovarian cysts treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what is causing your cysts and what your symptoms are. Possible treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Waiting &ndash; Your doctor might want to do an ultrasound every couple of months. Your cysts might stay the same size, get smaller, or even go away. In those cases, you usually don&rsquo;t need to do anything to treat them.",
"       </li>",
"       <li>",
"        Birth control pills &ndash; This medicine can stop some types of new cysts from growing.",
"       </li>",
"       <li>",
"        Surgery to remove a cyst or the whole ovary",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H565474978\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what is causing your ovarian cysts. Many women with cysts are able to get pregnant. Even women with just one ovary can often get pregnant. If you can&rsquo;t get pregnant, medicines or new technologies can help. Talk to your doctor if you want to have a baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H565474985\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/8/5251?source=see_link\">",
"       Patient information: Endometriosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/29/28115?source=see_link\">",
"       Patient information: Polycystic ovary syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/1/11283?source=see_link\">",
"       Patient information: Ovarian cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/20/2371?source=see_link\">",
"       Patient information: Ovarian cysts (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/63/26611?source=see_link\">",
"       Patient information: Endometriosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/46/30437?source=see_link\">",
"       Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/34/41507?source=see_link\">",
"       Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/15/6386?source=see_link\">",
"       Patient information: Ovarian cancer screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=see_link\">",
"       Patient information: Hormonal methods of birth control (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/27/39346?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15670 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-41.78.124.10-D68EE5DB58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39346=[""].join("\n");
var outline_f38_27_39346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H565474936\">",
"      What are ovarian cysts?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H565474943\">",
"      What are the symptoms of ovarian cysts?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H565474950\">",
"      What causes ovarian cysts?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H565474957\">",
"      How big is an ovarian cyst?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H565474964\">",
"      Is there a test for ovarian cysts?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H565474971\">",
"      How are ovarian cysts treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H565474978\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H565474985\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15670\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/63/26611?source=related_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/8/5251?source=related_link\">",
"      Patient information: Endometriosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/32/22021?source=related_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/1/11283?source=related_link\">",
"      Patient information: Ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/15/6386?source=related_link\">",
"      Patient information: Ovarian cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/20/2371?source=related_link\">",
"      Patient information: Ovarian cysts (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/46/30437?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/29/28115?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_27_39347="MRI MPNST";
var content_f38_27_39347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI MPNST",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 563px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI demonstrating a malignant peripheral nerve sheath tumor (MPNST) in a patient without neurofibromatosis. A) T2 imaging shows tumor (arrows) with inhomogeneous signal intensity with areas of high, intermediate and low signal in a large mass. B) T1 image of the same tumor exhibiting signal intensity similar to muscle. C) T1 imaging of the same tumor in an axial view (arrow). D) T1 post-gadolinium showing minimal and somewhat irregular enhancement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James M Gilchrist, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39347=[""].join("\n");
var outline_f38_27_39347=null;
var title_f38_27_39348="Stricture at the hepatic duct bifurcation";
var content_f38_27_39348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Stricture at the hepatic duct bifurcation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AfYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDy9J5Q+VkYA9j3q9CZCudzZbrz+lVLVSqq5GSBxWkowI8/ifSgCzFJICSSeBjr0HpVuOV+AG249TVOFDz781dgHIJUY9+c0AXIJnjAJYnP3jnirQuWKqxkJB7YyKzwwLknnjpipZZfKUKOZMcAfw+9AFmW6aN/3eQ5APP8P/16dCXbLAbiOSSeTVKLcSXc5Y9M9/c1LGW6hivqaANEl8ZBOf7oNCRu/wDFjPUk5quko6EbR9amSVuQAemfagCwschABcleg5pUDoVBJIJPU4qFZm4V8AZzxTmdmyHyVPHHQUATswCHBxn1qCGVlJ2/rRtITByxxwM9KlihIOWwPWgB65PJOB6mpFJAxnj1z0oA9V4/nTY4/m5//VQBIGI4V8D1p6swG4SEgHkZ70KgUZ5LdqlCB+Sgz/dXrQAKxAHPOTj1qQbxgK3YEYpMAPuIAIH6U3CjGCx449vrQANwoyecjB7A57/4VpeINw8QXu5icOpGPdRWbI2EOAMd60fErn+27lm5yIyMDqSgoApFyyjL5x/FjGRTGlOcdc/lTSWGN33ccHsPeowy5XGQc5JPSgCRpHZR1C9sVH5zAZy3H500tkfM/wA2eeaae/J56E96AHNMW+8Se+QcU3zGGOOCTgZpoAK7geRyARSAcAHGPSgBVfCFiSD0x1oLE4G5s5HFNYdRgnPcd/pSbchnBA+YZJPIoAVjxnfz1x+NIQCcHIx/dpVUMCduMHp60bOSec+p6igCNQeMElj61bdWLkfMFPIbNEUWTuOAB+lTmLcWzz/SgCttbnnJzgU0q2eg/DtU23bkBhxwSO9M+8GJJ4GM9zQBE4I4DhjjJ29qailgcZIHWpmRVZCE+ue9PRCpZV+8eoHegCjtwwGN317UnlsT8u5gewFaSWhwzOw54Cr1NP8AKVMbc4z26igDMW0kyDIWVM8gd6nis4kPKtjBxnmr7IwcDBA7FqQortnaSQMtg8H2FAFZYN0kY25xyCpxirKQjA8zYAv3QDzmpI9zFlUqi9gBz+NPhtSWyx3Z5znHPr60AQeSIW3MEyDjnnGanlABKLE2wjh8Y/Sp40wxCqpx/EQef8adcjCFdxAPPJ5/CgCjBCTu3NlU5wAPyq2As8boQS2eo9KpvNGjhACp7nv+NSxylLdlQEAcgscAH8KAGSwyodyZyOgIx+NMFm5uQW25HJGcZHrSS6ijRANK+4scjrxSSXcYUNEiOAOPMY4+goAuNDI4XByV7r05qZ9PlniKiN+B0Jzn6Vzt1rjxfJD5SMvXC5x+NUV12/WQOLySQAcKpwAaAOu0+2uG8y1khcBTlDmrltFMHBkDg57dK5O28RXRO64Ro9zA74znFbovnBEiuzcZ3Bv6UAdBqjGSIeZkfLgd8mue+ylyUCgBu/c1Pb3sl2BI5IRRwCfvGpQ6szbgW5z6Y/woAqRaaybm24ReOoNej6HbSWPhqzt8BJHBm+fnknrXEQQvPNAiAbXbA98//Wr0jULaO5ktbaKRjFAgVCvU4H8qAKmo28os4bcgSBznr93PpVpISLzTLM8YGSCOcDk1m3MUkmuQxJclYcgEOOncmtrSMy6xPIxysI8tGPr/ABEfhigC7qbE27kDscc9M14J8Y3S1m0rRInJ8lXuCGPUsa9o8SzlNuHzGMZXHJycfia+ffjBfrfePL9odoWALAo6nAAoA5BJTAWMikEnABPaiqkkhEpLlQcdGPSigBbdQhYt97+lWYwMYBySckVBD8zADkDkk+tWoY+mD+P0oAnQYHuKn4PAPb9aiXgOffNSxyiHspJ+6p70ATu/kBT8vmnoOtRoC0mS2c8sB3NVotzv5knLcirkAFAEq5AJxg5yKlj5UF+vU44FNTGOODUm3GBQA8LgFs4yeKmRW2EHO4nmm4GeRkHnHpUg6E80AL82TkYHp3qRVY8AZ/pRGofrkHsKtIu1MAbSR1zQAkSAdPvdwamKtlm257kA0sCcgsvfHNW0iBA4wRQBWWNj95QM84J6U4rjaAPmxkirW31GfeoZOAcnC56nqaAGqoJOevT3pycEMQwPpmmK/UsoyOAadngAncSPzoAduwhyQoJ4yKb1zn75OM98Uzc2Qp4Uj8qRmHVd2Mce9ACzkNGQPl478Vo+IyTq5bafnt4j+G0dazJOYn2k9MZPatLX1P223bOCbOEnB4+7QBnt8p6EnAHrUTNlepPbin5OcgcE8HvS4x2wcc+9ADAMEFgWHQdqaFy33v8AdAqRRzxx7UHdxxgjt7UAMK5JHQ/WkwM8Z96lKnB29D+NNHqp9jQA0ZzkdeoyeaRFLAggZHcVOsZORhdo4yakWIDpgkc+1AEUcZ7fmRVgRBskrtzjr2pQAGAIxnkmpgScEngjIoAqspSX5Y8rjHTinQ7gpO/Axyc9KspllCjoRzSJakli7AKD6dRQBH5PmIQAdw5HfPvSeQ5bO0YHTtV6CNEXhSCo65606VVVlbJCkcZoAom2XJZiN5OQFqYIMGNVAB7ipQAnLDcAOCf8KVmOMDlj3HagCqQowRkk8DHNIAxYE42jqR608M3mZKkAnHPB/Ch8FmLbVCnIHc0ARbWckc5yKcWRSNwzt4G0dacG3KT0GOinqO9REjIIGBjGDQBIsmFGE4bhiRiovOPPl4GOC46n2omI2Afd9l71Eo+cAZyew60AXbbeXLAFtvHPP4UmryRxKsan5jyMdvrT0dYY/KVW3L8xJ5BNZs+5mEjk5J6HrQBSdGDbQA2ejHqabDOIpAgXcOmM/rViaPODnAYcetQxQhJMjI4570AUr9yThlG7qV/+vSyozRiT/ZHHYe9TX1vkAAAevrmnSQhotrbhxjPpQBgSSKsh43D1HekO2Rxs6E9CMVHPHslKsSvPHuKEOxsAsVzwp9KANiAIsARk6Dp71usrfZY2Hy47gVh20arACTuB4PtXTQL/AKMgI+Vscdc0ARaY3ybpM/IcjaOua1YCGVgTsJ5wwqraQEs4LAd8VacASDjcW4JoA3fCVj9s8QWUZxJGmZJOegA4rsbaRvPuSWHlJ8qEnA+n5Cue8EW/lte3qHamPIJHXJGa3J4EXS/3Uv7yVt24989qAG6TPHNPdTCNj6Z5AzWxpKpFHKTlRyWbPBPU4rN0m3e0075wAWOSBzz2FalthLJlONxygGe9AGbeSpK0j3GRBFHJO+R6Dg18karqBmvJriSZXeaRn6ZyM8c17/8AE3XWsvDmtyQkFXhFoWBOMk//AK6+ZtQKsoBKKgA4HGTQAtxcDzdy5JPPzDtRWNJM6kqx5U4wfSigDthwgAZvb0FWISBkj6c+tRvD5b8MCpPIHYU5SsSM8h/djoO7GgCbeqEvIc9go6n/AOtUCM8mZM8njHoKiBMrMzyAnHAx09qswrxn8KALKYBzyB1H/wCqrUQHOcYxnPrVeIjk5JwO9W4iMnqBj86AJEXPA71KobOc9sUxB+R4qdBkn2oAenynOOlTLHg5kbAPIBFES47gjr+NThgR8w5+maAHxxhlBC8HoCeTUqR5JGOnIpgPK4B29/Y1at8DgZYnrmgB0cRBUgc98859auorE8LgDsaijXC7sce3apwxbIO4Hv6UAMlwBjeT3Hp9KqykgYxnuDjp7VYmKqvy4P4VTkJ3dMjHr0oAj3fKAvUdqTeSylQM55x2NMB5yOD2pwY4KgYXr70AGSzhnJB7cUHG4HOeo9/rSnj2I79qXGYiMgZ9e1AEcpwjL1yM8Vq60xEunseA9jEAcemazsAJx0I4bvWrrI3W+lscAfY1x+ZoAy0YFcMpx1Jz3p+CRkZz16ZIoTgYzn3p20ZOAfu560AMbJ6jGP0peWwD0HNScNngkZ//AFU9Y8E+5/IUAQKrMCFB244p4ixtH6YqwIwD8xIC9cUKuMAfMQOD0zQAxUVDjZ175p7JtIzxn8akWFmOF6Hr7VPHApBJyxoArpG5YFUb3NTiFQzbm3d+B0qcIEz1Gen1pqAk4b7w4PFADVj3DgAL1I7VJJlgN/3R6cUrYU4XHqBn9aHIVGAfc3Tp27igCvhUf5CTjg4P6VccE26OFHJ5UjgCqj/N8g+Rs5OKmTJG0YOP73QUAR85wOTjqKikcrwuSfWrcgBB253Dr71WeNc5LFQeuKAIg4B5/wBYOSDzUUoJZg5xgZGTxTmjXaGQ5HXk80xlO4HJoARsthWA9dqjrTHXPzMTkEDr3q0kZMfmOdp6A+ntUTkeexAwg4z2zQBBKcOCVLE/dFLGCuSOD3bHSlkK4wrYUc7gKSPLLlvunt60ASKSY2zjA+bPpUO3JBBz3555FTRHClP0FCJjcF4Pr60AVpIAQDgg9eOcVCuFbPHBq4w3HlACfXtSBRwCMg9TQBWlVWYHOSD0qOWPcXx09PX6VIzZcDOcnnjpQR8xwMAjjntQBzGpIqsJAMv90H+tMij3PhypOOe341rahAJARjGen1rJtFeRjsByh+Yn1oA1raMNKiDIA/lXQIfKVVIGCOO3FZ1jAI2ycCQgFiB3q7tMzsG+4MGgDSscIjM0YIJ9ecVaKAOD82W+Ycc//qplgAQE4JzwcdvSp0gkvtRtraP700oTPt/hQB2+mlbPw1aW8UEjy3DFmx8uPc1neIdaC6hHZJEySNgI23IBPrXSzGNbxkRwvkLtHvgYx9Kw9Lt5b7xK0twitFC3mb+2OwoA3Zj5UMMauAQNzBTjJ7f4067IW03uwxGh5BwOnJ+tQTqzM8wHzO+APaqXiNbp9MSxsVIvJiscbEZGSec+1AHkvxzv1j0DQdKiIie4LX04UZJzwua8SugF3AoOBuGea734r3T3fje9tt3mLZotuGHQsB8xH41w0sZJCK6kFcDNAGOVMn8Qx23DNFSG2dQQCAQehooA65LgKxMnCCo5WaZg5B29gP51nzzb5AqNlF7/AN6rNvKchHbKY4GOlAFmNgOBwfWrkZOzrmqKnLA1aibjA+lAF2I/Ic8ev0q3GSwBIwMYFUIyeM9KtxknAA79KALke0rjbn3zVuJUwSDgkdRUMagBdo5PUk9KsKTtBPJAoAdHnapX9asIw5CZ3d6iGHxxgY4FSJzhR8o7ZoAnQgJt4LH9KkL7MHcCe+KhRyDkkg4wf/rUE85U49qAL8DfKMErzxzU+8Y4HJHX1rMiIyCCcj1NWw+Fwudo6AUASSM2eDhff+lUpSDnk5xzViQgJnBGaqMc885oAAcnpkeh6UqDC5xjPHPamqcdOADznnNLkcE59vagBRyvBzg08EA4wT057UhJJ+bqPWnIuRkZyKAHptAfnp046Vp6khbTdHxg7bYrz1+8aywC3PPua17on+ztGfHAgdSD7OaAMuNDvIbIHQEDg1MqAKNxBOf4hg1IiFgSMYJqQRnOGXp+GaAGgY7gEHgY/pSuAFLDoQB+tPGCCFXcT+gqSNRuHBIx0NAEJQ4ADBVJ4J/lUscKxEFgDmpE65UgEHjd61IQc5OCOoxQAKpIyVz/ALIpyAErhhuHbFMbIfDNz3APJ9KFchSoO3PUe9ADm9CDn0HrTCxDEk5JGDTXYZ5LEelNJyB2z39aAHFsc8ZGBxQXZsKvBByBjmoWYbuRwR92nq5AO3A9hQBIIirZkOCR1x1pqyYG0LuBGQPQ1G7lt2C7YGRjtWhY2+5keTjK9e9AD7SB3w7DIx34xUzQxthGUfMMN8vWnR/IdjvkA9xSSSpzu4xyaAKclrF5mBGCe/bFVJrZftA+YlepPr7VLe36IwER3euKpT3xkRcLtbsPWgAmlKsVHTuKqOAFO4nk7uKn4bJwMkc89zThGjKCQC2OT3oAokllPUKfTvT4WCtgjhuAfSpZeGAKqD/s9aryKQzbQfl/KgCdM+YD0HTnqamQgMcAj3zVeI/u92OelO342qc+vHfNAEz5BHcsKjIGDliMHoelMLkLtIIwc9e1SsSwJfp/KgCqQA5wCf8AGh1B5JxgZp5+U5JUDGaSRgrJnlSevtQBUkiVgT13dBnoaNPsA02zAUfeJParHks7ZUgLngVuabaQqwkOct1AOeaAGx2CBm2Dc3QEjmpLbTpC4VU4z1NdDE6mIrsBbHpUauwbaUEQHP1oArJYSQqVJHquB/Wtvwjpj/2hJdSKCLZCy4P8Z6CqpPmRKfMCgHADdDW3pyvZ6CkiMsUt1ICG74HFADNWBjsLq5kTy55gSSTyPp6VJ4dtJLPRWkdiZp2DKGOCR0Wk1KRby4gslYPGBmTP90Vp3kiRxoWG3y1yqg8Z6AUARRTF79UPKKQobP3j1J+lVdc1eG0knnZw0lpA86hj1Iq3p1sttA3z8MpOM5yTXnXxani0Xw1dKxja81FlgQqfmEXUn2zQB4vqV4st29ysiDzHMsmf4smsi+msijADkDICVBcSB5ijxlgo4JHH1quQARtLZ7kDtQBVVoTlkSQDOOTmiqt8iPtbdOOcYBooA0IiAQQMD0q1GxJ4yKgjAPY1NGWLYUZ9qAL9v1Oe/WrsIAGc1nI23gkA+9WoTuIX1oA00xx71egXack5J6VTtwoA3Crkf8DD149qALka7lx2qwqkfSooAQBj61MG7GgB4IwAelS5BUFOvQj/AAqHK9hk+lBGMYOBnOKAJg2c7fm70wyc4/iPSod23pyc8EU0HKnGMmgCzH8zctgVejy6jnHsKy4vU5xnoec1pwuCvzjIHIX0NAEjEeWBuJI9e9VyMurjqAeKsvICCVjwAMVD5GRgABe3qaAGH7uO9SKMnjH0p0UIBOQWHqxqwpCqAdvp9aAGohJwPvHin7EDneDnGOvIp+0BshsYPOR19qZcMDgrxzwB3oAkRlVfmGccY/rVq/cf2ZowBIj8uQYYdcNWep75LZ5KitO6GdJ0lfvNsk5HruoArpIM7YwuT1J7U8R/OpclsHHJoRMqOORipJRtf5SQMZ5/lQA0LncM45wAO9L5Y/vMv0pSo3Z7d6GbHGF9cA9qABSSAzAVLgheflzzx3qJT8574HIPrTQFAAYs3uaAHB1yWUj3PfNITtbO38c00nsEz9KikY7xksD/AHRzmgCUknaBkfWo26EjO31pu8gfMSWz+C0rgsflZiCABzwD70AL5oye3v6UxQx6ABTzSMyI3A+tISGH8IPXnpQBYt42eeMFh1yecY/xrdjCxLuyQcYz1rK0yMrmQjt1/wAK1N3yEg9ecfyoAhuZlWPJcAZ5H8qyZ7tyHRXwD/FjNWtTkxGFA+8e44+tZTAkdMgDPpQAwAcEA+uT602VSfu805gm8DaeOvORSNx369vWgB0Zwu0cf409sqTk5GOMColZc/N8o6E/0qwuSd3G8daAGn5zkrwR1J/lSTLhQGYc9h1pxVY8IvI/vDtmo5FDyYXLbf1oAjCBEBycH3oDjaNucHnnip3HmAgEHvjHSoBHuY9evAB60AISE6Y59aVGZicZPt6U+OEbiCuBj071bETMipEMN78UAUVgeZg2VU56d6vraKiLzg9iDmnwwbDmQZb+93qd8MNxwp9KAKbwOM4+6Rgk9qIJXtXzGxf1A7ipLhAQQQ3TnaelVpHVkCkN6AgYFAG5p96soDxMQTwwNbMSrdwgsckcVxFm5ivlIIAJ59DXWW8nl3IMZ2+YME/4UAWxZyNIkCg4cgFj2rqnltWnZGBxbLsHHy/5NZ/hyRXvJLlk4tk2KO7MamlLxxy3CpuQkvs/vN2GaAI9MtY/tct0oY+Z8zKev+yPp3ouGe4uxFGgYM+0Nn+EdTU88/k2MSEMs8+cjHTjnH06VBFMtpYy3NyyLFGu1eOo96ALFzNJACFULAoJLd1PYV4l8arp9R8RQWisn+iQAOc/xkZ5r2hp7eLSprpiCvlGWRz04FfMGq6pDqOp3l/cbxJPIxG7sfWgDG+zyox3TR4PvUF3azxxlTKCpHOBin6pOkRYRS4yOc/0rJku5iUEczyADJXPGaAHSWwdFV5sDrkUVPBfMUKzwsxU/wABooAniwpAHSrKJGzfMCD6rVKI5brVqJ8MaALUcB3ZBGPXvWjYQ4mG4fP2qnajJ3HkelaMbc/LwTQBajizghgS3p2q0kZRQG6Uy2G8c8DOSan5GEboCSD60ATQs3boTxVglcL6kYaq+7D4OM4xkdKkZ8BfyoAcDgHPXpUbSFh8vKjrUbuWJUj6igHPTg9yeKAJNz9SACeg9qeD0/z+FMVSxIGCB0wev404qW5AJx6UAOXO8bc4HXHatS0QuAqjp3PWqcaE48zA9MVpWkiKPm5A4oAux2yL/rFOR2pWiUlTjaOmBSJKc/IvXjIp/m7+jDPfPrQBRuFf5gpHpjvTHBXHGSO1XnVfvYIPfmqMqHe5A4A79/xoAeGwPmPTqTTkjGAWPOTgGmoMDoTg8ipI3O45ByenHSgCaOMg7QvHTntWxLHu03SgVH+rcDH+9VC2GV5U+2eK6NLbzLDTcjhY3wuM8lqAMc24XcCCSOCKZNGQ3T8ugrY8vJIGRjrnmoZrchT3FAGOw5GWz7008Y4OPT0qa4Tyzgjt6YqsiSTXKwwlmdztwKAJLaOaefy4Iy7Z/wC+fqa2YtDLNm4kYnAJVelbOm6fHZ2wRQoI6sTyxq6FAGAM4Gcnjj3oA5yXQIinytIp9AarxeHY1wXmkYZ9cY9s11JReM9+Qp6GonTIIYDBPA7CgDnpNAgVSIpJA2eMise9066tQSw81FPJWu1dVbGVyOg+aqk6/KQpxnk+/tQBw27cSePXPp7UoG/HIODyG7CtXUrAo5lhUfMckZ4zWRO+0BAduDnn070AdFbKI0VQOMZJ71K+Np459aigUgA84296L0+TFu5AxzxQBj38rPNtyQF5z7VWBPJB56U+V2dy7KQrHIB647VGRhcHk0ADDq2Tj0FNLHA4/OnMwz8oIbpx3poxuYZIPrnNADQrFsYLAY47Gpon7HIYdagfnIBYH1qRMk7h1B5oAsuDIAuc57UxQwYc7Qf8mrkMeAOcE+tOdSDjdtx2/wDr0ARxx43cZx2HehogvQYz2A6VPEqnGBtB/wDHvYUMOcEDJHY0AVRywZcHHTPrQrE9B05we1SMnzcgYAByB0qqZl3YVmY+pOAKALXnLgjnP86aXYAbTnNVvMPRFLDHHFKX2oN7Dn7yjj8DQAkjsrFcEf3v/rULjG3II6bTyaiknjUGSWQoBxjFJFeBoz9lj2g87u5oAstbLmMZKHPHqK6WOIm3j8wAyqM59a5SyMkkyGZyU3Dr9412umJJd3kaRxZjQb2JOMqO2aAN21tWs9MsoiN08+XfnkA9K1DD5lzHCrBUj5bnIJqnavLNfveu4dEO1MdMn09hUFzM0NsxHEs7EEei9PzoAtMzT3JLMNhO2PBzlV6n8TVXU4xczx2KorIp82Udhg8A/jVhEFhYKTgSBdvHpWXYq9u8k8kw23EgRR/EAemaAOM+L2uTaZoV1p8JEYvWRVCDH7sct/hXzxf3RCyu6hmxtTnqK9K+MuspqPi+e3gYfZbFPsyYPDEdT+deWXiO6HzAQc9hQBXu5neGMgDJ7elVLZnKzBvvAfSppoma2BKMpJ655I9arRkLJ5m1/m+Vst3oAmtpn2lt3HTrRVWHKtJ1wT0NFAHRxttIq7bIWc56YzVOFCTg8nPJrQQbQBu49qALsfYdDjpVyLPAH51STluSSPrVxW2pkdaANO0ZimFGTnFaKxg87SG/wrKsZdrLjg5ya02vERArnDjjIFACyJgZP3/TtUeHZ+x+lL5pYbyMk1KoJXOfzoArorMTuUkE4PvU6R4YDOBjp70+dtqDYTnH93FVmbJBYYP1oAtfKowSV6/Q1NkIqnPJ6CqcbLn52ypPFS5DPnnpmgCwVZiOSB1qWJyu1h1xyKqwswP3jtJzz1qRRyAWJz3BoA0ILoH5c47irMU2/PTjg1kY+bABJrSsISxUyMMdNvv70AaEaedxnK9M+tPaBQoCnIBzU0JKBcfjxinHkAA8j7vGaAMmTiQ9cipYv9o9PzpbojIChiT3x0qNGRSMg8HpnJoA2bGNmbCHIJ5+ldZ5ONHtmiY4TcpP1NcvpmPLXHBb+VdTZgtpLRIw8yF95Hqp6mgCoEG3BwMcDHeoGIzz0HXHSrZRVDBc4zjJ4P51WliLAjHHQe1AGPfr+7fGCc9+gqfwda757m5IOQRGpPb1NM1IfuyOmT29a1vB640ZG6M7Fz7igDYiChs9B0yf6U/ZnHJPH50/YB1HuD2pWXnjOSMY/wDr0ARFCSu0biPyAqORcuMSeuSR0qyQN3Uqw5xjpTSPl4PXk+/rQBVe3GD84B7juKpTxkEnlsYxxWooBbHPqRjp9DVeSRTuyMgHsaAMa6iO1iR845INczdaZK007gbMj5R1BrrZWGAWHOCCPWmWkI8oDB3e3egDOtDut492ckc57U6WOSSM/ITmr89oqSbwTtPGFHepJwY7faCOOvGcUAcdNaSq5Lhs88VAyFHA6gjgeldQ4/dbgcq33fr3rB1OFUnzGSARkn0NAFR87sKW6e36U0KDhTjJPB9KeiEhScDr1/nUiAbioAJ9T3FAESpiPlsdwMcn2qYIWUKmB3JHapEUseSAD6nrU8CDaAo+T3oAnt9piUZAPA560PjAy2Xz1Azge9Inl5OWxnpniluDiMHcPegBqsNhCksw6HHWmysMhWOcHgdKj80BcoCpU5ziqk9xuz83HrQBNMW2lS+DjGKy5r2FJDGsbSY4z2qK5u2YFAScDg1RYgqvJxgcjigC5JeysmAuwEcAHpUCs2dwY4J5zUG7AJBye3vSZ255JGM9aAHytkNuBI6jnrVzSSEjZiTgc47VmnDcAkZ9DS2U7IzorNhuCc0Ab9lO1xeKSQY9w29sV6NohSDSp5SGe8uWMKLnGF9vTNeaeHbSTUtat7KEY3yDJxwB3NetmFDqBVF2qmEjYjqFHLD60AOJENrHCo69W747mmwN9ouDI6Dy05H19DTrkebK8D5UjuR936VAz4kjtYQVDAySN7DgA+5oAW5lNxcqCWCfpWT4ruVttCv9QZvKgtUBTH3nc8ACtC7vFsbIzk4VTtBByTnqa8s+KPiISQadoqO7RpvluS3DSFvuk+woA8c1W7bz5ZXYiSZixJ5zk1SbcYnhk/eYB+YHlfatK6hOMsyswO1h14rLSMsxVAck4+Y9KAJCuNMi2tuZT361QJBy24fNzjFampZijSJdoKgEk8jPesa4LLE5QgYYYA9O9ADcojHcpI9qKpvMxADOvHaigDsLdSsYz1NW40OwFT7VSRssr9hkYq0jHgdqALkZK8jrU8GdhJUNz+VQxt8uO9W7ZFPzSHaB19/agC1CuNrkgenvUqgO4MpGT0FVjvlkLEbVPQCtC2DHCq6+4IoAtwAKv9PWpW2gYbrUMZVMgH94OCKRyH5yaAHh1bIBx70hTLHOemc0xBvcAED3NWDIqNt6j1I/lQBCGC7UYfOe1PjHOCwXPTjpTWILHhfangKwBJ5xk/WgCYN0GABnGfT3p6nkhRlicg0yLkhcgZHU1bRdqjBGTwTj9KAHRDBB6kdTWrZtwCBg4zn2rJOSgCngHir1tJ02nI6fWgDZhZSoOQce1SOM4Y8Afmfaq9uQ0eckDpVyNdydcY9OTQBSuUBjO3HTjPXNUCjJhmQBeoYdzW4bf5iMc9PWs+8tpDkByq9aANDQGLRO29SQcAEV0+mMVbaNuG4Oe9cPoEog1H7PMwHmHCk+tdtACwGQA3bHb3oAfJF5ZMZABU9u9RyIxHQfUdqskbmBJLdeepzTGTkgceox1oAyLyElTlcA/lV7w18ulxLgfKSp9RTp4wwbJ6dsZFGkKEGcgZY57cfSgDYVhs28H+6cdBQOmMbh0HoTQOSAQMDpTjg4IyFP3ff1oAXIJPzZAHGDnFRPlgefm9TTxnJJ3jPcdqjdhtxgDjBJOaAK90+3y3Y8A88/54qncP5U00ocGOQBdvYVYuAxbacAEdfSuAvtVvJLq4RZR5fmFRxyQKAOhnu0IO1x06+lXbW4JTJ27QN3BrhvtcikcqDjPqBVm0v2hQAyMF680Adu8mdu3nnnPpVXUJB8yq2CTyB3rCi1FpWUpJgZHOeCasy3QY98nueAaAGW9z55eNwEZDxiodQXchXAYnnjtVYkecXJOW9KkDbFKngN+dAEABG3uAaesSrGC2GT19DSkkkjHHtxSGQ/dAH3uCaAEcsfn4A9e/0qRD8oY5J9+1QknJBAyMk5pjNzkZJxkc9TQBNI+ATuJHsOlSLKChVSMtwTVGRznPI3Dio1n2KCzDGcdMZoAmmlO4kthBxkVmXU7yKAcBAc8VavRuwynC4w3tWe2SRz+H9aAIWJBO3IXsO1QsSepqaXtknjjFVW5HPDD17UABYg9QR/KmowOOc+opjMBkDqf0pu7OMnA7/WgCQvnIYY45qSE/MhJBJ/Woxvb7wAA5HGM1teGNFuNS1KFGQhMljgdutAHdeBdHkttO/tEEpcTsUjPovQk10dvGY43uFbr8iA56f/AK6PN/dxRQRFFVfLQHjCjvV1Asp3EgRxctnpQBVR2sbTNwQZmBLHrQqtDbmS42+bcfMzKMbQOgpUjW8mM7EbAcKB6D1rA12/uBdbIow7M2CwbGwUAWFW0kuJ728VZbCyiab5jwWUdPrXzxq17da7rd7qsyMGuJCRHjAVegH5V6V8StbudE0mHSLudftt2xlMSgDZF6n3NeXNrphUJLEojGAMD5h9aAFez+1DzXWJJT8uGyOlU5LE2rHJTc2QD7itSW8gEof5t2BgDnrWfd3qo5LQsxPOMcCgDHvocwnd8zn7xNZ0sSMjZXGRwa357iKZMNF5ZA596zLlYivPypjJ9ce1AHNXEIZyOmDRT5LmCVzucjmigDqUarULcfT9KpwZ5xzmtG1t2JXcAM9Oev1oAs20e9d5OEXnPpVtX80KCNqfwVVa4BUrGvyJ97/aNRxyszgZ460AagcggdMVMJnA4OPwqkG6DPJ71IDtxyTn3oAvK5Yfe5OOakMh24xgdRVaFyPujH4VOAAfagCxGCxAWpCQ464wcVAhIQ7TinkhnBI//X60ASDuowCOtSQrv6McZzTFUzMckZH3iOKsxbdoA+6PSgCRNuNqj5s5PtViMhhgggdB7f8A16hTC8Yy3UY7VKrdBnJP60AT49ycH8BT4MpJgHbz1BqPd/ePy0sbL5qtxtBoA6Ozjyoxzjpu71ohQGCqcHHYVmWUirsweTwea0Y5T0B4zQBMF3j5n3A9Qf6UjQgqAAFPIzipIypAHb19KsBAV+fPqOO1AGJd6e8pzAxSRSGUkdCO9b2kXRuIT5q7JVO1x7+3tU0cf8DZJxU8UCrwqg+gHBoAsLhQQeDjtyM0Op2EZBHQZPFNRSAACSmOv+NPQHBVsFVGPQUAQ4zjA7EenNRWXy3DIc568irBPHyj0yP5VDGCLhXZhk9QaANGMnbgntzjrUi/xEsR9OgqvGx+Vo8nnHI6U9WDLhexwT2PvQBJkgjng0xyAdoUbyM89Ce9JlWAIJOOM0HGc46YGPX6UAUNTKpaTSNyyoW2/hXmAbcxkYfOw3E+9ej67Js0u6GRwhxXm0anYoPPHT0oAX5iMAZ96lVCTjHOOnvSBWTBf5RnBBqwuVTrjH50AKo2qgHb7xx1qXcxT52Y/wB09B9KYnB5bOf5VKGyDg5XsfSgCRCUG8YZzwB2pJXIwHzk/MoqHzMFcZP14psjYBKjPY5Oc0ASbmIJOOP4T0xTWkdmBPJ9faoCQW45b17UrMfo3pmgCeVskHf16jGOKiLEDrgDqaY56ZwQMYzTGbrn8aAHM2E3OcLzjHc1UkYk9sjt6UrS8AdUHQGqs8mOQefWgCyW3nr0GeahlXAyyk/561Vt5NsmWYkeoq25XqOvpmgCCQjAxkjGPTiqkhxwO/OaszEpHg5CjnFU5PvjPHqe4oATaMD5jx27UyU8AEHGc4z396UkBcrgj3pj5x8o+U9eO/tQBfs4w1zCp6FhmvVfB9gtnYyXLsPOnfbjsqev51wPgzTm1XXbePafLi/ezEdAo7Zr1R4d65jwm/5do7L6fQ0AXrZRM+4bcYxhveodSIciGEhkBG4L1Leme/vTnDWVofL+Z26e1VILlY1a4O0Rjgc4ye5+tAFTXtVTTLUxqxjnkBCepPc1ztlfWk8s0l1N5xRDMykEZ2jOPp71cvootbuxO6kiPKpk9hXN/Eqax0jRI9LtJAt9eri4dThhF/d/GgDx/wAY6vceJfFF/qtyMtM+I0H8EY4ArHfK52sMMMYJroSLONCkaAkDGc1XlvYF4W2Qqp4yoyaAKIKtEAxbJABCmpPKdYWDbtowCduTV1L4EApaKvPXFQ3lxOxYR4RSAS1AGdLGygEBnD9+/wCVReazQeWY85HQjBFOZpvtCh95x1IqG68wFcAgt0YdqAMq6sgWDAZB/wBnmitOSKYvy4ziigDTjRiGJJwvY96sMwjQInDtyT6D0qpFdEDMvXd8uPWmrKx8wv3agDRj2xwnBG0DAFRx7Q+N3zHoPaqSv83BOKtx4xkcH1oAvoDjrUyA4HPNVIsd81ajKjoaAJ0LVNG5w2R16VAGOART1duvagC0hOMevqKmjy3HHoeKqwszuNtXT8o2AHnkkd6ALCFVwu4gDseh96mCn5SeNx5qFBgjjg9/ep433LgnK+vegB4wrZ6+/YU9T8x5UN1OOwqAnaAvHsPWl3ZHJGSO1AE4f5TsA44yaY7YIPTPOajeTGMjIPX61AWAJJO7nOKAN7TLoE7HJyOh710VtKC+MA9yfUVwUUhDrIWw45A7EV0ej33mtgnB9D/SgDrLYqEUgcMOc96vxEgjAGDzwOBWZbMC4VTnHFX4zgZ5xnJHrQBbTcSx6Lxg54P4VOAVB3cfjmolIOSThQcen4VLHzgdSo9KAH9uTkdePenMuMgHpxjFKrKGweQw4x60qspYhRleg96AIsDIyTwRgkfpTZVViRnpyDUyDJU4J6nJ7momwMnOecg+lAD4WJIYjaCcbvf0p+9Qq7eFBA4/wqJXyS2ST7CnE4IBAK4GCO9AErOCW6DJ7cflTS5GMr06E1WaTD4JBHYnrUFxMUIyxHOOaAMvxVchbB1yAZDsGetceiYUEqfl689av67d/ar5gBtii+XnuaoFjuOzqc0AKdo4HSm7jgt2xzikJJGT8x6fWmb+hwQOwoAso59jTo3+YZ9wKqCUcgHIYcnFLuznnbxwKAJy3TIwOo5znFRswKkZyc560zf3/wA/WmE4GeMCgCVW+TqCevFAJHUKvHWoi/Ht64pBIOnBHTjpQBIH4IYgD19KhuGJICHIPr3ppfvjOaikbjbk80AJLIDkAjj/ADxVKaTdgrgjp7U6eT5HbIByAD6VXzk8jJ9DQBIp2kbV79BzmrMcnVCRgcf41SDbsjBXApVlxgL1HT3oAuS8gBemMDmqTn2/XpVknKDHUnnHWqzgF8j+E80ANbJAyKUKeyk5O0D1NLGScqa6jwLpguLxNSu4GextGyNxwC/9cUAdP4e0ttD0xFck3Nwge6A4VB1A+tdNpEjzIss8ex8A4Pb0FUtPk+1DdMQGkbdjvjPANaV5KtraNhsvnAOOWNAEt5ILiQRqwJOQSvZfSub8QxSXERTT9qGH/V7+MHuc06a5msIiclpbg4U+/wD9as5L+F50VC5YfL8wwDzzQBWsotRsRJd3lzssYFMskhXhFHb3zXjes6rJrerXeoSAYmkJjUnO1e1eifFzxG9pbx6DZ5WI4eYgjJ/2SPSvMoJrKTCz2+yQnGVbGaAMxnKyFOBzxiq5eXIBAGTgHFat1Hp5Iw8yEnBxyarx21rLhlkuH9OBQBMu6NUJUenBpxmdYyFOQeenSra26yRE7eMcHPOPpUO2Mk7twPp60AZsksgcKd3POM0skZJByu30z/StFbeFmA3kE85IplzCsYCrOuc+nNAGZKyoF8wKSenFFWLuDIUFwceoooAyC2+Q46A8VOzsp2kc/wBKqxjBznvxVnzN5BwC3tQBNDwcHpVyF8dKqwIB85P4VLE20kmgDSQAoTkLUg2hVw2TVZZA+MZGKnU8dc0AWkPAp4LM+0CoUfCgAE59atxIVTkYagCeMBE2j7xqzCAyZ3ADpkf0qvEASFPI9anViq8EbRxn+lAEyHDBc8Dr9KmRgHwMAd+earEkDg4z+tSAgfxcDr/9agCwx3ZPPA4wM4qMyd1yPwzTUc8At05H+FBcDkZAJ/WgBJWwBvwSfypqHJ9QO9JvDH5skZ/KnqedqLnvzQBIAB949eNvcVPbztFKrJ95SMen0qrneQWGTnknvUwBHTb1yKAOx0u+8+BXBwe61vW8+OVYHj6CvO7Sd7ZwytweoNdDp+phufU4AoA7OKTdwMlvUipw2CPlwenWsG3v42AyeQcYBrTt5gSGUbVPp/8AXoA0EA2LxkbieaeHG043ZJ6dMVWjlLfd69T9KlVSVwCSeuD0oAmZjwMjnstI0jkDpn19KZlWBAYhTzz60nynOBlh2J/lQAobhuOpzhRS7xuO4hlVfpTGxkZzu6YpvAQLnOBjBFAEN1hvnGMEdR0FYOp6gbWJiq7nzhea176Yxrydp6bR3rj9cl3MnBA5yM9DQBnOQQfmy+SSSfWk3YUE/eHc9KbyeFClqj3YyeB6igCQOwIAbDDNRhvTn696bkngcCmA8e/tQBK0rZA3detODcZYHB6+9Qlzxzx1wKUOMAc5brQBKwwwBI468801iB2wQc9etKx6E45HUd6hLHcDnkDgGgAkYnJPJPNR+YRnPc04qSAB6EYqF8oR0XnBFAD2fkjuKhklJ/i6dPamyMc59Tmq0kmV3E/hQA2eTc2ScgetI7E7jnrwRUG7LE856DFKDhRnrQBMjHpuwPSkLfMGHUVEG446dCaQnPFAFiKUdG6+tPbAycHBNU1fDAcn+X4VZjkK7S46cCgC1YWj397DaoQskrAbj0UdzXqkNpbiCPSoGzZ2xxLjozD39TWL4P0caZpT3dzDu1C7I2CQcwp/jXVaVYra5TLOCfMkb1PYUAW7a18pTKFUM54HTA9TXP3+txzarJFcZSCEY3Y7jqT7Vu3l6km6OMgvxkZ4ArltZhjv4TZ7lCE/O464oAIr77SxuIsOjfJGD/Cn978auX32TSrP+07sh/JX9zGT95uw/OucstKnXUhFEJGibCxknhcVS8YasNSvfs1oytbWZ8syZ4eQDk/SgDzvWJJry+uri8LSzTyljx61VaKKNRj7w7VualGI5CThgBnI9apx25dgqsMHqTigDIliiA3R8tjv60ttD5CnD/vCOO3FaZspFRmj2tuIG0daSW38hiuACq4z14oApCSWLbyM9doP9adc4DK543DJ9jU3lYkVSBu7k/piq5jdVkyDjg89OaAImcBSC+WHNQ24NzJtGMA7iaY8UglZuMbcnNaVgI0CrwGxyaAG+RG3MgJJ560VNOgQAhN2e+aKAOLgYhSAeCcYqSNgOF4NQ224Emplj+fK8HvmgC3E/wAuDU6ruGe3pVUA9utWUOI6ALERwwA6VbTrwcYqlHuxV21jywZvujqaAL9onG9+/AFWRu/iPNMVSTknH90etWUABHygfqaAFUbV+U5z6VIAGI3D3AH86TOD60Z2/KcbhxQA/ORz2pu/LBgQeOoqJpQfUjpwaY7FgDn5R296ALYkPQYP4cmng7uOvtVeIZyeMnnBqccDggfTigBfmXPy4HtSq3c/SgZYEckDqaAM9aAJhnO7+HHSpAeVJ49jUKn5vQY9akUjKgdCOR6UAS5wAD19DUqSMj5B6DPHWoAu5h6CrCFuDkKM4zQBZt2lbLJIV55Iq7He3cAHlXLFR1DDJJqh57CM7CA2MD/GqxLbSo44x16UAdfp3iRfNSK8ARm+UOvT8a6eK4Rl3r8yHhdvQmvL4E56/e61es7u4s5M28pVW6J1WgD0lWDNyRuxninIRjLHn0NcTaeIJxKguwqx92iHNah8QWG0mNnduwIxQBvySqCAOucZNU7u/SINmTgDvXNanqV5LbeYjxRRN/CnUfWsJpXbzNzsxPByc0AdJqGopOjZcDAxnuayGl3gqwDRn7vqP8azVwc5BGeuD1poY9T1HIANAFmeLyu4aM8Bv8ar9OMgkcdKmt7kk4lIO7quOCKWeMY8yPDIMLt6Y+tAFZvm69/50124JzwPbGMU0tuYEAAelIp+7nrnrmgAB+XkYJPApxOGyMHHBpuVwecAnvToyNwycj1oAsSY2A8k96hJGcbskDNShgcg84A6+lRyEbc7RgdvWgBjEZG7IXHOKrzNjOPxzzUsrBRnPJ6A/wBaqvmgCOQgjbz1FQyMdjgVKSAOaglI5ydvtQBFHyvPSkZgO+P6UqjHAGfb1pSpbocEdutAEQOTk9ccYp4bPBUc96RUwfvD154p8cbuMr9wZHzd6AFTv0JHT2rqfBHh19XuWu7tvJsrUgszD779lrL0XSJdQvorW1QtLLyTnG1e5Neo2ggsraKxRfLSFcbcffb+9QBctmnlvXM4VgcMD1wOwrQvbgWkCoh/fzEgAjqO/wCFFuiWdq8lwevPP8q5fUNQn0sXus3p8zzMRwW5/hXsFHqTyaAIvEEJjjaOyLGY/O5B5Wsmyu7gS+RcIEkIBc45A7D61f068F6nnySnzCR5qj+96H6VJdjSbKF9Tv5WSOJ9zMozuIGdtAFXxlrMuiaRBHBJHFeX6MinqwT19q82sSINORXYuWyWJ6nNZ2u+J08T+IVuJIZo0ZgkSA/djHQV00ul+dHF9mZSvTPTH1FAFS4tzNHCGwOue59qYtjgosMZLgfe9/WunEEcdlF5ahmHDepNUHfAO5GUgYB9aAMWWB1YRnqOWIFQ3cMrOVCAEgfNkD863JbbyrePCsWbnJHc1nTRyBHaRiJCwGQKAKBsJsOpZV2jqeT+FNltNzsFPLDnPrVtrZ3dHlGGXvnOa0Rb7ywcZO3nt9KAOVuYCJGXhjjnnpUCQSqzOF4HX1rZlt3klY5GfSoQjFZBs6980AJJGwRW2g5HpRWittJLCmcnHYUUAeYW7FT068VMeWJPFVoS3l8EirEYYjkUAWId+e2KsRgEYNVomIb5uBVuABjxyaAJ7WEyk7c8VpwALgYHy9u1Q2wEUZx1NTQ+rd6ALcXY84PNWAuNwz1GR9arxts5xUm8scjpQBYLBcE8VBLJuOFHXgetI7D1zUA3FsA984FACjnPbJ/KrCcgAdB1FRY+TjoasRjKkjGR1oAkjIA9R61MScgEDkZqtyCAWPuKnX5scHI/lQBKnGTnG4UpzxyDjj8KZyRjB/D+lSdSMDHbntQAgJ7jGOfrT0xhSWyTUTZyO3NSx9QFAAPr60AWYyMbeMn9KeQvVuBnjnrVaQjPPQdeaegPcDHrigCRvnb5elSxoD1+5n86SNA33sADoTUyeo4/CgCRcKnGPfjg03qV29CefalVtykY+UYwTSbQB3Az1NACLyCeevanA5HQDjPPamMM9OOtDthck5zzQAFgFI3Y9s9aYz/PheAO9MfJ43FcHJ96ikbbudlZmAzgDJoAmSQ84PT261Fd3cNlD513LFBEvVpWAANavgfwtqPjhi0GoWOj2yHLxyMJr3Hr5IOIwexYn/dr2Pwv8NfDHhmRb1bU3uoRjP2/UX86Vfdc/LH/AMAC0AfPdvqvn6kbM2d5CogFwJpoWiDKzEKVDYJB2tg4xxxmtSC4K59T/EfT0NVrrVj4i1vVdffJGpXBkhDdrdQEhHtlFDY9WNLu6D055oAtyxrMC8Qxj76r1HuPaoZoHWMHaPLOQHXqaSGZkOCT6gg9K6KxUeWjBfvDLRj+Y9DQBzOVwQoJ9zSrzitzVdHwzzWgyCOUHr7VhICr4fIPpigCQkqvU57+9MMhIz/D6U/7xBHQ1FLhepxn27UARs3zdue5qMnr1pzdODwPfOKRB64/AYoAiZC3cZxnFQMoJw3J/nV2RRsIIAzyT7etVBljgDKjv7UAMAwOmBQVJ+4ScdTUyQ7/AJh8pz2qeNMAKoAyetAFZYVX+Hc3bIyKtpAw2vgl2ICrjue2KekaqMk4Cnk/5612ngrR4/8AkKXhyif8e8Z6sf7ze3pQBpeFbAaZauUAOoTrmYnqi9lHtW5Z27SutxMoCRjKk96haAXNys8fDH7xHepbu4DEWocJFF/rGPAPtQBUuLv7XdB5GZbRc7CDjI7n8elYl/cjVbxvKAaGDIjBHQ9z+FP1+dpLYrC+wtxHg4JFczDdf2dIbO63iLZ/rD1X6+ue9AGlLaXEVwg0uJ5IDgBVGG5PJJrjPir4ga+urbw5pgXyrVi1y8fSSTHr6Cut8da2nhzw7HDb3DSanf4MSI2Nq+vsK810fS3muGjY7i/zTy+ueduaAJ/CulRxSeaVMjKMmQjj6Ct9vNlkLRtznqKuyW0VtbBYByFxj+lS6fb+TEC4AkIyVoAYqObaJWZhk5HvU0kLSrGxO055B5FWI4VkxheW6j0qeKFEGJI8HPUelAFB84/eAkBcAd+OlVblPMB6K44Oa6GKANtAAkDZHuKG06V8FUGOCc9jQBzKWDMARwevWmmGVY5GVSGyQoFdR/Z6yZQMCc88YqG7s2iOzbkYwcUAcmsM8hJdWPHQCo4bF23FsjocV0jBUyAMY9D3qupySqg8+2cD0oAksbVUjBVWJI5zRVa5vRG5AY4Hfp+FFAHiCyjOVGB6VPG7E45qgnymrcBOewB75oAvRKXwOtadtGsWMHcRwao2ylY1x95hnNX4EK4IoAtxDd14q1DhWBYZGMAe9Qwxlupq2iKMZOaAFVTtAY80SyiEbSBv/uinSXGyIHavzcDPUVTBO4k8n1NAEo65bnPalHJ4yBTBz1qROnc46mgCVeOCOfWpIzgkg8d6jXKgA1Jx/CO/PsaAJ1UdQBz+tPXKnA4+vWo42ByM8dyDS7v4se5NAEwJyRkYHJp6nI9u9REgLnj5qUN8vORx2oAkbJ9DmpFYEj1/pURyyKepWpIgpAPU9x6UATom592OD0FSqP7/ADzSBeMAnK1IgDfePHTn+dAEiY6HkHpUo6emOPpUOCWBJ46U9TjGMfjQBIwBJLA885FNZgvXr6dcCkLDJ5HIx05BppbAPOKABiMAY4I4qAsR1HJ4FOYFjleaZkk7cDj8KAHccgdqGbnJ6AZJphJyuOvQ8cGp9Pt7aXTTrWuxPL4dVjFa2gO2XWZx/wAs0/6Yjks/QgH+EHIAumJaw2tr4n1mCd7CObOkWUR2SapcLzuDdUgXqW6N7jAfsvEfxCu9T+Ed1a3kkEfiLULk6U4tsqAsgLs6AncAId4Df3lriLy7vdV1GTUtYlSS9kQIkcQ2xW0Q6RRDsg/Mnk+1KSzie+jvCv76JDGOeMEjt68dfc+tAE0aiJFSMBURcKoHAHpThgrz24ppPXvn0NNYZfBx19O9AE6gFkUccj8a7Czt/NjR+UYdBXG2pH2mAMMZfOa9DsxwPLPI/lQBGRlmCjn+JfT3rC1nSzKr3FsP3uM4HeulnRXJcEq4OeB0qvgbioHXqPT6UAcCJMrgKFz/ABelRt8zbvwzWt4ismt7hp4RiKXIYDsayF5xk84780AKOGXpxSNgFhk57UjNnPTJ4PtSPy3HOOOe9ADWJk4Xjb/nFKkQ37myAfSnrHzubqOKsouXwOnOKAItmOMDOMe1KY/lLg8D9an8vcCADnqfXNXNK0yXVNQjtbdW3Hlm67R6mgCx4W0Z9Zu1Mo22UB3Sv2b/AGR713TQGC6H2NQIGwu0jtUNja/2ahslI8gHClRgE+taQItIFPVicA55yaAHlokidI/lb17A1zeuSt5JiiX90vLux+96irF/c72eGNjz96T+dZd/OoDJgOjJk98L6fjQBnW94bm6kdeJtuI43xzjv9Kn1dLeDw7d6lrEKiGEDY27aWk9KyNR0/7UjXVizRPAgyBxsGeK4T4k+LH1+/hsrWQnTrECNeMedIB8zkfWgCpfanPr3iM393828/IgGBGo6KK6rTylvZL8w8yVt7EVxGhgm9jfOMA5B6V1satHHG0inDklXPQUAdNbAy22Au7HJZqms7Rs5mXCepNZWm3ZiUOXbbnr7e9dIJVMcZVg8JGRg9aAI8qHIUN0x8vepxxjCEr0Jaj5OqKSQRwR29KkIkIxj5R2P9KAII5HjI2kBRzwKZNdyIPllZASOtTbXeNgqEn6c4qP7PIwI8lmJ/OgCJ7x8g+YMk5BAq4swkhRuW44rOngYHABGOKmtSUVU5z1PHSgBkpGWOB0yBWRfXbRBwgXJ4yO1atxliAeAMjI4rA1AK45IUZyT1z+FAGZczoZSGUk9TzRVe4XDbgN+eOKKAPLI8tz3q7aRl5Y155NQKVU4FatidkRAUHcc59KAL8aqHCt0A5xVuKTJI7dqpxkjJxkGpkY4HFAF1HJ4qaNlXliaqRkIR71K78Y/iPH4etAA0hkfe3TGBUqguAT2qAEZAXsKlQ4OaAJVIHWpV4wW6VAGGeTj3p8Zzww46gHvQBOpzg9qk9ee9R89c5HANAIwwYfe9OMUASBiMEY54yKlzluDx61AOgxjAqRGwCPegCZTycnI/SnbiQQDmolfPGc/hU8MfzZA6jrjFAEtuhYH0q0q7fX0z6U2FcHGOlSuNox1xQA+P6gEfnT1BxhehOcetRxHkgkHPp2pwHOOM9aAHg+4+tG7/aHHf1qNmx6HjA47UmT3A/A9KAJSx6Bc45HNMJIIycD9aZv2sRxkdaTzC3GQv64oAlZiCCPTp7VGeMnABIpu5lHGCTxmpbGxt76xl1XXJ5bbwvbyeVI8GfO1GbOPstuO5JBDMOnIBBDFQB2n2Vvc2h1jXWki8MwSeUscZ/e6tOP+XeH/YyCHf0DDIAZhFe3l5rGonUtVMIuNnkwW0QxBZwjpDEOw4GT1YjsAADUby41fUlv79I4RDH5FnZRf6qxgGMRIPXAG5sZJHYAAMJHf8qAHcdjn60jH05IH60mfbOemKbuHzEA49qAEbljgjnqKG4HTFITtFHOBkknv6CgAyRghiCvNd1oV2JbWJwc5HJ9+9cFu5PB46cVueFb0LcPbOfvDcn1oA7lG+ZmH8XUioJ4sDzFJLD171LExfAPtipAoyVB4zzntQBmTxpcWzROP3bjA45rh7u2eyuJIJhtKnIJ7ivQJk2yEnmNuTk4/IVg+JNPa4iEy5MsQ591oA5dVJxwcZ7elOwMdAM+npTndEi+8Rn1FRPNgjZkZ/GgCdBjGSR65o3ZPysAB3IPH0quZCFU+vHPrQ9wAdrff6KBzk0ATo7zXMNtbIWuJW2og6sf8K9E8NxjTLSW2EDxz5/eTHq3+FZ/gbT7a1SS+kdJtTf5CB0gHp7GukSATyrIOoOWz3oAsxFXjEsnCqMfSsW5vXlkkaJgFB2oeuAOrf0qtrWpi5mOnWjEBW/fSj+HHUfWnW1sHZ3CqsCqGYZ49h/jQBJKsUcMpmXYzLu6YwOw/GuIu9QubC/jcgPC+cRnrj296259Vh1G68gvtUH93kYMh9fpWH8Q72y8M6AsdwnnazcndbRt1ix/EaAKHxU8Vx2Vkvh/SGImmRXvJ14KgjIj+teSQABlB3ewoaWS5d5Z3LSyMWdm6sT1qe1X94uQD6igDY0fKyFiAQOMetdnbiMqEYfNsyPQVyenAEAAc7ueO1dRbwyp8zgMG5DA9qAJ0h82MIzFAB361s6W0cXyAl1GDlu309qx3lw2H2gHqe5qWzkZSQ4ZQw4A6kUAdnHLuG75ecYKinhiwb5jknHFYtpcMYVUkhge3XFTiUofvsB7mgDQkLAlSwA+uB7VG8xQfMx9jniqTzElsNn0/wBqmEPJJsClR3zQBI9wCW3sMdcUWpDHeDhgeag+zKW2jkYyS1JZqwEqgZIOevagC1frhCQWx79zWDOzNId33SMAEdK1bmVvsx8vnHc1jzyOsWFCluhNAGdJs8xspuHqDjminPJkkCMbs5PFFAHkVmhaUDGR1BrZjXKjHFUbcBFCr1A61ct2656YAoAuRnAxmpo/vCqqfMowSDn8KlNwsS7SNzHv6UAW2IVdzYwOg7k02OQ79x5J4PtVISMWyxzn9KsxsABQBaUAdKkH1qFDTy1AEyHmplO054P1qqhweelSbsnnrQBaDE5z7UZyTn6dKrrIc9aduA7nP1oAlLdO59amiDM/IOT+VV4gZGwBj3NXolwMbtwHp1oAngUbcsFJ6cCrKJgZbBPpUUYVWBIO3GMHvUykhccYH40ATJg9BjHH0p7EnDE5OcZqFTT8jAz26mgB4Yg9BkHtRkjLDio2buD1pNxoAlzjO3OMZOaYxJHTINNzxg0mT+NADsgE5OT7Um7jBHyj065pMnuam0yzh1RL26v7mWx8OafgahfxjLFjgC3h7tKxIHGduR3IFAC6fZ22o2t3f6reS2fhqxkEV1cQg+bdS9rW3HUue5H3R75KpqN5LrF5b3U1rDY21pF5Gn6dEf3VlD/dGOC543N36DgUahqMmry2jGzj07TLFTHpmmR8paR+rf3pW/ibnrgdy0eaAFyRg8Yz1xSbtuBkik/hHYFTkUnsOKAFP/j3rSZI+916cUm7jd2zikDepoAdu3KcAfjTCcru4OaCfz9qYWoAXPJwevc0iu0ciSpt3ggj8KYzc0qDIORkUAelaXcia2il6PIAfpWgCSBv9eMg1ynhCc+RJCSMoeAewrqQ4+8B07UAPZQ2M/dPc9azLs5VonK4/h4ILCtFmOCeMms7UU81S3OR1OaAPP75Wt7qSInncSM+naoQQAeRhuPrW7q9ml0pVdomP8eelcwzvA7o6YZDhh1xQBLPPtGc8DgCu38B+GjEU1fU4N87DNvA3QD+8fes3wR4abUC2qaiClqOLePHMjep9q7iythYoYEZs4zvJJC5PT+lAE626pI3lAKr58zHr6VR8RaoLOFbe2ybhxgsOqr/AI1b1DUI7G224/etwq/571zOmRST3Uss/wC9XdhW6ZbuPoKALel2TQx+XGN1xNyxPc9gfp1qxqdxE8S2ts5K4+dvUnrVi9c2dn+7+aaRSBjsK423nk07UIri9idbJzmVjnHHJ57UAL4mt49L0uPV7mZI4YpAqRn70h7BcV4z4i1a81/WLjUdQdnuJGwAf4FHQCt3x54ml8Ua4ZwDFp8BKW0IPCr6/U1zDqegOKAGRjAGB7c9Kt2/MoxmoI0O3BJ96v2MeTnr70AatmWjmRwOR29a7TT5lmsgUPzL39K5C3AA46+9bXh2Yi4e3c8PyAPWgDRuVG5ZATuYgdOh9aVZQshAJO0456GpZQVkdJCR0xioYYwhOFPXJoA27Z1YAnj5asxxZC/OpHrisVS/yABl4wD9OtXbcMFyJMY9TQBohGD4RsBuMkVaa2kA2gqwHPWq9jHKWJdWwf4h0NXNoTaTgZ5oAT7G4Rt0a8r0zxVGCzm86UhD0wSe/tW05BtM8+/tWbA37yV0V1Y8AryKAKctu0gOfXFZ1xDIuFx1HOK2nYNIzKWyuBjHBqtfIJWyGwpPOKAOektZRjaNpxz60VauTiQ7W2k/3jRQB4zGwHToauwYKkdjWfDjoe1W42656CgCxJL5cIx1zUcchPzN1PWqskxdt/bpTo37GgC8jDPFWYzVFGqdHoAvLJjipFfIz0qqnzDnoKfuLHJ60AWQ9SqeKrIc/Wnb1Bwc5oAs59h9akjG/wBMeoqGEZPXAq/Gg7Y+lAEkCFjt6CriKNpz2qGLAwe9SE5B9O9AD0bmp1bj3/pVQNnr90VYjbgMvQ0ATK1O3Y5BIPp2qLOOO9NLc0ATM3HHr+lBboPUZqEHg0rH5FFADw1PBqI8N1H4UoOKAJPpzVeG3aJI4PtVw9jDI88Fkz5hgkf77qvYnJ+mWxjcczZpfwoAXOeuB9KUE9xikx7A0fiQe1ADuoGe/JozznvTc9s5YfeoLCgAI7ds5qM8YJ4AHPGc089cUw5HU0AISfTH40n4ZoNNGTQAFTnkce9TpHuGMADuTRHGePvZ9PWnyyFQFPBHf+7QBo6XcfZbxJM5ViEf6V3COGBIKgdj2ryyeQkE7iuT2rr/AA1qQu9OUBvnj+Vv6UAdGz5wVwAex61AxZQ2QCD6UGQFRgH3NQSudpO44+nFAGRqKbZSWJx644AqvY+GpNUuFvZosWcZAfP/AC0PbA9K37SxGoTIZi62ikEkfxeorpoUZIeUAVeEReMD3oAgtxIkQEmNycKp4CL6Y9qbc3KqkjE7Il5BPViKr3MyzGSNHYRxnEjDuf7o+tYGpXZ1CfyLZWaIYGM8Z/pQBEHk1q+KMzoVbnjO1fWuijSKztmZlxbwoMZPJx2qvp9nsjEcJ3E8yOeC2O30FRi4XWpWt7bDW8bYJHHI7n2oAytM1JNU1aWO4mSAAZUNwFA71wPxD8WnWpjp2mMY9HtmODzmZh/EfarPxD1uxa+bTtEVSYVMU90vV/VQfSuFC/I1AFMqzPnuTmhkPtkdcVYK8D1qQgKgzjJoArxJuXcOK0LJMnkDPrUSJxz1q9aJjnBH1oAuQRnB4596mgc213FKM5B5wKdbjKnAOfWpIojNKsajcx5yKAOouY8KJx90gZPXmmxxAtu4BJy3etCJEWzeInLKqtiqJTyXxyA/ORQA7y9xjwQXBxxwKvQKNrblyc9MVAkIZGJbgHIz3rQiV8KNobcM59qAL1lM2VQ5CZBOP61LdhfMZ1IwPk61XjTZGwRsLjjmpIHUAocZYYyfWgB7khByAGGOTUFuvD9Dt6Z71PIBtQNgkdsYqNcxQSYBO4kKB2oAoy7d5APfoBUV1PHtMWVHbJ7f41FcS+WMjrWewMsm9xznIx2oAhuGLEcHA/Wimzp5gCyE7gc8cUUAeLxN+73HgdKkeUiIg8buKqIwYgZ+Qcmk83zAX/hzgCgC0GwvvUicVWjJIx1qymNwFAFqM9KsLngDqelU4j1q3AcnJ6ryKALStghfQYqVOBn1qGJS2GA4J5qwvKHHJB4FADkXI3GrEUat1qCLLHj7o61cQYAxQBYSNQODk1YjAHWqyD0NTKfU0AWFxwScLTixIUH73cVCXwvt6UbiOe570ASqeRjpUwbpiqgb5gPbNPD/ACmgC0Xy+fajOTVdGPfrUq0ASqad9elRg0uVHXI+lAEg46cfSlB9OB6UwY7dKcKAH85ApQcGo/lHXgUDgcZx70ATAignnFRbqTJ6Dk0AS7eSccnuDTsoBljx2+tV5JcD5ageXnrlc5+lAFoyID94cDGD3pu9D93pVJpO5XikXLHOdooAvg7qmjiwMnrVaAFcEnJ9KvRPt+tADtpCE859qpT5JJzk+hNXmlDHBOB3qpK8auw6jGeaAKEhYrg4x6rV3Qb4Wl+YmJKzcdehqpJIjfdIA9qqyyDduI+YHKn0xQB6VBcE4HH0xWjp1q17Lt+7CBln+lYXhHzNZt1ZCFC8yueg96722giWFfKj2QoDjPBJ7GgCa3CqmBGEjHRSao30kkkmIG8s5+cj+77VPczEuqxYMXTBqtfERQN5W0t3PtQBhavcB1msrV/KA5dvT1JpNKgdHUbcblxn+8v976n0pwtjdziUY8sHBXH+sPqfar19KbOMQW5L3Mg/dYXv60ANvmeQJZWClmPDbeMD+7n371554y1ePw7cXemaNdMLiVAk5U5CdyAfXtWhrmvf8Ixp91aadPJLqNxwzP8A8sf7xHua8vcMXLvuZzyXY5JNAEYGOATjvSqMsTSgZXNSIM9aAGbOTSleOMD3qYrgA44pzJhQRkg+goAjjVTgZ5rRt0Bjxg/gKrQW7M/yqPqa1ba1zgMSzeh4FAD7VWYFAuWPStazt2t1jhT/AI+bg8442KP8aS0VIY2VF69SBnFamkwiSRrl87E+6T6+tAFy0G6/dMcFMYA7CnrEWUjaO45PShHSJzKTzyBjvU8H70FehoAit4gWVQpyAMc9a1wgAjHAUcDvmqMSLHKCwBwQMrnvU6yBgSxwoPT0oAcy85K5wcADgD3pYv3d2u4ryQPu5x+VMbBIVio2ryRmiNWMyEH5QMnn0/rQBpthIHzjcSQOO/1qhPIFh2hcnuOn50l3ctIV2jAzwBVC6eQ87RzzjNAFCdXYsWJ65B61Cqk5wcDHPap3dpMjr3JFMEQAJJyDxg0AU0Rs8kse5HSir6qwIAj4AooA+cp5diYTjcf0qaD/AFJHbiqDNvYk9c8fSrsR2xAetAFyI4jqdDVWPkYqdDQBbiPNW4hgjnFU4RzmrkbcCgC1Hwckce3Spossx2cZGBVdOvfmrkaFF2j7/XNAEy/LhVHXqPWrMaEAFj+FQRYaMkj5xUg6DNAFnhRSeZUW7IwGz/s+lIOvWgCzyVp5YbRUathaTOTQA8HNSKePXPSohnjBGO9PJ24I6UATL125+b+9U6HIqsDxip4zkUASZpwNNH0z7Uo/X0PagB4PUmnj19eajHr6c08Y/vY4zigBc4ppNBNMzmgBwNEjbR8vX1ppbA9qqvLlsL0oAcXIOBTSey9D1ppz3NItAEgXJ5A59qlRR0PTsKRBnFTIlAE0CEn3p1wQPu8U9CUXI5qs5Yk5ZTnsBQAqy885yPSobpw5z6DB4x1qCRiW78VGzsM4yT6elAEbAj+4R+VW9D0i41q+8uJtkKjM0rfdjWpdG0241u8Frb4ARd0sjcLH7E16l4b0pLTTzaQCMW/Vmx/rD/hQBY8N6XBYQCLT962gAJYr/rPetGaYSv5akiMcBs8Gse+vjeN9mtcpBCcFgMByP4R/jV60dJYkDnYuOhHpQBZBEKhiAFHrzj/69VDG9zJIBjYx4/2vb3poZruc5jPlqQOD+oq+FS2ifOFQD7o7H0oArX+y0tmYKPMZQAp6Mw6Ae1cf4g8SP4ZtZHlkhn1e74iQciEdyR2x2FdLrWpR6fam4uIs3cmRBFnp7n2rwzxAsh1aeWY7zKdwY/56UAVHnkubmWWdzLO5LOzdzQVG3GcD86iGY2PcnvVmNSRknigCrt5wOlTxIf7uD71Mka/wj8hUyQNnPIoAjW3J5Y/hUgiI9h7VZQKo55qRVjPOxvrQBHaxszAYwtakaAYXofSooowQCBWtptqJpTuHC9d1AEtnYtLgklYu59fatlY1WIxKhRSuNuelTRJsjyFIT7qr6gUS71i+6Ax/yKAKKAmbAAC/w9wKvRKzSAhgwHcVSTImJOQV4IHTNWYB5bnccL14ByaALDjE6nPA59s1LGEAxwSf4gKdt2bSyHcSMDGaFiJYNIoUjseDQBGNpmKklgcDaOfxpWVQNwznG49jmp1gf78gXyxll/2jUW0bxGCEz3XmgCsxAB3YGeST2NV2jcyjyioyOMj+tXWh+UhTuIPp1qpOfkXgjHH0oAryxAknfhjwcDim7WVc7cg+tJkqz7GJOOccUwTtwD/D1JoAnUFVwN31FFL5/wA+PlQYz+NFAHy9DzirydAKoQHGPSr0Z3UAWc/uxjrVmIjjNV4+lSr1zQBei61PE3zGqsDVbtk8xwR0HWgC/ZrgGR/4un0q5ENqY71FGMnI6elSg9qAJE4pxaoWfaKQtx7YzQBOG4yOKC+B3x6AVXV8KFo3ZPvQBZVz+FSB/TrVdGI6gfnVlWHoAaAHKuTkk1MpOMVEpzn2qWI5GTwKAHg1NGf5cfWodoHQ5qRO350AWk98A+vannp0x9ajH9aeDmgAp47/AJ1GOtOoAG4GaiJwCe1SS8rioidoHfFADLlsIMdaqnnmpWOTimhM8UANVB3JqeNR2U/U0ijnGM1MvBxQA+MGrMaHAzUcI5q0AOuBu9RQAIuWxhs+oqCRWyd35jirQBJwRn2BpSFIPrQBmOuBxkmnadptzqt20NmrMqf6x1GQnua0LXTLnU7kW9sAoz88u3IjHv716LpejQWMKWlmQLVAN57yt3JNADNE0azt9PitrRCtuvzuxPMr+pNRalqDzSC0tDstV4kkX1/urU17f+dJJY2siIir88oH/joqjPI1q6W9uE8wr8qgZEY7k0ASbVIiS3c/Kv08sen1qK2vRqMjwQvhIWw7gcE1Bl42SCxYBPvSynkr7/U+laljHDYqkoMUKqOnuf5k0Aa0CLBFlhwgwB3x6fWodSuoLW2FyzAynmOMn+fvVa91BbSOOWdVweYoSOBnoTXOXVxNd3DTTnMh6YHAHoKAKmqSTXckk87lpTgKc54rivFFnhUlUnap2t9P/wBdd06L5YAHU8jrgVja3aCa0lj77Dj6jkUAcXDGMAAVK0BByenrTUG0Dpgc5NWEk7EkUANRS3AUj3qQDPRs460nJHOKcVIYqAOOORQArHApN4UKS3Xse1LgjDNketQkpwPvY9qANm2f5VG5Tk8fWt+wcRMVxkhckDv7Vy1m5DqSPlHSumsI2b5icKOOvWgDSSSZ4WOedvSqkm5nbbK+/A4FSLJsckZbHU02RipYjjdxkUAJHKQo3kcYHXk1dguUWYNs4Iw2TnB9azRGA21mHJ6VaQ+WMnHTGTQBpM6yjO5/mPBVsDFTq0UUgMjM5HPJyP8A69ZqyBgo5wQDtpC2X3AcZzigC5LOZNxyAucbT0x7VVLESEZI756cVJDLEku6RRhuNwHIq3LNbuxGAB/ezQBFE5ccE8jA+lRXIbYAuC2c5p3mQ+aCi/IDjPvUUjpMxA49cjGaAKDEFwxVwfXHFRMEOADz/ePANSTj76j7vpntUGPl5clSetADSmS29h170U8spXZnJzksP5UUAfM8f3RV+36VRTt9cVet+goAtxnnFTgVDHVpBk80ASwjBBAz7VrQReSgTqzfNn09qo6eo3NI/wB0YA+taK5LHnmgCzERjnihjzxg/U0Dbs+frUbsM4HSgBzNupoft6U0HajZpmeQaAJc85qRR65/CoRzkdjxUyHPZT74oAmTj2Pt0qZBgewqJKmWgCVO/vUiHAAqJcdScfhUi8jPA+lAEoqVKhX8fpipVoAsI3Q/hinLkDB61EmemAR71KvpQAtOUgjrQVwuSc1Epy3HFACTvtYUzcW9Mmm3BzIKmiXjkUAR+WwOSMUAYOanIUdKYSDxQBHnByvNEeWbkEUEEH5MfnmrFtGRyxJz60ATQg8Zx7etWOhweD6VEo3EgcCpAMYGeOwoAfjgAHnNaWh6Pda9cSfZgI4YyDJK/AUeg9TS+HNCm1u6IDeXZR/664PRf9kepr1Gwgt7S0W3tIfJgj4Rc53epPvQBk2GnCzg+xxx7IR1boZD/eJpmoXTzBrax2hh/rXX+H/69aWpyZU26Z3MNxYfw1zGozQ6Zbl4QSSxIHRpT6n2oAZeyJZReQiASnhD/ePrSWqyRxFJQGmYfvHPb2FGn2wula5u0ZZCPl3HlB7e9aEUQhQ3NyCEQYBYdB/UmgCO0tEsYjIwxCo3E+59fU1ma9rtjYWMtzqqZkQAwWY4Yk9Mn171P4j1S10uziv79lB/5dbJWyXP+16V41rupXOsXz3d44LuxIVfurnsKAO8s9WuNYK3d4yl5eQgPCegFail8YDcenWuM8HTE2xR2H7tyBnsK6+FhtVgTknjmgC0r4DcAnpmqtyBjJBJyM1bi2hgRgjrVe6XI3YGQeee1AHB38Ihv54QuAG3D6GoVySd3rkVreIYs3yuCF8xRz9OKysfNwSPegC1HsH3hkUyRssSOhzn1pi56Hj2zSkY5HOO2aAI2Q8HP60qgk8D8qUk9+PalRCxwM/hQBo6dEJZQvPr7V0dm2wsuMAKfpWJoinzlwB0OQf881tRIRIy4AJGTgdqAHx4VD2B5JqVZUI2sRj1pYbQu+HzgenOfanyxJEWKgbcdWPIoAXarAbACT3pwt5Anzpu79aqK4bByT6YFTGUnG1sMeCTQBNtfIGQBgHPpTkjAbl/lPAqJZ85DOD6hR09qmWdQ3zFORnOMYoAbIg3jDAkfpTMAIWbbn7pOf6VIMSHKsc9Tx29aTZ5XPUM2AB60APCMtsBtyV5BHeoSXDg4JBHFahcKi7sDd2qszqozsYL0DDqaAKRGUGdxfORxxSsqqgLLlgecdgauMY1JLn7w4B5OaieINu+Zc7eOaAMxlDjnaeemKKsPa4IUHbgc+lFAHzBGMgk/X8auxcKKqwjBUHoRzVmHOTnsc0AXU+6MVZjBYqB99uBVOM4x6E1p2igbpD91SQDQBcTChEHRKtwjA/GqUIwRnv0q7FwnP0FAEjtUanMnQmgnIx3ppOOn3qAHO27ikHNJwRjvTwM8EYoActSp1qNRjipkViRgd+aAJkqZemahUY6+uamXoaAJhwgPrUqDjFQpyuPSpUPAoAkUYqVRTEqQUASIM8VIOmfwpinAzSjjj3oAU5PSkAJ60/HAqRlAFAFULhxVgYwAfTNRFgGqWPoB3/pQAmwMOKjaLnpn8atCmlc9KAIUjI6HNXFXABNQL8rYbg1M5BABOB3NADtwOAODXQeFPDr61KJ7nMOnqw3SH70hH8I/rUfhrwzc6x5NzInl6XvAdpPlZ177fWvR7aHMaRKpiigOFVeAV7Y/rQBYhhghtktbeFY7VOAijge59aguHkjKxwBWVj17L71OJGX5Y9pfqRnnFRTgJG7BM4Odq9aAIri4SNFWUoisflbHJPqfast9Oa7ud97t8qE5DDrn29quRRG6luI7iI+QyjaM/d9h7VadQAqNhUjGVI46dsd6AMmaNEYyXGUgTgY/wA9ax/EWtR6FFHfalFv+Umzs85Zz2ZvQVqeLL+DSNJa81FQWY7bSFT8zse+PavGNSup765ae8Zi5G0BjnaPagDN1G/n1O/luLtgZXJIA6KOuBVZFBbg89cdqklgHDZIqNFVe+frQBueGZNk86YzjDV29sSwAP3SM8CuA0GZU1JQNw3DHsa760aR0Gf04oAuqcfd61Fch3jb0HWpO2cEEfjUsgDIOCM9aAOS12EGKOQZwrd/cVjAcdDXVa5CWsp0XkgBx+BrmUwVz1FACAcev86kC5HTHuegpgHcAfXvT9wZcDn3oAgfg8Ln1p8IyQAeoxQyk9PzqSBfmX6YoA0dMl/fA9McZFdLG6hN7dRxXL2KlJBt+hxXS2xH2X5uWPPTtQBN5hXkA5ziqlyX81t3IFTM2VABUgHPFIWRiofpnJNAEa8DGB9fSl5+UAYJOPr71c2W7Lk5DZxUb28Rztdhjn2NAEDMVBUjBHHHen2qyG4SIYIJ7+mKUKiZ56YY47j61e0qNPPkmwCqjjvk0ANiicyMueH4Cjt+NLeR7buFASflwfc1pQSoGAEann+IYxTbh1Fwm6MZ74NAFJyXRQP4eo75qj87FtjYJyorfu/KRi0aYyvLDnBqg3lDDleo7DnNAFElkb95lpANvHSmSyAx/dy/oTxVh5EycKV77SKgM6bsPGM+hHSgCqJS/wDe3d8UVO7W/wDCP3ncUUAfM0Qyo9qnQVVhD5xu61bRWHOcgUAWYxkADknpWxH8q+WBlQo/E1RslEcZk+bc/CkjpWhbLgDr75oAlizuAbg1ZY52gdqrq2ZcnrmrSAAsW6YzigBCdpJP3jxj+tIBj/Gmrln3t9KfQAijnmplHFRqKsIOKAGoOanAPbio0HzVYAoAEHrUq0wU9aAJQP72Mf7NSjj+dMQcVIBzznOMYNAEij5M1KDhcd6jT7uKf1IPpQBIMqAe9PUZ6dKjB3cVPGMCgB64G0HvTXbIpCefr0ppPzYoAiYHdViI1CTzUqcGgCanfLt+Vh/WmA/nSDlsEigB2cDB6+prq/B3htNR232pblslJ8uI8GZh6/7P86yNI06SaL7dJAsluDtRXbaJG9K79BLN5U/mLGAAPLT7qj+6KAOgjbdGpUKsYXAUDgD0AqvfzMqqkGPO6BT0H1qubsCRUjf5u2O1WFCqrFiN5+9/hQBBbSRrwQpY9fc/4VKU847oi6Oh+ZexHpWdPaTXtykkbmNUPLjsK14HVAqAg4GQM5oAYcfMCCAT0z1NZ/iPXLXQNOFzeKss8pxbWwb5pG9T6L6mn6/qllolot7ft8/Jig/ic/SvGtY1G41fUJry+O6WXOAOiL2UegoAg1vU7rV7+S/1CUyTtwBn5UHZVHYCsqcl0OTz29qsyru5zg9OKhlChcjJb6UAZb5KsCDn1qJA3OenvVqVRnOTTfLyM46e9ADLNzFdwSZOEcZxXpdg5PQ4GOPevN1QAeuewNdz4dummsoXJG7px2oA6NCNuM5wOtTFflGe9Ni5GWIwRjgVMDkYByPegDLuUDiRTgkjArikDbW3dQea7u5ADg+9cbcxeXdzp1+Y5oArFCRkdKcOBjkCnk4j4OaCPlxxz+dAEeQ3HpU0WOnT2qNFy3PT1qeIfO2CD+FAFq2wHzj8K39OZZLN0yFbr+FYdqmTlgfp0rbsECLjGNwPegCYw/OFxx2PrSeWecg5H6VcYMm35cDt9arSMS2Q4b6UAREgAl2OOvTrSxruYAOcY5zTGbcrn8Pyog+UtngkYPp+FADgWZhgHJ+XKjjFbVrb+XZhiSCx3GqmmWhklC87FySR6VqTzxNLsU/IvBWgCCFcTrxzjk9qluiGnXJwQeMdKDuEmTwG6L6D1pIsG9Vtx6YxQAXp3NKCVUlRt4OKz55toyNoII/OtHVSI9oUFmPbOcVzOoXJwwRdw7L6UATzXCbcs2Ac5PoazL24Ms/7v5UwAAvSsxLh5GHmgjHIqyjh5AuMMRxzwaAJ45SsjE85HWiom2pIeSoxjjnmigDwOHGM96uWqtIxC9D1qlDnoOpFbllCsMKOfvOOKALCwqzBhkKg2jFWFznI4A7ZpbcHyyjD96w3Y9qBhRkDr6c0ATKoJBI4OalZvkBb7xwKYi5UDOQe2KaW3ucDIUY4oAlXnjtTgc9OlRxnI4GBUvfjpQA5alU8VEtSLQBInWpgahSpBQBKKctNHSlSgCdDU4IxVdTipV5oAkB71IvJqOI7xjrU6rtHNAD0FPyaYRxnIH1p0fTHX3oADnGadQ/yoKa5oAa55pEfB5phNNOcgigC2HzxuP0qxZQi4kJBwicufaqKDAzzk+ld7Z6Bbw6fYQooa+k/eSZfAyein6CgDQQ29/pyWbRrbpGP3IPQf/XNOuLuKztdpJGOAoPOauXatawB3iA2csfXHpWDb2w1O9F+z5iiP7vHRj6GgDW053jjM0+PtEq5APZfUe9adlc/ajtXJjUZB7H2z61h+ZLfXJtIyFU8ytnhD7VrxIdOUJICkCDMh7Aev1NAG5CQ8alT8oPLdhWH4t1a10NYJpoDcXTtmNVfbj/aPtU+qa7baHpH229IYyLi2tlOC7f4epryHU9RudTvZbu+kLzv2/hHsB6UALrV/daxevdX0plnPT0Ueg9BWcwI+VwSAM8HpVnIdfT9KYy4U46E54oArOu31+tQSbsHpj0FWpgAfp0xzVVxz8yk/TigCpMmRkf/AF6Yo4xkkVYkHfGfYVGBmgBoXHC8Cug8IuVMsRBwDkViKu/jB49K1NCkWPUkBcgONtAHeQMSqYye2B296sqpPPIqGzxtXae3UVewcgg9KAMy8BK8fw8DiuY1CLbqMvAwTuz9RXY3SAKpBwS3Oa5vVo8Xqg8Exg57UAZJTjnkUhxirTodvFQNGqnvuI5+lAEW3J+Xg1Jbx5kwTz+lI24HAIx71bsQGDg44OcmgCyAV4yDV2yOdgweDnPrUSJs7gHHpk5qRZcHrkgZOOlAGu+10VW+Ujnr+tU5kdSf4ge4GDUgcMiucDgEgd6R3PmZ5298dqAKbMQfkz7qB0/GrFtEbiQIA2f0qWGRMEsqnHZuM1pWk+XVVVUAHIAoAsyYsbNo4QC7jBbPSs9XZVHQ5HLDvTgd0rZywJ9eRUcUfXHBHALUAXbVjIu0AZUE4zzj1qxtT7WCx+6oIz6VFp4LSkkqpVeQetRTyt5rO5VQR9QKAK2pXAeZyuQCeDXLycyvu5AJH1remDPIVJBBHB6DNY13GoEoyCWxkjt70AZTgbiFBAIyPaoJTgKQv057VdSF5GYICCBtNRz2rIqmRWVenqaAGxXTqpC8gnODRUCw7pSu7AA4NFAHjliqu/znAxx9a3bcEhHkGCRt2+lZen2xYCRh8uOlaoJkeMjgDj/69AF44Clx1A20xOmelNyQxRhwfm+lSxoHXJbaBQBIW2KDnDdqrqQCTxuPU0srhyAOdvQ0qqeCSuPQdaAJ0+6OcmpFpqAdvyqQUAKKetNAp6igB6VKKYoqQUAPHSnJRtwMc5/ShMqc5A+tAEoxTlySMDNNG6QjI4Pep4wIjhSSe5xxQBOBtjBzlvpTlJGCME+lR5yMg1JkcYGKAFJzyevpUkf3aiYfmachIoAczblwaazfL70PwKgLUAO3c89KRW+b2pnJPFKo6k9qANLSoWnvERUL4y+PXFd/oUSLaLIPmuskSNnPJ7fhXO+AU8qe6uXiaRTGY1x2J6118tkdPsmltkZgBuYHrk//AFqAKd9qDS3EdgySHK5ZgMgD/wCvVmVEhtlhtiqMeF28/N71maE0zCW9vImTcSAP9kdKn0oRaheNdOxjHKRY6lu5x9KANjSLNbaFsqZJM5ZiuM+9VNa1ZBDBcGWPbGxaNHGd4H3mYdh6ZrVnH2RoBE5kV22kLyduOuK8q8YajHf6tcLEAFL/ADIvAOOAP6/WgChq95NqeoS3NzIZWdsrz0X0+lVYyQMfl7UKwBBOATnp2px9qAJgWxknI9DTWbbyMZNNBAX69eaibIPqKAEkwevNQP8AKMHrUjYAyc/hUT7sccj1NAEJG40Yx15HoKdtIpwVQMjNADU4POcnsOlWrMrFdRygY2HJFQoh7dD371bjjDDBxnGOe9AHoNi+6NWLLlvu+laKlcYzzWD4cmElmqsfni+VuM/St5BuHU/lQBUvSNmBzj0rA1JCZ4sjrGAB0PBNdHcoBEx/2hn6ViahGBPA2MjB/nQBQeJeMqfxFIYUYcj9KnlAbcRn5egz/OoMkAEkYJxxQBD9nH3RjirFsPKDgdx0xQMHjrTguASOnf2oAnOM4OcUyQdMYIz0PU0RtiPJ4X3p9vCZ5lQcjqc9QKAL4Ty4BgqAVxg9aYMkfMTjHA9allUthUAx2z3qIqRw2eP0oAVIxJwCAW7Z5q5a/LFMo528A/3apRsC3AbPqBV+2QEyLnBZcc+tADQOSQp/3s8GnISWZgc9e9PRSzMrDGOvpmhIt27H5Y/OgCeykGWLHtwRyAKhuFD4c5G4cnGMn0qaCJthGSFJz7Ypl6hTA5IGSPSgDOuHV1yOXXgrjqaqNAJEy6HHuOgqSaJm54CHkkE1EruvclRzyaAGrEAWCtzn8DQ0AJAJyW42nlR+FP4dOAD3z0xTw4wGTPPftigCO20yKEEsgc9AduRiircN15bHeCRjqBxRQB86+co2hNxA96uW7HO7PFUbNd2G524xg1akdYwM/d7UAaAdXVZJjkDjHeoTO0qlH6dsccVUUl+c1NHjNAFqLAAHepo+pA61BH94VYjBBIHegCxH6D73c1LioYhgAGp1U0AKBTl605AO9OIGaAHKKd/Filj6HNNX72aAJs5/w7UEFunWmqCx4qUcc9zwfpQBLEAF+UEHvk1IGPTtUcZ4qULQA9AMYqQdMmmLUv8ADQAhOcUZ5pi9/ajNACyH5arFuamc8VXIyfT3oAlBG3JJH0FPGMA5496hQ5OAQfapgpkKADksFA/GgD07wtZQDQ9PtixDO32qYjqc9BmtPxVeyxWiRWwRjO4QhjjisizulttZl0+MBo7ZMu+fuvgce9F9cSzajbASAhYi59OuBQBburk2unKgjcFzt/d/NwKsWbxREErgQpktjv1NULsyNd2kSSbVUAuCOD3/AKVr29pDe6dL5reUWwN69cnnn2oAx9Y15LCSeYRGQCICJRwN7fyxXlr7i/7w/MMtu69a77xrb/2XpNvBO8clzc3BYFR0QD/9VcLKCXJHIoAYh3Ak8cYqQvioEUk5b71SkE0AKHPcAUb/AFwKaBkcdfT1pSpU4brjOPSgBjPtOajfHXvTpOeh/CoACSQpwKAHxtluufrU4Tmm2qEgYAIbnmrOzBxQA1Fzzzwcc1ZiQ7h8vBFEcft+NWFUAAZwPU0Aa3heQJPLGG+9g/SuyRcpjHPqK4CxdrW7ikA6MN3uK9AtHVkB7kdKAGXaf6Pszk5A5rB1X5ZIVAzweprpr/CQAjG9mHFcxqrD7RDuwMRgBT9aAM1zjgZweMj+tREggbTjrzSPksQFGM9RT0TI7Ee3GKAHKTnkDPYin9+SVPqKVVIfJAweue1IGBGGOe3FACpGWBAPBOeOmK0baAQgvnEjcBsZIFQWUDTTDB+RB8x7Yq1IyqrCLlSPlB9KAGAFVyXPBwB70gdCQJl2n1z1ppY8k9SRxSMAfm4yTjI9aAJwP+eZXb7mrlsiiRt7AAfN0rLVOSMgMOM1cSbbvYEkADOR1oA3I4Y/L+ZsIMdVqSONCQWdcKOoGKxobt2QIrNhskg+tSRzlkBb5sdz1JoA03jDE7QAG5+U81RuU6/Oc989MU6OUq4JYM44z7elSOWkwNi4zwKAMiY4jAVl6EDmq7REAZ5AGSBWlewMQuwKcAg54rLNvIikIec4HOAKAI1J3/d3HOB/s1IhLAcE9h7U1I3Ukp16kg5pyTKJCu3qe1ADuYlydqgn04oqQzhRkxbx/tGigD5ye7GAqAChJGf71VI1HBz+NTqDn2oAvRjipwuHA9aqxkggHH4VbJIkU+1AFiIZq5FwBVSLgVZhOWwaALKjPcCp0OFwaiX5fu8U5Tk8Zx70ASjmnheKRcYp2TQA5emKXGGxQvWp44/42IHt3oASHCA47cmkzk89e1KoPIbjNShQBjqT39KAETIPNWU5qtgg+tTIcY60AWFShqRScfNxQTQA0cA+9NpWNNBzQArdKh6ZOBnHBp5NNoAaPlc46Z4q7a8XFuw6CRT+OaosATnG4jtUkU3lBHAwUbP070Aet2tpZz3Nzf20W2WdMS7f42PO72qh/ZN5FfPdS/u49oi245znPSt/SRbQRx2tuCI5oFmQE8srAEkH61UvvtAvnxJuXqcnn8PyoApysRrBLBXOwj02/LW350UWlSBXTzGGCp4wcdqyZIGbWmBIXc3ceq1qada7reVvKV8gEOw7+mKAOC+IrSLqdgufMiNquxiOvrXMRgMWHrxXX+PradYrSSQKFt5DAWXoN3zAVyShlxuxj9KAGyxfdIHAGKb5ZPtV5VGPm6+lNkjx0oAp7ce386a3I29+TUzqT9e9RMCQSuAR696AICCD6+wFNAG7IAxVkoTx096Ty8jIHHtQAka8DBAAGKsxoePT3psKY5PH61fhiJYAgnjPFADI17LwKsLGSNufwHSp4rUheVyO5q1FAqjDGgCskJYBlHTgZrqdGdkiBdeB15zWFyCAegrS02fkqaANnUCWhTa3zA7wB6Yrl9UIa6xnhUA/EVuXszPKI1I+6Msfc1gX7LJcSEHncaAKcYGSevpmrKLyBgZxjPWoVTceOKsRqyDaRkdaAEKnGeNvvTolBYEgBe1K4yo+UYHb0oj+Ug8UAaan/RGEfCnAz/Sq54xuwAAcCo4ZWjAH3hn+LvVpIopULwHJPO0+tAFYgsBnIPXjmpIYmyTsOOwxxUqqy8Kn4tQEIbligI5PWgCJcADBGAOcipXIVXIbJUA8jrSgHYD82PQUOS5ywB9QvFACk7lG5MHtTjIQxIHBHQUwPlj1x796YhHVdxwe/NAFyGb94FRFJxgEjtV/5WPmMjDI/HNZsJbzQihfm5960JJHTpgDsAO1ADpFjZAGHGO46VUa2Q8+h6CpXlJI4/LtUYOU+b5CO/p7UAU5YlMoWPAY9QPX0qBtqghlO3PQDBqS68sPhS2AO3AqqsyK5zKUP8RAzmgCQAhjlBt7DrRU1vMJSQjLkD+OigD5lgGVA7HmrkZG0ZHNVI/lAHap1PGaALI7VZfnb9Kqrxx6cGrajJBoAmjPIq3EcNVGI5De1Woz8ooAvJzUwNQQHIqToaAJ1GOvSpB0JGDUSPVhF3emD6UASW0RdgRjHf2qyQBnaBn1aiPhAqnA78daJHDPtKmgCEr8+0sC1PUHuRx6UoTDgqGA7EjrSmMkkhSvr70APVc9OaePkGcqPpTA+wY3c+g5pFfc2Q2fwoAc0hP/ANegOOnU0rAdwPwqIgf3ce4FAEnJPOB9KE+Vm6EUwAgdc/QU7GRyMUARt14zRmkY4PJxTSR/f/SgBpbAPY9jTSeDu5PcZppPzZzzT4yAOSMjoAKAPVvB199o06wuZxyqNapKOSAvbFT32oCLWPJ2yBpYSQWHde2PpXO/D/WXtbObTzglrlJEU8g5GMfpXZavp0f2gXl5OkZtmEgLDll7j8qAMLWr24+0wyW6O2Qsn0xwa6PS5njwkhLoGJU56q3I/HtVHVZLZLWV7HMsUWGU+qMKg0ud5IQJcDy+MqODH/8AWNAEniqFLnR76wgjyf8AXN6oV5z+Vea/I4G0fL25r2+Ky0+OcXgczStHtkZW3KVIx/KvJ/EGkvo2pNbSqTGTmKUDAZTyPxFAGbG27HQmpkJPGOO9QEc9M9+KUuoIAHPpigCYwqw6AY/iqNrPOMHk1IsjYxn5getSB1J+Zj7AcZoApm3b+IEU9bfqR97pkdqtM+CM4BPJ7804Pkemf1oAjhtsMW4znrWjFCq8HkD0qup65GR2qZZAOAflznGetAFknC9cYpPqTTFY4DBsgfrT06ZI69/SgBpxu75GT9RV3TI986AEkdT71Xg2AFm+bB4rZsJEa287bg4Iz3oAayf664z8iA8euK52Z9z/AHefTNa+ouYbEqD88pxjpgd6yEyxC+lAE0Q44zgipO3PHtmmRqM9+PSp1GSSc4PtQBGByP0pMEAtjnuanji3A5HP8Jp/kZ5B/DFAFXGF6knt6UqOwIIOCDzT5F2nC9B1pkaMTkEZz34zQBKLmYcBgcdAakS6zxImf92qzwSN90Hr1xT4oJS33CT2+agC4ZrchQxkQ+3OKTegIw45H4037FOQdwGByct0p0emknBcH26flQBJHG7wM6sHUEAGkMMu04QjbySOw9614LMpAu3aPYe1Xn09zaMNyHA3Y645oAwNNTdcufvAfpWhKNq7fl6dBU+n2hCTMvLH07VFewyb0XJDAZPFAFRwuF52jp1pmA0gUSA5656UtxbSqQ0hBH8IHb61ELfau9jt2j7pNAEd0FyF3KQOTg96oPCPMGwclsgetPuVctuXHrtJxVfdNu4B298HrQBPbx8FQOeucc0VE88gfCqVAGBkdqKAPnJOg4xViMgYzVTeAoPqKljbcBQBox4OKuKMFfTFZ8HpV3f8oFAEsQw/sanX7xx0qqrVYiNAFyBsAVYXnmqcXXFW4uFoAlU7enJqxAcnCjr1zVaMklgvpjPpVu2XZ7n1znNAF+NcJgDAoJVCuW5I5+tMMwVcEZPvURfC5kGR2oAlw2CzZ2+uajknwMBmJ9fSq0s7F+Tx6CkBB5OKALKPk5wc9yKnUgjiqW7A7c+lTROQACaALWemcCkJyzHHB70gce1GRmgBSMnoRSE4FLnHr+dMfkdR+dAELkEngfTNNGfWkON2Dyf0pTx6fhQAYGeSB9adEPmI6+9NY5xSqASCuePwoA6bwNqMWmeJbeSchYHVoZGI+7uHDfgcV6XpOq22pxyrM0JeE+W6k7sj1rxMnGGHJ4rvPCV2DaS30+0gERSuRg8fdJ9TQB0trc2ttNLZ4QyoCQijloyf6Vz1/dGx1SNWZ8BhtYDC7SeRj0PSrGrwyu0d/b5ivYfnHbenpV+LTofFFlG0SFMYJBOGU9wfagDds5oEVZLdkWE8H0U+hA7VH4ht45rKZb+FpLZ1LBxjfbMBww9q56S4fS5AUG2WI7QmflYfTvXU2M325BcXrKHbDeWv8P09R7UAeY3uj3NpaxXJSWW3k5V1Qrn3waosvGB17EV7VLcNMNh2Bc4w0YZSPp2rndU8JadeyTNblrSYn76DdHn6envQB5sFwcgDHTNKwyORxitbVfD2paYC1xA8sCjPnwjen445FZQO5Gxg8YyORzQAIu32B/KpVTC4b73amFDnABA9c1MAMr3C96AJIxjGR/Spo1IbftUgUwBiQAD/APrqQjIYFQB2I60APA+Zj29qfJjoBk9cZpE4QbRwOaaQSBzkdQB1oAVG3SqqDAPBB7Ct4kLHFChB3AZH8q55MRypkZHpmtN5fItWnPyyOSFBHf2oAranMHu2jTDJGMAHqD3qog3ck/TNRkl3AGcnocVOoAJXH3aAJY8EnOOOPxqXJ8sAjnuaij+ox/nrTyCD3H40AW4FYqp3KeOR3qz5WcdOecZ6Cqtt8ucEnnuehrRlT91uXjPBPvQBTaEY2k4yckkVOltEpD7vlzjJGc0NLhMMAT0y1IjuIxgDBPAxxQAk2E6kEE4Az1pqEq2cUGNpMiMjOc89qdHZyln3bFGfvBqABpdwPT0JqSKQkrweOvt70hgjXiQlhj7vYGrEWA2Au1iQDk9aALUJLYfJKZ78fWtS3Df2dL5a89snkj3qpCQkfABAPRquxTk2rs0ce3udvJoAo6YHEjrtKkDj3+lJfLMZVODnHbrmr1ttJ82IEKfeqOoDMsmCV5yQaAKcqSZywwe/NMdJueUAHQGps4C9VB6DHX8KoX16iHywGdiMkjjFAEE3yKTJtbJ4FZ0jTeZuQYT1xTp2lkI3fLt/iA/SmKWcPg/MCDmgAy0mNykemcg0VNB5j5BOSPWigD5lh+aM57VLCcVVhbHFWoiM4oAvwH1q0ORkdPrVSEcZz+FWVwVzj8aAJl6VPCearx/dPvU8HXHegC5EcPn05+tWVb5uP4ucelVFP51PHkH5gQaAL1qnyDJwQTn3qw0gUjGGNVIrgJ94cYxTPOZt3QD2oAuGYKSW5z2qMsd24H8Kq57k5zT9xXggkUATZwd33vam7iueeD2qIvu6DaPShPvZOSKALCtn8KmVjxj9aqoQMZJzU69OBmgCdWI3dPUVOkg28E496oyYAzkj6Ui3AGASfbNAF5n44I64IpMgjnP4VHG+6pCQAcGgCM5z/s0jcdKByc05h6cj1oAav5n0pwA69/5UgX+6cH1pRnnbyc9fagB2XJAbp2NdF4R1qPRtQZbyJbjTboeVcxH07MPcVzg5J6KfX1qZTlQD+PvQB7PbW8NzGslo4kgH+oUnOF+vp/KrNrFJaOxsokVJG3SKRyCPSvNfCXiZ9GElvc7pLGX5XI+/GP7y/wBa9DbVbYSWyw3ccwkQyxuv8Y9G9D9aAH6lYW0/+kbd3/PP+9Ee/wBRmssi7soDHO5dCd2R059PStN7K5ju0vbdmE0gx5ecgL9KvSLCYgJuB/FxlQaAMrRrm5w5MnmIOBG/Ue+a27G6j8540l8qSPnbJ39gelZllpbz37yQSyQwZ2hR8wYeo7Vrz6YogYzkshbb5gXBH4UAbCTeWFYxFG746Pn+dczr3gm01OVprM/YbluWKL+7Y+pX1+lbGgrPHDKs7ia3DjyWHUeowe1bgiAPK9egzn9aAPE9T8Ja1pjO01sJrdTxNCd4I9cdRWQm4MQg4B646GvoPYVAcIQBxx2+teXfESzjGrwy20ZR3VvNPQMc9aAOUjUnvnPvSN2zuNPMeNo68dqTBwcHIBwQaADcOV5OOgFPGNhI5K+vWkUM6soOPQ+lXLe1Mx3NlVxnd03f/WoAjsrfe3mzcIvJJ7Duah1C4FxN8hOxfu59Kkvbrf8AuYOIc4bn7xH9KoFQMAPk+/TFADo8s684bpirKjK8ckn73aoI+2DuYcBcVaiXHbCkdfegB4/Xv6ZpxHXGMdqaucZPSn5wvTnHegB0biIEEEo3X61oQTFSoBJjPy8EGs0fM2Qo4/WiGTy5Ds4Vjz7UAa07x5VgN2eDmlMzBG2qF2gEVRkYMN4A2Zweec07zCU2c4Vf4u1ACmUlMlsAr+VRRy7TvyTjBPPWgv8AKRwWPtTY8FTv57ZPXNAFpSzfKDuzzV/T7cyXBWRjjrn/AAqtpiGSZ0fBU4xgc1uyxR2EQKqCx4AoAHeN1AUjao4xUka7rYrwBjO7NZqSs+0MfmP8q1dNHnMyYAVlPegAsATb+uRx7GoNRdgdzgYK4455+tSR5hDjkn7oGOlQXqEK+4AEDOfSgDLmlCqzE/M3Ge9Y90Wllb5uTyADU9zKzMoIPynKk9/pVcxkgqmSM8tjmgBjSFvmG1exLH+QqGCTy5WyOD04/Opiu4DaOcc1VZJMsXYKM4zmgC7bzK2VOBjnnvRTIIk27vMxnviigD5ii6KT1q1Hw1VITuC4q2nWgC3GQBkdavRlzEcYqgnI4q9CP9HOetAEsOeN3arEY+Ykd6rR/L/Ev0qdnAC4oAuLg7QBlz1oVyB0AGegqINlRilzxigC5uGOaQkHoeKrxOc81KTnpQBKGXGAc+9ODejH6VXHHO0/hTlb3B+lAExYen40K/NRDaT3pwbCsUGcN39KALCnnOAfrUqPnjAql5+5wqirMDL/AB9aAEu59kajnnmqqyZOeBU98jMeOQBxVM7t2SQAPSgC9Dd7GAzkZrR37hisSD7+RWlbybsg9qALirx938c0p465oh5T5hwOtSMoxxn6GgBgZP7n60rtuGCNopNij1+gpVAPQ49jQAz5cHLHA59M1Lt4AzUT5zjH4EZFKOCeu0dFoAsBx909a3PCfiKbw7qQnaFLi1biWIpuOPUZ71zxbuCQfWhZAGHzHPc5zQB7hrOtWMUcGoxXSSWV4A0UsfVfVcetRXge/t45Yn8t8ZTbyD7mvIbDUZ7Fw0IWWI5zDKuVbPXHvXqvg66stXht1067SGaNfnspThj/ALp7igDe8M3UsMb2dwjBmO8k4Fa+qotwsUHzAFsnHeoYrKWSFvPhznK4I5FOtbea3iygM6gdDkEfjQAtojQTAhvkUYGOa2YHYj5j749KqW9uJI0kKHcTkr021ZMeG4BySGLAdcUATE8Ekjk5PauG8YWtyssl5DE7ZIVosbgy127SbuNoIPX2x3pxUSYIHXkmgDx+TRbhrbz0t3jJ5Mbf0rMaylZzmNk2nkHjH+Nezy6ckpY7tpBx7ZrA1/R3niIKbJukdyo3fmPSgDz4Wa26I9w67D0yDyfYdT9arahdNIjRQ/u4vQ9W9zWzBo1xI0kN+T1+8p/kar+JfD502xS6hJEZIDKxzjNAHNlsBVzwBzTgOSSCMnkUnAHPHpSK4Y7Q3PvQBPGDtwh59TVhM8nA4PHvVaFsYPA9jVhMHn5voO1AEoxgg4ye9KcucAHnt60qg4G1c49v50uwLgnO4cjmgCQBRGFBzuFQ8KDuXg4Ix2NPRiYwuMBec0gzu3H1496AFtZFhkJ+Xb/d29ver6pEyiRfut0qg3LY5x9Kt6cGeCVVAbY27OM8elADjBHKcAYPQA81PDbQqwSTPyjt61AoKqWDEc5z60RsBGSchwcc/wAqANizkWJiIlxzj1/Gop5zJcMS5YjgY71Dp/OSCwx69aa4P7wggsTgMPX6UAOyWZt2c54PtWlpbss4ZRtjA25zz9aylZtuIyOMHDcEY/nV61kAnSRMg56etAF6Sb9+4LZB/Wqd3JnEYPGeSvrVi5j3ODESQwxkjGPU4qgAWbaBkfe+Y4wKAM+4RWkAYAA8E461JHAo+VVyc8gnr61NwwcOoPp9KHyrq0fDE5z6UARCIlhkgMrZB6gVHHZ73JIyrNyD2p7f60hzj6U8OsIbc/JxtyaALsOlwPGT90g8kjrRV3TjI4ZTh3Tjn0ooA+K7P7mSeT2q9GDxxRRQBZQYNXEysXrzRRQApJUKcdsVOpHljnmiigCeBsDmn7sniiigCQLz1GevBp0Z3Z4Bx60UUAPDHd1B/SntkLnGPpRRQAqgEZPzH3ocZjYLkCiigB0IUKNrYPcjvVqAc/dJH0oooAbdo/mbu3YVmMx3dCR3oooAntiFBwoGatwtsO496KKAJ0mbouAv86kjv0DlZOp9elFFAEwuw3CqCPY1IkiE/Nwe3NFFACt1yCDnt6U3BBbJxgcY70UUAOIJHDZFNbcoxjGaKKAJomOSeg4BHpU0a7XDAlWX7pU4IoooA7Lw58Qdc0hhHcOuo2oGPKuPvgezda7/AE3x9oWtvEDLLps+cGOf7rH03UUUAdrB++VZIwCCP4WyP/r1KwypzwR6UUUAL5IJYpgKRg+tOwVAABC4444oooAbhQxIOPY85p+zkHj1Gf8AGiigCG4sreYKzQqJAOGxj61xHxQSK10FEBBM0wUKfzoooA8ubBbAHXrjv/hQASACR7dqKKAJ4wQM4B5wOatqpyAMcdeaKKAHqAnPftTyNvsMkfWiigBYiM4Pfp700hNnBJHrRRQA8DIBJ/BetWNO+Uy5YsTxuB6+1FFAEkiqi4IZgepzUEighgrfKMZ4/lRRQBe044lVgQD2wc/nVmSMNuwjbW5oooAhCZYnfxjI46Vbs490qID8wbOB60UUAaE+Duk25Oceh461nyFdp2K5OdoHXAoooArAOshTJC/TpTJiX2luDnbkd8UUUAV3djIFwCO4zio0UsVDg7ScENRRQBoWkptWYq3DDGAaKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangiogram showing a stricture at the hepatic duct bifurcation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39348=[""].join("\n");
var outline_f38_27_39348=null;
var title_f38_27_39349="Protein C concentrate: Pediatric drug information";
var content_f38_27_39349=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Protein C concentrate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?6/50/6949?source=see_link\">",
"    see \"Protein C concentrate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/51/31540?source=see_link\">",
"    see \"Protein C concentrate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4594766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ceprotin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F12809651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticoagulant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Blood Product Derivative",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Enzyme",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12923413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patient variables (including age, clinical condition, and plasma levels of protein C) will influence dosing and duration of therapy. Individualize dosing based on protein C activity and patient's pharmacokinetic profile.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Acute episode/short-term prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial dose: 100-120 international units/kg/dose (for determination of recovery and half-life); followed by subsequent 3 doses: 60-80 international units/kg/dose every 6 hours adjusted to maintain peak protein C activity of 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance dose: 45-60 international units/kg/dose every 6 or 12 hours adjusted to maintain recommended maintenance trough protein C activity levels &gt;25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Long-term prophylaxis: Maintenance dose: 45-60 international units/kg/dose every 12 hours (recommended maintenance trough protein C activity levels &gt;25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. Maintain trough levels of protein C activity &gt;25%. Higher peak levels of protein C may be necessary in prophylactic therapy of patients at increased risk for thrombosis (eg, infection, trauma, surgical intervention).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Purpura fulminans secondary to meningococcemia: Limited data available. A retrospective review of 94 pediatric patients (0-18 years including eight newborns) reported a median dose of 100 international units/kg/day divided every 4-6 hours was used in the majority of patients (78 of the 94 patients); the other dosing in the remaining patients was an initial bolus with the remainder of daily dose administered as a continuous I.V. infusion (dosing specifics were not provided); median treatment duration of 33 hours (range: 1-645 hours); daily dose range: 28-375 international units/kg/day (Veldman, 2010). Further studies needed.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F12809660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/50/6949?source=see_link\">",
"      see \"Protein C concentrate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patient variables (including age, clinical condition, and plasma levels of protein C) will influence dosing and duration of  therapy. Individualize dosing based on protein C activity and patient's pharmacokinetic profile.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     I.V.: Severe congenital protein C deficiency: Infants, Children, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acute episode/short-term prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial dose: 100-120 international units/kg/dose (for determination of recovery and half-life) followed by subsequent 3 doses: 60-80 international units/kg/dose every 6 hours adjusted to maintain peak protein C activity of 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance dose: 45-60 international units/kg/dose every 6 or 12 hours adjusted to maintain recommended maintenance trough protein C activity levels &gt;25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Long-term prophylaxis: Maintenance dose: 45-60 international units/kg/dose every 12 hours (recommended maintenance trough protein C activity levels &gt;25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. Maintain trough levels of protein C activity &gt;25%. Higher peak levels of protein C may be necessary in prophylactic therapy of patients at increased risk for thrombosis (eg, infection, trauma, surgical intervention).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Purpura fulminans secondary to meningococcemia: Limited data available: Infants &gt;1month, Children, and Adolescents: 100-150 international units/kg/dose every 6 hours for 72 hours then 50-150 international units/kg/dose every 12 hours until target symptom/sign resolution or treatment duration reaches 7 days. This protocol was used in a Phase II, double-blind, placebo-controlled, dose-finding study of 40 pediatric patients [median age: 2.3 years (range: 2.4 months-16.1 years)] (de Kleinjn, 2003). A retrospective review of 94 pediatric patients (newborn to 18 years) reported a median dose of 100 international units/kg/day divided every 4-6 hours or as an initial bolus with the remainder of daily dose administered as a continuous I.V. infusion (dosing specifics were not provided); median treatment duration of 2 days (range: 1-24 days); daily dose range: 28-375 international units/kg/day (Veldman, 2010). An open-label, prospective study of 36 patients (3 months to 76 years) reported an initial dose of 100 international units/kg followed by a continuous I.V. infusion with an initial rate of 10 international units/kg/hour adjusted daily to maintain plasma protein C concentration 80-120 IU/mL (White, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4595369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ceprotin: ~500 units, ~1000 units [contains albumin (human), heparin (may have trace amounts), mouse protein (may have trace amounts), sodium; actual potency is printed on the vial label; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4594768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12809661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Allow vials and SWI to warm to room temperature prior to reconstitution. Using provided transfer set, reconstitute vial with appropriate volume of SWI for final concentration of ~100 international units/mL (ie, 500 international units vial with 5 mL and 1000 international units vial with 10 mL). Gently swirl vial until powder is completely dissolved. Use provided filter needle to withdraw solution from vial; remove filter needle prior to administration. Administer by I.V. injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neonates, Infants, and Children &lt;10 kg: Rate should not exceed 0.2 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &gt;10 kg and Adults: Rate should not exceed 2 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F12809657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. After reconstitution administer within 3 hours and discard any unused portion.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12809652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement therapy for severe congenital protein C deficiency for the prevention and/or treatment of venous thromboembolism and purpura fulminans (FDA approved in neonatal, pediatric, and adult patients). Has also been used in patients with purpura fulminans secondary to meningococcemia.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4594763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ceprotin may be confused with aprotinin, Cipro&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Protein C concentrate (human) may be confused with activated protein C (human, recombinant) which refers to drotrecogin alfa",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F4595343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all drugs which may affect hemostasis, bleeding may be associated with protein C administration. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the concurrent use of multiple agents that alter hemostasis and patient susceptibility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Hypersensitivity reactions (itching and rash)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Fever, hemothorax, hypotension, hyperhidrosis, restlessness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12809653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to protein C or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F12923398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in sodium-restricted or renally impaired patients; the maximum daily dose of Ceprotin provides &gt;200 mg of sodium. Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces this risk. Consideration should be given for patients to receive appropriate vaccinations during therapy (eg, hepatitis A or B vaccine). Use with caution in patients with hepatic or renal impairment; data on the use in these patients is not available.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12809654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Formulation may contain trace amounts of mouse protein and/or heparin from manufacturing process and allergic reactions could occur; discontinue use in the presence of hypersensitivity/allergic reactions. Trace amounts of heparin contained within the formulation may lead to heparin-induced thrombocytopenia (HIT); if HIT suspected, discontinue use and evaluate platelet counts. An increased risk of bleeding may be seen in patients receiving concomitant anticoagulant therapy including thrombolytic agents (tPA), heparin, oral anticoagulants, glycoprotein IIb/IIIa antagonists, platelet aggregation inhibitors, and aspirin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4595347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4595332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4595333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproductive studies have not been performed. It is unknown if administration during pregnancy will result in fetal harm.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12809662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protein C activity (chromogenic assay) prior to and during therapy (if acute thrombotic event, check protein C activity immediately before next injection); signs and symptoms of bleeding; hemoglobin/hematocrit, PT/INR, platelet count",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F12809663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintain target peak protein C activity of 100% during acute episodes and short-term prophylaxis. Maintain trough levels of protein C activity &gt;25%. Higher peak levels of protein C may be necessary in prophylactic therapy of patients at increased risk for thrombosis (eg, infection, trauma, surgical intervention).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12809658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prepared from purified human plasma as replacement therapy for endogenous protein C; converted to activated protein C (APC). APC is a serine protease which inactivates factors Va and VIIIa, limiting thrombotic formation.",
"     <i>",
"      In vitro",
"     </i>",
"     data also suggest inhibition of plasminogen activator inhibitor-1 (PAF-1) resulting in profibrinolytic activity.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F12923399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12809659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Limited data suggests that infants and very young children may have a faster clearance, lower AUC and maximum serum concentration, larger volume of distribution, and shorter half-life than older subjects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Median: 0.074L/kg (range: 0.044-0.165 L/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Activated protein C (APC) inactivated by plasma protease inhibitors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Median: 9.8 hours (range: 4.9-14.7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, serum concentration: Median: 0.5 hours (range: 0.17-1.33 hours)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F12809664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/51/31540?source=see_link\">",
"      see \"Protein C concentrate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This medication can only be administered by intravenous infusion. Monitoring will occur during and following infusions; report immediately any difficulty breathing, rash or itching, or difficulty swallowing. Lightheadedness may occur. Report immediately any unusual bleeding or bruising, restlessness, difficulty breathing, or persistent dizziness.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F12923483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conversion  to vitamin  K antagonist therapy may cause a transient hypercoagulable state during therapy initiation due to shorter half-life of protein C than other vitamin K-dependent clotting factors. For patients requiring conversion to oral vitamin K antagonists, it is recommended to continue protein C therapy during oral anticoagulant initiation until anticoagulation stabilized. It is also advised to begin with a low dose of oral anticoagulant instead of a loading dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Prescribers should register their patients to assist in the collection and assessment of protein C concentration deficiency, treatment, safety, and outcomes of subjects. More information may be found at the following website: file://clinicaltrials.gov/ct2/show/NCT01127529.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      de Kleijn ED, de Groot R, Hack CE, et al, \"Activation of Protein C Following Infusion of Protein C Concentrate in Children With Severe Meningococcal Sepsis and Purpura Fulminans: A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding Study,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2003, 31(6):1839-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/27/39349/abstract-text/12794428/pubmed\" id=\"12794428\" target=\"_blank\">",
"        12794428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Veldman A, Fischer D, Wong FY, et al, \"Human Protein C Concentrate in the Treatment of Purpura Fulminans: A Retrospective Analysis of Safety and Outcome in 94 Pediatric Patients,\"",
"      <i>",
"       Crit Care",
"      </i>",
"      , 2010, 14(4):R156.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/27/39349/abstract-text/20723255/pubmed\" id=\"20723255\" target=\"_blank\">",
"        20723255",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White B, Livingstone W, Murphy C, et al, \"An Open-Label Study of the Role of Adjuvant Hemostatic Support With Protein C Replacement Therapy in Purpura Fulminans-Associated Meningococcemia,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2000, 96(12):3719-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/27/39349/abstract-text/11090052/pubmed\" id=\"11090052\" target=\"_blank\">",
"        11090052",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16776 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39349=[""].join("\n");
var outline_f38_27_39349=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4594766\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809651\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12923413\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809660\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595369\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4594768\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809661\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809657\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809652\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4594763\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595343\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809653\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12923398\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809654\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299957\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595347\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595332\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4595333\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809662\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809663\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809658\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12923399\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809659\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809664\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12923483\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16776\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16776|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/50/6949?source=related_link\">",
"      Protein C concentrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/51/31540?source=related_link\">",
"      Protein C concentrate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_27_39350="Aldesleukin: Pediatric drug information";
var content_f38_27_39350=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aldesleukin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?29/33/30231?source=see_link\">",
"    see \"Aldesleukin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/28/21957?source=see_link\">",
"    see \"Aldesleukin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12806506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Proleukin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Proleukin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Biological Response Modulator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/33/30231?source=see_link\">",
"      see \"Aldesleukin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A wide variety of dosages have been or are currently under investigation (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     AML: Children: (unlabeled use; Lange, 2008): 9 million international units (9 x 10",
"     <sup>",
"      6",
"     </sup>",
"     international units)/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion over 24 hours daily for 4 days; repeat 4 days later with 1.6 million international units (1.6 x 10",
"     <sup>",
"      6",
"     </sup>",
"     international units)/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion over 24 hours daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metastatic renal cell carcinoma and metastatic melanoma: Adults: I.V.: Initial: 600,000 international units/kg every 8 hours for a maximum of 14 doses; repeat after 9 days for a total of 28 doses per course; retreat if tumor shrinkage observed (and if no contraindications) at least 7 weeks after previous course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage modification for toxicity (Adults):",
"     </b>",
"     Hold or interrupt a dose,",
"     <b>",
"      do not dose reduce",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular toxicity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Withhold dose for atrial fibrillation, supraventricular tachycardia, or bradycardia that is persistent, recurrent, or requires treatment; may resume when asymptomatic with full recovery to normal sinus rhythm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Withhold dose for systolic BP &lt;90 mm Hg (with increasing pressor requirements); may resume treatment when systolic BP &ge;90 mm Hg and stable or pressor requirements improve",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Withhold dose for any ECG change consistent with MI, ischemia, myocarditis (with or without chest pain), or suspected cardiac ischemia; may resume when asymptomatic, MI/myocarditis have been ruled out, suspicion of angina is low, or there is no evidence of ventricular hypokinesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CNS toxicity: Withhold dose for mental status change, including moderate confusion or agitation; may resume when resolved completely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic toxicity: Withhold dose for bullous dermatitis or marked worsening of pre-existing skin condition; may treat with antihistamines or topical products (do not use topical steroids); may resume with resolution of all signs of bullous dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Withhold dose for stool guaiac repeatedly &gt;3-4+; may resume with negative stool guaiac",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatotoxicity: Withhold dose and discontinue treatment for balance of cycle for signs of hepatic failure, encephalopathy, increasing ascites, liver pain, hypoglycemia; may initiate a new course, if indicated, only after at least 7 weeks past resolution of all signs of hepatic failure (including hospital discharge)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infection: Withhold dose for sepsis syndrome, clinically unstable; may resume when sepsis syndrome has resolved, patient is clinically stable, and infection is under treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal toxicity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Withhold dose for serum creatinine &gt;4.5 mg/dL (or &ge;4 mg/dL with severe volume overload, acidosis, or hyperkalemia); may resume when &lt;4 mg/dL and fluid/electrolyte status is stable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Withhold dose for persistent oliguria or urine output &lt;10 mL/hour for 16-24 hours with rising serum creatinine; may resume when urine output &gt;10 mL/hour with serum creatinine decrease of &gt;1.5 mg/dL or normalization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory toxicity: Withhold dose for oxygen saturation &lt;90%; may resume when &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Retreatment with aldesleukin is",
"     <b>",
"      contraindicated",
"     </b>",
"     with the following toxicities: Sustained ventricular tachycardia (&ge;5 beats), refractory uncontrolled or unresponsive cardiac arrhythmias, recurrent chest pain with ECG changes consistent with angina or MI, cardiac tamponade, intubation &gt;72 hours, renal failure requiring dialysis for &gt;72 hours, coma or toxic psychosis lasting &gt;48 hours, repetitive or refractory seizures, bowel ischemia/perforation, or GI bleeding requiring surgery",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proleukin&reg;: 22 x 10",
"     <sup>",
"      6",
"     </sup>",
"     units [18 million units/mL = 1.1 mg/mL when reconstituted]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Reconstitute with 1.2 mL preservative-free SWI (swirl, do not shake); resulting concentration is 18 million (18 x 10",
"     <sup>",
"      6",
"     </sup>",
"     ) international units/mL [1.1 mg/mL]; further dilute dosage in D",
"     <sub>",
"      5",
"     </sub>",
"     W [plastic (polyvinyl chloride) bags result in more consistent drug delivery and are recommended] to a final concentration between 0.49-1.1 million international units/mL (30-70 mcg/mL ) and infuse over 15 minutes; allow solution to reach room temperature prior to administration; for continuous infusions, dilute in D",
"     <sub>",
"      5",
"     </sub>",
"     W maintaining the same final concentration; final dilutions &lt;0.49 million international units/mL (30 mcg/mL) or &gt;1.1 million international units/mL (70 mcg/mL) have shown increased variability in drug stability and bioactivity and should be avoided; addition of 0.1% albumin has been used to increase stability and decrease the extent of sorption if low final concentrations cannot be avoided; do not use in-line filter when administering; flush line before and after with D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ: Reconstituted solution may be administered subcutaneously without further dilution (",
"     <b>",
"      Note",
"     </b>",
"     : Subcutaneous administration is a non-FDA approved route)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F131293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, amphotericin B, calcium gluconate, diphenhydramine, fat emulsion 20%, fluconazole, foscarnet, gentamicin, magnesium sulfate, metoclopramide, morphine, ondansetron, piperacillin, ranitidine, sulfamethoxazole and trimethoprim,  tobramycin, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Fluorouracil, ganciclovir, lorazepam, pentamidine, prochlorperazine edisylate, promethazine, sodium chloride",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dopamine, heparin sodium, potassium chloride.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in refrigerator; do not freeze; reconstituted solution is stable 48 hours in refrigerator or at room temperature; since aldesleukin contains no preservatives, refrigerated storage of the reconstituted solution is preferred; reconstituted solution packaged in tuberculin syringes for SubQ administration are stable 14 days refrigerated and 6 hours at room temperature; compatible",
"     <b>",
"      only",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     W; incompatible with sodium chloride solutions; do not mix with other medications; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic renal cell carcinoma and metastatic melanoma (FDA approved in adults); has been used in the treatment of acute myeloid leukemia (AML)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aldesleukin may be confused with oprelvekin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Proleukin&reg; may be confused with oprelvekin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F131292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, cardiac arrest, cardiovascular disorder (includes blood pressure and HF and ECG changes), edema, hypotension, MI, peripheral edema, supraventricular tachycardia, tachycardia, vasodilation, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, coma, confusion, dizziness, fever, malaise, pain, psychosis, somnolence, stupor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Exfoliative dermatitis, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, hypocalcemia, hypomagnesemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdomen enlarged, abdominal pain, anorexia, diarrhea, nausea, stomatitis, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, coagulation disorder (includes intravascular coagulopathy), leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, AST increased, hyperbilirubinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, anuria, creatinine increased, oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, cough, dyspnea; lung disorder (includes pulmonary congestion, rales, and rhonchi); respiratory disorder (includes acute respiratory distress syndrome, infiltrates and pulmonary changes); rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Antibody formation, infection, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic interstitial nephritis, anaphylaxis, angioedema, asthma, atrial arrhythmia, AV block, blindness (transient or permanent), bowel infarction/necrosis/perforation, bradycardia, bullous pemphigoid, capillary leak syndrome, cardiomyopathy, cellulitis, cerebral edema, cerebral lesions, cerebral vasculitis, cholecystitis, colitis, crescentic IgA glomerulonephritis, Crohn&rsquo;s disease exacerbation, delirium, depression (severe; leading to suicide), diabetes mellitus, duodenal ulcer, encephalopathy, endocarditis, extrapyramidal syndrome, hemorrhage (including cerebral, gastrointestinal, retroperitoneal, subarachnoid, subdural), hepatic failure, hepatitis, hepatosplenomegaly, hypertension, hyperuricemia, hypothermia, hyperthyroidism, inflammatory arthritis, injection site necrosis, insomnia, intestinal obstruction, intestinal perforation, leukocytosis, malignant hyperthermia, meningitis, myocardial ischemia, myocarditis, myopathy, myositis, neuralgia, neuritis, neuropathy, neutropenia, NPN increased, oculobulbar myasthenia gravis, optic neuritis, organ perfusion decreased, pancreatitis, pericardial effusion, pericarditis, peripheral gangrene, phlebitis, pneumonia, pneumothorax, pulmonary edema, pulmonary embolus, respiratory acidosis, respiratory arrest, respiratory failure, rhabdomyolysis, scleroderma, seizure, Stevens-Johnson syndrome, stroke, syncope, thrombosis, thyroiditis, tracheoesophageal fistula, transient ischemic attack, tubular necrosis, ventricular extrasystoles",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aldesleukin or any component; abnormal thallium stress test or pulmonary function tests; organ allografts (due to increased risk of rejection);",
"     <b>",
"      retreatment",
"     </b>",
"     in patients who have experienced sustained ventricular tachycardia (&ge;5 beats), cardiac rhythm disturbances not controlled or unresponsive to management, recurrent chest pain with ECG changes (consistent with angina or MI), intubation required &gt;72 hours, cardiac tamponade; renal dysfunction requiring dialysis &gt;72 hours, coma or toxic psychosis lasting &gt;48 hours, repetitive or difficult to control seizures, bowel ischemia/perforation, and GI bleeding requiring surgery",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution in patients with normal thallium stress tests and pulmonary functions tests who have a history of prior cardiac or pulmonary disease",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; intensive aldesleukin treatment is associated with impaired neutrophil function (reduced chemotaxis) and with an increased risk of disseminated infection (particularly with",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     ) including sepsis and bacterial endocarditis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; patients with indwelling central lines are particularly at increased risk of infection; treat pre-existing bacterial infections prior to initiation of aldesleukin therapy; standard supportive care during high-dose aldesleukin treatment includes acetaminophen to relieve fever and chills and an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist to reduce the risk of GI ulceration and/or bleeding; closely monitor for thyroid abnormalities; mental status changes (irritability, confusion, depression) can occur and may indicate bacteremia, sepsis, hypoperfusion, CNS malignancy, or CNS toxicity; use with caution in patients with known seizure disorders; use with caution in patients with autoimmune disease or inflammatory disorders; may exacerbate condition; exacerbation and/or new onset have been reported with aldesleukin and interferon alfa combination therapy; may impair hepatic  function; concomitant hepatotoxic agents may  increase the risk of hepatotoxicity; adults must have a serum creatinine &le;1.5 mg/dL prior to treatment; may impair renal function; concomitant nephrotoxic agents may increase the risk of renal toxicity; enhancement of cellular immune function may increase the risk of allograft rejection in transplant patients; an acute array of symptoms resembling aldesleukin adverse reactions (fever, chills, nausea, rash, pruritus, diarrhea, hypotension, edema and oliguria) were observed within 1-4 hours after iodinated contrast media administration, usually when given within 4 weeks after aldesleukin treatment, although  has been reported several months after aldesleukin treatment. Should be administered under the supervision of an experienced cancer chemotherapy physician in a facility with cardiopulmonary or intensive specialists and intensive care facilities available",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . High-dose aldesleukin therapy is associated with capillary leak syndrome (CLS), resulting in hypotension and reduced organ perfusion (occurring within 2-12 hours after start of treatment) which may be severe and fatal and is characterized by vascular tone loss and extravasation of plasma proteins and fluid into extravascular space",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; CLS may be associated with cardiac arrhythmias, angina, MI, respiratory insufficiency requiring intubation, GI bleeding or infarction, renal insufficiency, edema, and mental status changes; therapy should be restricted to patients with normal cardiac and pulmonary functions as defined by thallium stress and formal pulmonary function testing. Monitor fluid status and organ perfusion status carefully; consider fluids and/or pressor agents to maintain organ perfusion. Withhold treatment for signs of organ failure (due to hypoperfusion), altered mental status, reduced urine output, systolic BP &lt;90 mm Hg (in adults), or cardiac arrhythmia. Once blood pressure is normalized, may consider diuretics for excessive weight gain/edema. Recovery from CLS generally begins soon after treatment cessation. Hold aldesleukin administration in patients developing moderate to severe lethargy or somnolence as continued administration may result in coma",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; may exacerbate disease symptoms in patients with clinically unrecognized or untreated CNS metastases thoroughly evaluate and treat all patients with CNS metastases prior to therapy",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F131224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contrast Media (Non-ionic): May enhance the potential for allergic or hypersensitivity reactions to Aldesleukin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids: May diminish the antineoplastic effect of Aldesleukin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons (Alfa): May enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F131239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal toxicity and embryocidal effects were noted in animal studies. There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if benefits to the mother outweigh potential risk to the fetus. Contraception is recommended for fertile males or females using this medication.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline chest x-ray, pulmonary function tests and thallium stress study; CBC with differential, platelet counts, electrolytes, BUN, serum creatinine, hepatic enzymes, vital signs, weight, pulse oximetry, arterial blood gases (if pulmonary symptoms), fluid intake and output; cardiac monitoring (in a patient with a decreased blood pressure, especially systolic BP &lt;90 mm Hg); ECG if an abnormal complex or rhythm is seen; monitor for change in mental status, and for signs of infection",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aldesleukin, a human recombinant interleukin-2 product, promotes proliferation, differentiation, and recruitment of T and B cells, natural killer cells, and thymocytes; also causes cytolytic activity in some lymphocytes and subsequent interactions between lymphokine-activated killer cells and tumor-infiltrating lymphocytes; causes multiple immunological effects including activation of cellular immunity with lymphocytosis, eosinophilia, and thrombocytopenia; production of cytokines (including tumor necrosis factor, interleukin-1), and inhibition of tumor growth",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Not absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Primarily into plasma, lymphocytes, lungs, liver, kidney, and spleen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 4-7 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized to amino acids in the cells lining the proximal convoluted tubules of the kidney",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Distribution: 14 &plusmn; 6 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Elimination: 51 &plusmn; 11 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Distribution: 6-27 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Elimination: 85 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: SubQ: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Clearance: Adults: 7.2-16.1 L/hour",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     18 x 10",
"     <sup>",
"      6",
"     </sup>",
"     int. units = 1.1 mg protein",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bergmann L, Heil G, Kolbe K, et al, \"Interleukin-2 Bolus Infusion as Late Consolidation Therapy in 2nd Remission of Acute Myeloblastic Leukemia,\"",
"      <i>",
"       Leuk Lymphoma",
"      </i>",
"      , 1995, 16(3-4):271-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/27/39350/abstract-text/7719235/pubmed\" id=\"7719235\" target=\"_blank\">",
"        7719235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lange BJ, Smith FO, Feusner J, et al, \"Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for Untreated Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(3):1044-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/27/39350/abstract-text/18000167/pubmed\" id=\"18000167\" target=\"_blank\">",
"        18000167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sievers EL, Lange BJ, Sondel PM, et al, &ldquo;Feasibility, Toxicity, and Biologic Response of Interleukin-2 After Consolidation Chemotherapy for Acute Myelogenous Leukemia: A Report From the Children's Cancer Group,&rdquo;",
"      <i>",
"       J Clin Oncol,",
"      </i>",
"      1998, 16(3):914-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/27/39350/abstract-text/9508173/pubmed\" id=\"9508173\" target=\"_blank\">",
"        9508173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whittington R and Faulds D, &ldquo;Interleukin-2: A Review of Its Pharmacological Properties and Therapeutic Use in Patients With Cancer,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1993, 46(3):446-514.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/27/39350/abstract-text/7693434/pubmed\" id=\"7693434\" target=\"_blank\">",
"        7693434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13299 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39350=[""].join("\n");
var outline_f38_27_39350=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708605\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806506\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131251\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056354\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056347\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131230\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131215\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056358\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131293\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056350\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056357\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131296\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131292\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056361\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056346\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056345\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298698\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131224\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131226\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131239\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056353\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056344\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056360\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056362\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13299\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13299|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/33/30231?source=related_link\">",
"      Aldesleukin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/28/21957?source=related_link\">",
"      Aldesleukin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_27_39351="COX-2 selective inhibitors: Adverse cardiovascular effects";
var content_f38_27_39351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   COX-2 selective inhibitors: Adverse cardiovascular effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/27/39351/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39351/contributors\">",
"     Daniel H Solomon, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/27/39351/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39351/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39351/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/27/39351/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39351/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/27/39351/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary effect of the nonsteroidal antiinflammatory drugs (NSAIDs) is to inhibit cyclooxygenase (COX or prostaglandin synthase - PGHS), thereby impairing the ultimate transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes (",
"    <a class=\"graphic graphic_figure graphicRef66146 \" href=\"mobipreview.htm?33/29/34269\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two related isoforms of the COX enzyme have been described: COX-1 (PGHS-1); and COX-2 (PGHS-2). Selective COX-2 inhibiting drugs have at least a 200 to 300-fold selectivity for inhibition of COX-2 over COX-1 at the defined therapeutic doses (",
"    <a class=\"graphic graphic_figure graphicRef82145 \" href=\"mobipreview.htm?5/51/5950\">",
"     figure 2",
"    </a>",
"    ). The differences between these isoforms are discussed in detail elsewhere, but will be summarized briefly here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      COX-1 is expressed in most tissues, but variably. It is described as a \"housekeeping\" enzyme, regulating normal cellular processes (such as gastric cytoprotection, vascular homeostasis, platelet aggregation, and kidney function). COX-1 activity is stimulated by hormones or growth factors.",
"     </li>",
"     <li>",
"      COX-2 is constitutively expressed in the brain, kidney, bone, and probably in the female reproductive system. Its expression at other sites, including the cardiovascular system, is increased during states of inflammation or, experimentally, in response to mitogenic stimuli.",
"     </li>",
"     <li>",
"      Both COX isoforms are regulated by physiologic stimuli. Increased expression of COX-2 mRNA and protein has been noted in patients with hypertension, heart failure, and diabetic nephropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, differences in a given non-selective NSAID (nsNSAID) or selective COX-2 inhibitor's (coxib) toxicity may in part be due to the extent to which it inhibits an isoform of cyclooxygenase. A presumed advantage of the coxibs was a reduction in gastrointestinal toxicity compared to nsNSAIDs. However, an increased risk of ischemic cardiovascular disease has been described with rofecoxib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , and valdecoxib. Not enough data are available to be certain, but a risk may also be present with etoricoxib and lumiracoxib.",
"   </p>",
"   <p>",
"    The adverse cardiovascular effects of selective COX-2 inhibitors will be reviewed here. An overview of the therapeutic use of agents in this class and the cardiovascular effects of the nonselective NSAIDs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ISCHEMIC CARDIOVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the COX-2 selective inhibitors appear to have potential cardiovascular risk that may be dose-dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/3\">",
"     3",
"    </a>",
"    ]. The magnitude of the risk may differ between agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/4\">",
"     4",
"    </a>",
"    ]. As an example of dose-dependence, a retrospective study suggested that concurrent therapy with low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may have mitigated the risk of myocardial infarction associated with use of low dose rofecoxib, but not for doses higher than 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/5\">",
"     5",
"    </a>",
"    ]. The issue of concomitant aspirin use was also addressed in the TARGET trial but the number of events was too small to have confidence in the results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/6\">",
"     6",
"    </a>",
"    ]. The effects of individual agents are discussed below.",
"   </p>",
"   <p>",
"    Selective COX-2 inhibition is associated with reduced prostaglandin I2 (PGI2 or prostacyclin) production by vascular endothelium with little or no inhibition of potentially prothrombotic platelet thromboxane A2 production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/7\">",
"     7",
"    </a>",
"    ]. The relatively selective reduction in prostacyclin activity could predispose to endothelial injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, selective COX-2 inhibition, as well as nonselective inhibition of COX, elevates blood pressure. These are two of several proposed links between these agents and ischemic cardiovascular events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rofecoxib",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmaceutical manufacturer that developed rofecoxib withdrew the drug from the worldwide market in 2004, because of evidence of a significant increase in the risk of thrombotic cardiovascular events, such as myocardial infarction or stroke, associated with its use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/9\">",
"     9",
"    </a>",
"    ]. However, it may still be available in some countries. The decision to withdraw the drug was based upon data from a study of rofecoxib in the prevention of adenomatous colonic polyps (APPROVe) trial in which 2586 patients were randomly assigned to rofecoxib (25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo with a planned follow-up of three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/10\">",
"     10",
"    </a>",
"    ]. Safety monitoring indicated a significant difference in the incidence of thrombotic cardiovascular events (eg, myocardial infarction, stroke). The rates of thrombotic events per 100 patient years in the rofecoxib group was 1.5 per 100 patient years and 0.78 per 100 patient years in the placebo groups (RR 1.92, 95% CI 1.19-3.11). This represented an excess of 0.72 events per 100 patient years among patients taking rofecoxib compared with placebo. Thus, for every 139 patients treated for one year, one additional cardiovascular event occurred during APPROVe.",
"   </p>",
"   <p>",
"    A similar increase in relative risk of myocardial infarction (RR 2.24, 95% CI 1.24-4.02) or thrombotic cardiovascular events (RR 2.66, 95% CI 1.03-6.86) with rofecoxib therapy was noted in a 2004 meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/11\">",
"     11",
"    </a>",
"    ] and in a randomized trial of rofecoxib versus placebo for secondary prevention of colon cancer that was published after the 2004 meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/12\">",
"     12",
"    </a>",
"    ]. Findings resembling these were also observed in a 2011 network meta-analysis of large randomized trials involving rofecoxib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , lumiracoxib, etoricoxib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ; in which rofecoxib exhibited the highest risk of myocardial infarction compared with placebo of all the NSAIDs studied (RR 2.12, 95% CI 1.26-3.56) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/4\">",
"     4",
"    </a>",
"    ]. The increase in cardiovascular risk may be greater with rofecoxib doses above 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between the duration of use of rofecoxib and the risk of MI is uncertain, as is the duration risk, but some evidence suggests that risk increases early with use and can remain elevated after the drug is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. A nationwide Danish cohort study of patients receiving NSAIDs following a first myocardial infarction (MI) found a significantly increased risk of death and recurrent MI among the 3914 patients who received prescriptions for rofecoxib subsequent to the hospitalization, beginning within 7 to 14 days of starting the drug, compared with patients who did not receive subsequent NSAIDs (hazard ratio 2.27, 95% CI 1.69-3.04) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/16\">",
"     16",
"    </a>",
"    ]. Risk was nonsignificantly elevated within 0 to 7 days, persistently elevated during therapy, and remained elevated following its discontinuation.",
"   </p>",
"   <p>",
"    In elderly patients, an increased risk may have been associated with the first prescription of rofecoxib. This was the conclusion of a Canadian case-control study of 239 patients all aged &gt;65 years; first time users of rofecoxib (27 percent of users) had a significantly increased risk of acute myocardial infarction while longer term users did not (adjusted rate ratios of 1.67, 95% CI 1.21-2.30 and 1.17, 95% CI 0.98-1.43, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, the final analysis of APPROVe trial found that the risk with rofecoxib became elevated early and remained elevated even after discontinuation of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/17\">",
"     17",
"    </a>",
"    ]. Continued risk after drug discontinuation was also seen in a randomized trial that examined whether rofecoxib delayed progression of Alzheimer&rsquo;s disease in patients with mild cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/18\">",
"     18",
"    </a>",
"    ]. The duration of sustained risk following drug discontinuation is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Valdecoxib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two trials were conducted using valdecoxib and its intravenous prodrug (parecoxib) for post-CABG patients. In one study, 462 patients who had CABG surgery were randomly assigned (in a 2:1 ratio) to receive parecoxib (40 mg intravenously twice daily for three days, followed by oral valdecoxib at the same dose) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/20\">",
"     20",
"    </a>",
"    ]. There were six MIs with a trend toward a higher rate in those receiving parecoxib (1.6 versus 0.7 percent with placebo).",
"   </p>",
"   <p>",
"    A second study randomly assigned 1671 patients to receive intravenous parecoxib or placebo for three days after CABG followed by oral valdecoxib or placebo for 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/21\">",
"     21",
"    </a>",
"    ]. The resulting placebo-placebo, placebo-valdecoxib, and parecoxib-valdecoxib groups, all of whom were also receiving low-dose aspirin, were followed for up to 30 days. Cardiovascular events occurred in a significantly higher proportion of those who received parecoxib and valdecoxib than those who only received placebo (intravenously and orally); (2.0 versus 0.5 percent, RR 3.7, 95% CI 1.0-13.5).",
"   </p>",
"   <p>",
"    The cardiovascular safety of valdecoxib was assessed in a study that pooled results from 10 clinical trials that included nearly 8000 subjects, and compared the incidence of cardiovascular events in patients taking valdecoxib (10 to 80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    to those of controls taking nonselective NSAIDs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/22\">",
"     22",
"    </a>",
"    ]. There were no significant between-group differences in crude or adjusted incidence rates for serious cardiovascular thrombotic events. In analyses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -using and nonaspirin-using subgroups, no significant differences in the risk of serious cardiovascular events were noted in those taking valdecoxib compared with nonselective NSAIDs.",
"   </p>",
"   <p>",
"    However, based upon the results of studies of parecoxib and valdecoxib in patients who had recent CABG surgery as well as concerns regarding Stevens-Johnson syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], the FDA requested the manufacturer to remove valdecoxib from the market in 2005.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Celecoxib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     Celecoxib",
"    </a>",
"    use conveys a small, dose-dependent risk of cardiovascular events similar to most nonselective NSAIDs. The risk of celecoxib relative to other NSAIDs was addressed in a 2011 network meta-analysis of large randomized trials involving celecoxib, rofecoxib, lumiracoxib, etoricoxib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ; the risk of myocardial infarction (MI) with celecoxib compared with placebo (RR, 1.35, 95% CI, 0.71-2.72) was lower than that for rofecoxib (RR 2.12, 95% CI 1.26-3.56) or ibuprofen (RR 1.61, 95% CI 0.50-5.77), but greater than naproxen (RR 0.82, 95% CI 0.37-1.67), which had the most favorable cardiovascular risk profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link&amp;anchor=H3#H3\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\", section on 'Effect on cardiovascular risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on adverse events from clinical trials directly comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    to other NSAIDs in patients with arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/23-25\">",
"     23-25",
"    </a>",
"    ], and from postmarketing population-based case-control studies of nonfatal MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/15,19,26\">",
"     15,19,26",
"    </a>",
"    ] and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/27-29\">",
"     27-29",
"    </a>",
"    ] suggested that celecoxib use might not be associated with a significant increase in risk of these serious cardiovascular events. In contrast, data from large long-term placebo-controlled trials of celecoxib to prevent adenomatous colonic polyps or treat other nonarthritic conditions suggest a dose-related increase in risk of cardiovascular death, nonfatal MI, or stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/30-33\">",
"     30-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adenomatous polyp prevention trial (APC trial), randomly assigned 2035 patients to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    (400 mg twice daily or 200 mg twice daily) or placebo; an analysis of cardiovascular safety at a mean follow-up of 33 months noted the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placebo - seven cardiovascular events among 676 subjects (nonfatal MI, stroke, heart failure, or cardiovascular death)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"       Celecoxib",
"      </a>",
"      200 mg twice daily - 18 events among 683 subjects (RR 2.6, 95% CI 1.1-6.1)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"       Celecoxib",
"      </a>",
"      400 mg twice daily - 23 events among 669 subjects (RR 3.4, 95% CI 1.5-7.9)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of the finding of a dose related increased risk of cardiovascular events and death due to cardiovascular causes, the data-safety monitoring board discontinued the APC trial.",
"   </p>",
"   <p>",
"    A second long-term trial in patients with previous colonic polyps (PreSAP trial) randomly assigned 1561 subjects to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    (400 mg daily) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/31\">",
"     31",
"    </a>",
"    ]. Although the increased risk in the PreSAP trial was not statistically significant (2.5 versus 1.9 percent, RR 1.30, 95% CI 0.65-2.62), an analysis of data on cardiovascular events from the two placebo-controlled adenoma prevention trials (APC and PreSAP trials) concluded that there was a increase in serious cardiovascular events that may be dose related [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increase in risk was less for patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      200 mg twice daily (hazard ratio [HR] 2.6 [95% CI 1.1-6.1]) than for those taking 400 mg twice daily (HR 3.4 [95% CI 1.5-7.9]) or 400 mg daily (HR 1.3 [95%CI 0.6-2.6]).",
"     </li>",
"     <li>",
"      An increase in blood pressure that was statistically significant was noted that also appeared to be dose related with the twice daily administration of a 200 mg or 400 mg dose, but not with once daily dosing of 400 mg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardiovascular risk may increase with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    use soon after it is initiated in patients with known coronary artery disease. A nationwide Danish cohort study of patients receiving NSAIDs following a first myocardial infarction (MI) found a significantly increased risk of death and recurrent MI among the 4000 patients who received prescriptions for celecoxib subsequent to the hospitalization, beginning within 14 to 30 days of starting the drug, compared with patients who did not receive subsequent NSAIDs (hazard ratio 1.90, 95% CI 1.46-2.48) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/16\">",
"     16",
"    </a>",
"    ]. Risk was nonsignificantly elevated within 0 to 7 days, and persistently elevated during therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lumiracoxib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumiracoxib appears to convey cardiovascular risk comparable to other NSAIDs. The risk of lumiracoxib relative to other NSAIDs and placebo was addressed in a 2011 network meta-analysis of large randomized trials involving lumiracoxib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , rofecoxib, etoricoxib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ; the risk of myocardial infarction with lumiracoxib compared with placebo (RR, 2.00, 95% CI, 0.71-6.21) was similar to that for rofecoxib (RR 2.12, 95% CI 1.26-3.56), and greater than the other NSAIDs, although the results for lumiracoxib are limited by their imprecision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cardiovascular safety of lumiracoxib was assessed directly in the TARGET trial, in which 18,325 patients with osteoarthritis were randomly assigned to lumiracoxib (400 mg once a day),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (500 mg twice daily), or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (800 mg three times a day) and followed for one year for cardiovascular events (MI, stroke, or cardiac death) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/6\">",
"     6",
"    </a>",
"    ]. The principal results in the lumiracoxib and NSAID groups were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The event rates for lumiracoxib and NSAIDs were not significantly different (0.86 and 0.75 per 100 patient years). After adjustment for cardiovascular risk factors, there was no significant increase in risk (HR 1.14, 95% CI 0.78-1.66).",
"     </li>",
"     <li>",
"      When lumiracoxib was compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      , the relative risk was increased but did not reach statistical significance (HR 1.5, 95% CI 0.9-2.4).",
"     </li>",
"     <li>",
"      Prior to randomization, patients in the TARGET trial were stratified for use of low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ; preplanned analyses of non-aspirin and aspirin-using subgroups did not show any statistically significant differences in event rates or MI rates among those using lumiracoxib or NSAIDs in either subgroup.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were a relatively small number of patients who were at high risk for MI (since patients with prior MI, stroke, coronary bypass grafting, angioplasty or stenting, angina, or significant heart failure were excluded) and there was a lower than expected number of events. As a result, the TARGET trial may have not been able to detect a small difference in risk of cardiovascular outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Etoricoxib",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular safety of etoricoxib was evaluated in the MEDAL program, which was a prespecified analysis of three separate trials comparing etoricoxib with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/34\">",
"     34",
"    </a>",
"    ]. The risk of thrombotic cardiovascular events for etoricoxib was similar to that of diclofenac. Interpretation of these results is problematic, since diclofenac may be associated with an increased risk of cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/4,35\">",
"     4,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observational studies have evaluated the effect of COX-2 selective agents in patients without [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/36\">",
"     36",
"    </a>",
"    ] or with preexisting heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The relationship between nonselective NSAIDs and HF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link&amp;anchor=H7#H7\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A cohort study used a large administrative database to examine the incidence of hospital admission with a primary diagnosis heart failure among NSAID-naive older (&ge;66 years) persons, the great majority of whom had no history of heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/36\">",
"     36",
"    </a>",
"    ]. New prescriptions for rofecoxib and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    were issued to 14,583 and 18,908 patients, respectively, and the outcomes compared to those of 100,000 controls. The demographics and clinical characteristics of those receiving rofecoxib and celecoxib were similar.",
"   </p>",
"   <p>",
"    The crude rates of hospitalization for heart failure per 100 patient-years of exposure were 0.9 for the controls, 2.4 for the rofecoxib-treated and 1.3 for the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    -treated patients. After adjusting for potential confounding risk factors, the risk of hospitalization with heart failure compared to controls was significantly higher in patients treated with rofecoxib (adjusted rate ratio 1.8 [95% CI 1.5-2.2]) but not celecoxib (adjusted rate ratio 1.0 [95% CI 0.8-1.3]).",
"   </p>",
"   <p>",
"    The effect of NSAIDs on mortality in patients with preexisting HF was evaluated in an observational study of 36,354 patients who received at least one prescription of a nonselective or COX-2 selective NSAID following a first hospitalization for heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/37\">",
"     37",
"    </a>",
"    ]. There was a dose-dependent increase in risk of death, which was highest with rofecoxib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    (adjusted HR 1.70 to 2.08). High doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (&gt;1200 mg daily) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (&gt;500 mg daily), but not lower doses, were also associated with an increased risk of death (adjusted HR 1.31 and 1.22, respectively, for high doses).",
"   </p>",
"   <p>",
"    In view of these findings and the known increased risk of acute renal failure when selective COX-2 inhibitors are given to patients with heart failure, this class of drugs should be used with caution, if at all, in patients with established heart failure. Conversely, patients without a prior history of heart failure, should be suspected of having drug-induced disease if symptoms or signs of heart failure develop during use of a selective COX-2 inhibitor or nonselective NSAID. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs, both nonselective and COX-2-selective, can raise blood pressure. The effect is heterogeneous among the COX-2 selective agents. A 2005 meta-analysis of 19 randomized trials of COX-2 selective agents involving 45,461 patients noted a statistically significant effect on the incidence of hypertension in clinical trials only among those who received rofecoxib when compared with placebo (RR 2.6, 95% CI 1.4-4.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/39\">",
"     39",
"    </a>",
"    ]. The weighted mean difference in blood pressure attributed to use of a COX-2 selective agent when compared to placebo was greatest for rofecoxib; a 5.66 mmHg increase in systolic blood pressure compared to placebo. Changes in systolic blood pressure were less for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , 2.6 mmHg. However, celecoxib was associated with an increase in diastolic blood pressure of 0.99 mmHg, whereas rofecoxib was not.",
"   </p>",
"   <p>",
"    In a 2009 update of this meta-analysis, rofecoxib and etoricoxib were associated with a relative risk of new hypertension compared with placebo (relative risk 1.87 and 1.52, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/40\">",
"     40",
"    </a>",
"    ]. In contrast, celecoxib, valdecoxib, and lumiracoxib appeared to have little effect on blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42674?source=see_link\">",
"     \"NSAIDs and acetaminophen: Effects on blood pressure and hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective COX-2 inhibitors when used in clinical trials have been associated with the development of lower extremity edema at rates similar to those for nonselective NSAIDs. The incidence of edema ranged from approximately 1 to 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/7,41-44\">",
"     7,41-44",
"    </a>",
"    ]. In the randomized controlled trial comparing rofecoxib with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    cited above, the incidence of edema was significantly higher with rofecoxib (9.5 versus 4.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/41\">",
"     41",
"    </a>",
"    ]. A survey-based postmarketing study found rofecoxib users to be 1.4-fold more likely than celecoxib users to self-report the presence of edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39351/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/1\">",
"      Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/2\">",
"      Khan KN, Stanfield KM, Harris RK, Baron DA. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren Fail 2001; 23:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/3\">",
"      Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/4\">",
"      Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342:c7086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/5\">",
"      L&eacute;vesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/6\">",
"      Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/7\">",
"      Caughey GE, Cleland LG, Penglis PS, et al. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001; 167:2831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/8\">",
"      Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296:539.",
"     </a>",
"    </li>",
"    <li>",
"     Merck news release. www.merck.com/newsroom/press_releases/product/2004_0930.html accessed September 30, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/10\">",
"      Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/11\">",
"      J&uuml;ni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/12\">",
"      Kerr DJ, Dunn JA, Langman MJ, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007; 357:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/13\">",
"      Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/14\">",
"      Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/15\">",
"      Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/16\">",
"      Schjerning Olsen AM, Fosb&oslash;l EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/17\">",
"      Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008; 372:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/18\">",
"      Ross JS, Madigan D, Konstam MA, et al. Persistence of cardiovascular risk after rofecoxib discontinuation. Arch Intern Med 2010; 170:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/19\">",
"      L&eacute;vesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 2006; 174:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/20\">",
"      Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/21\">",
"      Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/22\">",
"      White WB, Strand V, Roberts R, Whelton A. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004; 11:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/23\">",
"      Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/24\">",
"      White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003; 92:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/25\">",
"      Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006; 119:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/26\">",
"      Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/27\">",
"      Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 2006; 37:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/28\">",
"      Haag MD, Bos MJ, Hofman A, et al. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 2008; 168:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/29\">",
"      Roumie CL, Mitchel EF Jr, Kaltenbach L, et al. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 2008; 39:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/30\">",
"      Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/31\">",
"      Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/32\">",
"      Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006; 114:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/33\">",
"      Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/34\">",
"      Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/35\">",
"      McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/36\">",
"      Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/37\">",
"      Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009; 169:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/38\">",
"      Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 2005; 330:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/39\">",
"      Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/40\">",
"      Chan CC, Reid CM, Aw TJ, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/41\">",
"      Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/42\">",
"      Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/43\">",
"      Alsalameh S, Burian M, Mahr G, et al. Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 2003; 17:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/44\">",
"      Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004; 26:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39351/abstract/45\">",
"      Wolfe F, Zhao S, Pettitt D. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol 2004; 31:1143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7981 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-C33EB2799F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39351=[""].join("\n");
var outline_f38_27_39351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ISCHEMIC CARDIOVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rofecoxib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Valdecoxib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Celecoxib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lumiracoxib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Etoricoxib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EDEMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7981\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7981|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/29/34269\" title=\"figure 1\">",
"      Prostaglandin synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/51/5950\" title=\"figure 2\">",
"      COX 1 versus COX 2 inhibition",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42674?source=related_link\">",
"      NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_27_39352="End-stage renal disease due to lupus nephritis";
var content_f38_27_39352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   End-stage renal disease due to lupus nephritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/27/39352/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39352/contributors\">",
"     Andrew S Bomback, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39352/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/27/39352/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39352/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39352/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39352/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/27/39352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39352/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/27/39352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 to 30 percent of patients with proliferative lupus nephritis progress to end-stage renal disease (ESRD), depending upon the severity of the disease, ancestral and socio-economic factors, noncompliance, and the response to initial treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Overall prognosis has improved in recent decades, perhaps due to the use of combined immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/3\">",
"     3",
"    </a>",
"    ]. However a report using data from the United States Renal Data System from 1995 to 2006 found increases in the standardized incidence of ESRD due to lupus nephritis in younger individuals (ie, age &lt;40 years), African-Americans and American Indians, and in individuals from the southeastern United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to ESRD in patients with lupus nephritis are reviewed here. These include complete or partial resolution of lupus activity in most patients and issues related to dialysis and renal transplantation.",
"   </p>",
"   <p>",
"    The treatment of lupus nephritis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical features and therapy of membranous lupus nephritis\", section on 'Therapeutic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9521747\">",
"    <span class=\"h1\">",
"     LUPUS ACTIVITY IN ESRD PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of end-stage renal disease (ESRD) is, in many patients, associated with gradual complete or partial resolution of the extrarenal manifestations of lupus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. How this occurs is not well understood.",
"   </p>",
"   <p>",
"    In a review of the literature, the percentage of patients with active (eg,",
"    <span class=\"nowrap\">",
"     arthritis/arthralgias,",
"    </span>",
"    rash and serositis) clinical lupus fell from 55 percent at the onset of dialysis to 6.5 percent in the fifth year and, in a small number of patients, to zero percent in the tenth year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/5\">",
"     5",
"    </a>",
"    ]. During this time span, the incidence of serologic activity (defined as the percentage of patients with two or more abnormal studies for ANA, anti-dsDNA, CH50 or C3) fell from 80 to 22 percent. In addition, most patients in whom the disease remains active have only mild to moderate symptoms. As an example, in one study, the number of patients with severe extrarenal disease activity (defined by a Systemic Lupus Erythematosus Disease Activity Index [SLE-DAI] &gt;10), declined from 17 to 3 after the initiation of dialysis and to 0 after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these observations, some investigators contend that the observation that lupus becomes quiescent with the onset of ESRD is exaggerated and that dialysis patients continue to have extrarenal manifestations including alopecia, arthritis, myositis, pleuritis, pericarditis, fever, and vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The contradictory observations concerning the degree to which disease activity abates after the onset of ESRD may be due in part to varying patient population and the clinical speciality of the examining physician (ie, nephrology versus rheumatology versus dermatology). In a study of 19 patients with lupus who were undergoing dialysis (12 patients) or had undergone renal transplantation (7 patients), disease activity using combined clinical and serological data was increased after the institution of dialysis but",
"    <strong>",
"     not",
"    </strong>",
"    after renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/11\">",
"     11",
"    </a>",
"    ]. A probable contributing factor is that 16 of the 19 patients were black women, a subgroup that has a higher incidence of both persistent lupus activity after the initiation of dialysis and recurrent lupus nephritis in the renal transplant. (See",
"    <a class=\"local\" href=\"#H480100821\">",
"     'Incidence'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS IN DIALYSIS PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient survival with either hemodialysis or continuous ambulatory peritoneal dialysis appears to be similar to that in the general population of patients with end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/6,9\">",
"     6,9",
"    </a>",
"    ] and has not changed significantly over the past two decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    .) There is, however, an increased risk of death during the first three months of dialysis, due primarily to sepsis and other complications of high-dose glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, peritoneal dialysis is associated with an increased risk of peritonitis and non-catheter-related infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ISSUES RELATED TO RENAL TRANSPLANTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29563535\">",
"    <span class=\"h2\">",
"     Allograft survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/5,7,8,14-21\">",
"     5,7,8,14-21",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], studies have found that overall 5- and 10- year graft survival rates are similar among patients with lupus compared with those in patients with other diseases. This was best shown in a long-term study of 77 adults with lupus nephritis and 154 matched non-lupus glomerulonephritis control patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/20\">",
"     20",
"    </a>",
"    ]. The 1-, 5-, and 10-year death-censored graft survival was similar between groups (88, 81, and 71 percent in lupus patients and 91, 83 and 74 percent in control patients, respectively). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H257989415\">",
"    <span class=\"h2\">",
"     Timing of transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been recommended that all patients with ESRD due to lupus nephritis be dialyzed for at least three to six months and be on less than 10 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day, before renal transplantation is performed, particularly among those with relatively rapid progression to ESRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/6,8,24\">",
"     6,8,24",
"    </a>",
"    ]. There are two potential advantages to this regimen: it may lead to a further reduction in lupus activity; and it gives patients with relatively acute renal failure time to recover sufficient renal function for dialysis to be discontinued, which removes the indication for transplantation.",
"   </p>",
"   <p>",
"    <br/>",
"    Some have recommended that renal transplantation be delayed until patients with ESRD due to lupus nephritis have undergone dialysis for at least one year. However, a beneficial effect of this approach on graft outcomes has not been proven. This issue was addressed in a report of 32 patients with ESRD due to lupus nephritis who underwent renal transplantation after a period of dialysis, 22 for less than one year. The duration of prior dialysis did not affect renal outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H257989422\">",
"    <span class=\"h2\">",
"     Evaluation for antiphospholipid antibodies prior to transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lupus patients should be screened for the presence of antiphospholipid antibodies prior to renal transplant, as renal transplant recipients with underlying lupus who have antiphospholipid antibodies may be at increased risk for thrombotic events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H475340\">",
"    <span class=\"h2\">",
"     Immunosuppressive therapy for antirejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction and maintenance immunosuppressive regimens to prevent rejection are the same among patients with ESRD from lupus nephritis as among patients with other forms of renal disease, although the use of steroid-free regimens among patients with ESRD due to lupus nephritis is not standard practice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Recurrent lupus nephritis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H480100821\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported rate of clinically apparent recurrent lupus nephritis in the renal transplant is 2 to 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/5,21,25-29\">",
"     5,21,25-29",
"    </a>",
"    ]. The rate of recurrent symptoms of systemic lupus is also low at about 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/5\">",
"     5",
"    </a>",
"    ]. These low rates are thought to reflect diminished immunologic activity.",
"   </p>",
"   <p>",
"    In the largest reported series, the frequency and outcome of recurrence was analyzed using data from the United Network for Organ Sharing (UNOS) files [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/21\">",
"     21",
"    </a>",
"    ]. Among 6850 patients with end-stage renal disease (ESRD) due to lupus nephritis who received a transplant between 1987 and 2006, 167 (2.4 percent) had recurrent lupus nephritis. Rejection (categorized by individual transplant centers as hyperacute, acute and chronic by histology and resulting in graft failure in 86 percent) was much more common, occurring in 1770 patients (25.8 percent). Non-Hispanic blacks, females, and younger recipients (33 years or younger) were at increased risk for recurrence (odds ratio 1.88, 1.70 and 1.69, respectively). Similar risk factors have been noted in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher rates of recurrence have been reported in some later studies. This is due at least in part to the increased use of allograft biopsies and, in particular, the detection of subclinical recurrence by protocol biopsies. The following observations are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated biopsies of 41 renal transplant recipients with a history of ESRD due to lupus nephritis: 38 were surveillance biopsies (ie, performed as protocol) and three were performed for possible rejection or possible recurrent disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/30\">",
"       30",
"      </a>",
"      ]. Biopsy proven recurrence of lupus nephritis was present in 22 patients (54 percent), most of whom had subclinical disease that was pathologically classified as class I (minimal mesangial) or class II (mesangial proliferative) nephritis. In contrast, 34 patients (83 percent) had chronic allograft nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Classification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a report of 54 patients with lupus, 31 underwent transplant renal biopsy because of worsening renal function and proteinuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/31\">",
"       31",
"      </a>",
"      ]. Among 50 patients with at least 3 months of follow-up, recurrent lupus nephritis was noted in 15, resulting in a recurrence rate of 30 percent. However, the worsening renal function may have primarily reflected mechanisms other than recurrent lupus as suggested by the following observations. First, most patients had class II (mesangial proliferative) or class III (focal proliferative) disease; none had class IV (diffuse proliferative). Second, most patients had one or more other histologic findings that could have contributed to the worsening renal function, including acute rejection, chronic allograft nephropathy, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      nephrotoxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H480100944\">",
"    <span class=\"h3\">",
"     Clinical presentation and biopsy findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with recurrent lupus nephritis generally present with an increased serum creatinine above their usual baseline, new onset proteinuria of a variable degree and new onset hematuria on routine screening. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15258?source=see_link&amp;anchor=H25669040#H25669040\">",
"     \"Overview of care of the adult kidney transplant recipient\", section on 'Routine follow up and laboratory monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrent lupus nephritis can occur as early as the first week to as late as 16 years after transplantation (median 4.3 years in the large study cited above), with most episodes occurring during the first 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/21\">",
"     21",
"    </a>",
"    ]. On biopsy, the histologic lesion may be different, and is often less severe from that observed in the native kidney, as is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 177 patients with lupus nephritis and a renal transplant followed over a 30-year interval included 20 patients (11 percent) with recurrent nephritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/29\">",
"       29",
"      </a>",
"      ]. In the native kidneys, the predominant lesion was either a proliferative glomerulonephritis (class III or class IV, n = 10) or membranous nephropathy (class V, n = 6). In contrast, in the transplanted kidneys, the nephritis was most often only a mesangial lesion (class II, n = 12), with just three patients having proliferative lesions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Classification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mild disease is particularly likely when the recurrence is detected on protocol biopsy. In a report cited above, most of the patients had subclinical disease that was pathologically classified as class I (minimal mesangial) or class II (mesangial proliferative) nephritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of milder histologic lesions is compatible with the generally good long-term renal prognosis in patients with recurrent lupus nephritis. (See",
"    <a class=\"local\" href=\"#H21086407\">",
"     'Renal prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9521341\">",
"    <span class=\"h3\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serologic parameters, such as complement levels and titers of anti-double stranded DNA antibodies is not helpful in establishing the diagnosis. Serologic parameters are not an accurate assessment of disease activity and do not help in predicting disease recurrence in the allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/25\">",
"     25",
"    </a>",
"    ]. In a series of nine patients with recurrent lupus nephritis, for example, only three had serologic evidence of active lupus and only one had extrarenal symptoms (arthritis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21086538\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is suspected among patients who develop proteinuria, hematuria or an increased serum creatinine. The diagnosis is made by biopsy. Serologic tests including complement levels and titers of anti-double stranded DNA antibodies are not helpful in establishing the diagnosis.",
"   </p>",
"   <p>",
"    Among all transplant recipients who present with an elated serum creatinine we first ensure adequate hydration, measure a serum calcineurin concentration and obtain a renal ultrasound with evaluation for renal artery stenosis prior to performing a biopsy. Among patients who are well hydrated and have a normal calcineurin inhibitor concentration and ultrasound, we perform a biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2072?source=see_link&amp;anchor=H24#H24\">",
"     \"Differential diagnosis of renal allograft dysfunction\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, among transplant recipients who have a history of lupus nephritis, we perform a renal biopsy in the setting of abnormal protein excretion or hematuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87545593\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment consists of nonimmunosuppressive and immunosuppressive therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H587480215\">",
"    <span class=\"h4\">",
"     Nonimmunosuppressive treatment of recurrent nephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally treat all patients who have histopathologic changes of recurrent lupus nephritis and proteinuria that is &gt;500",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours with renin angiotensin system blockade (RAS).",
"   </p>",
"   <p>",
"    The rationale for treating with RAS inhibition is based upon studies in non-transplant patients with proteinuric CKD that have shown that RAS inhibition decreases the progression of renal disease. Most studies are of angiotensin converting enzyme (ACE) inhibitors but it seems likely that angiotensin receptor blockers have a similar renoprotective effect as ACE inhibitors in nondiabetic CKD. These data are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is less clear that RAS inhibition has a protective effect among proteinuric transplant recipients. The effects of ACE inhibitors or ARBs in kidney transplant recipients were best evaluated in a systematic review of 21 randomized trials with 1549 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/32\">",
"     32",
"    </a>",
"    ]. At a median follow-up of 27 months, these agents modestly decreased the GFR and proteinuria, but there were inadequate data to assess an effect on allograft and patient survival. A randomized trial published after the meta-analysis that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    to placebo among transplant recipients showed no difference in eGFR or creatinine at five years but the time to doubling of the creatinine was longer among losartan-treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/33\">",
"     33",
"    </a>",
"    ]. These data are discussed in depth elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link&amp;anchor=H23#H23\">",
"     \"Chronic renal allograft nephropathy\", section on 'Nonimmunologic interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of proteinuria that requires treatment with RAS inhibition is not clear. Most studies among non-transplant patients have only a clear cut benefit of ACE inhibitors and ARBs among patients with protein excretion &gt;1000",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    .) The KDOQI guidelines suggest the addition of an ACE inhibitor among patients with CKD with albumin excretion &gt;300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACE inhibitors and ARBs may cause hyperkalemia and decreased perfusion among transplant recipients. ACE inhibitors can also induce anemia in transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=see_link&amp;anchor=H20#H20\">",
"     \"Hypertension after renal transplantation\", section on 'ACE inhibitors/ARBs and other agents'",
"    </a>",
"    .)However, given that transplant recipients are generally closely followed and such side effects would be readily detected, we believe the potential benefit of RAS inhibitors in delaying the onset of ESRD among proteinuric patients outweighs the potential risk of a reversible decline in eGFR, hyperkalemia or anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H587480222\">",
"    <span class=\"h4\">",
"     Immunosuppressive treatment of recurrent nephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with recurrent lupus nephritis do not require any change in the immunosuppressive regimen that they are on to prevent rejection, particularly patients who have milder lesions on biopsy than they had on original presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selected patients may require immunosuppressive therapy directed at recurrent lupus nephritis. Among patients who have a histologic diagnosis of recurrent lupus nephritis and rapid deterioration of kidney function that cannot be explained by other factors such as chronic allograft nephropathy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    toxicity, or acute rejection, or who have proteinuria &gt;500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    accompanied by severe proliferative lesions on biopsy, we alter the immunosuppressive regimen that the patient is on for rejection prevention in order to treat recurrent disease.",
"   </p>",
"   <p>",
"    Treatment options for lupus nephritis in the native kidney primarily include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . There are no good studies that have examined the efficacy of these agents for recurrent lupus nephritis among transplant recipients. Thus our approach to treatment is entirely based upon studies of patients with lupus nephritis involving the native kidney. These studies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link&amp;anchor=H13#H13\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Induction therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment options include using one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increase the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil to 2 to 3",
"      <span class=\"nowrap\">",
"       g/day.",
"       <br/>",
"       <br/>",
"       OR",
"      </span>",
"     </li>",
"     <li>",
"      Administer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and discontinue the current antimetabolite (which is usually",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The optimal cyclophosphamide dose for the transplant recipient is not known and no studies have examined this issue. Based upon studies of lupus nephritis in the native kidney, and on our clinical experience, we use the same regimen as we use in the native kidney. For all patients, the cyclophosphamide dose is selected based upon ancestry. In African-Americans, Afro-Caribbeans, and Hispanics, we use a longer (higher-dose) course of cyclophosphamide (0.5 to 1",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      intravenous pulses monthly for six or seven months). In whites, we use a shorter (lower-dose) course of cyclophosphamide (six 500 mg intravenous pulses every two weeks), as was used in Euro-Lupus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/36\">",
"       36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Our clinical experience suggests that African-American, Afro-Caribbean, and Hispanic patients do not respond as well as white patients to shorter (lower-dose) cyclophosphamide induction regimens, such as the one used in the Euro-Lupus trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link&amp;anchor=H13#H13\">",
"       \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Induction therapy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Subsequent cyclophosphamide doses are selected based upon the leukocyte nadir. If the leukocyte nadir after the first pulse of cyclophosphamide (usually 10 to 14 days post-infusion) is less than",
"      <span class=\"nowrap\">",
"       4000/microL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the absolute neutrophil count is less than",
"      <span class=\"nowrap\">",
"       1500/microL,",
"      </span>",
"      the dose at the next infusion should be reduced by 0.25",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      body surface area or even transiently withheld if the counts are very low. If, on the other hand, the total white cell nadir is greater than",
"      <span class=\"nowrap\">",
"       4000/microL,",
"      </span>",
"      the absolute neutrophil count is greater than",
"      <span class=\"nowrap\">",
"       1500/microL,",
"      </span>",
"      and the patient has not improved, the cyclophosphamide dose at the next infusion may be increased by 0.25",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      body surface area. The maximum dose is 1",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      body surface area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients that are treated with an increase in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    dose or with the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    should also be treated with glucocorticoids. We generally give",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    7",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for three days followed by a tapering oral steroid regimen.",
"   </p>",
"   <p>",
"    For patients who have failed treatment with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , some clinicians give",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in addition to increasing mycophenolate to 3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and increasing glucocorticoids (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    7",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for three days followed by a tapering oral steroid regimen. There are no published studies that support the use of rituximab for recurrent lupus nephritis among transplant recipients. There are a few observational studies and case reports of the successful use of rituximab among patients with lupus nephritis involving the native kidney. These data are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=see_link&amp;anchor=H7#H7\">",
"     \"Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis\", section on 'Rituximab for cyclophosphamide and MMF resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for recurrent lupus nephritis is not known. Two authors (AB and GA) suggest that IF RITUXIMAB IS USED, one should use the same dose as has been studied for lupus nephritis of the native kidney (which is 1000 mg given on days 1 and 15) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/37\">",
"     37",
"    </a>",
"    ] or the same dose recommended for other glomerular diseases such as ANCA-associated glomerulonephritis and membranous nephropathy (which is 375",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per week for four weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/38\">",
"     38",
"    </a>",
"    ]. The section editor (DB) suggests giving one dose of rituximab 200 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When considering the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , one must keep in mind that long-term efficacy and toxicity have not been fully defined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21086407\">",
"    <span class=\"h3\">",
"     Renal prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of graft loss due to recurrent disease is low, being less than 2 to 4 percent over 5 to 10 years in most studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/31,40\">",
"     31,40",
"    </a>",
"    ]. This finding is consistent with the general decrease in lupus activity in patients who develop end-stage renal disease and in the less severe histologic findings than in the original disease as most patients have minimal mesangial (class I), mesangial proliferative (class II), or focal proliferative glomerulonephritis (class III), not diffuse proliferative disease (class IV) which is the most severe form of lupus nephritis and is associated with a worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In addition, the majority of patients who develop impaired renal function have one or more other histologic findings that could have contributed to progressive disease, including acute rejection, chronic allograft nephropathy, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    nephrotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9521747\">",
"     'Lupus activity in ESRD patients'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antiphospholipid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lupus patients should be screened for the presence of antiphospholipid antibodies prior to renal transplant, as renal transplant recipients with underlying lupus who have antiphospholipid antibodies may be at increased risk for thrombotic events.",
"   </p>",
"   <p>",
"    Patients with thromboembolic events should be treated with anticoagulation therapy, using a regimen similar to that for symptomatic antiphospholipid syndrome in general. The optimal therapy of patients with antiphospholipid antibodies but no history of a thrombotic event is not well defined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of the antiphospholipid syndrome\", section on 'SLE with aPL'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=see_link\">",
"     \"Antiphospholipid syndrome and the kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension, lipid abnormalities and accelerated atherosclerosis occur in many renal transplant recipients. In addition, lupus is associated with accelerated atherosclerosis independent of renal transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=see_link\">",
"     \"Coronary heart disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study cited above, the 5- and 10-year survival rates following renal transplantation were lower among 77 patients with lupus nephritis compared with 154 patients with non-lupus-related glomerulonephritis (83 versus 92 percent at 5 years and 71 versus 85 percent at 10 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/20\">",
"     20",
"    </a>",
"    ]. Cardiovascular events were the most common cause of death in the lupus patients (67 versus 40 percent in control patients).",
"   </p>",
"   <p>",
"    Aggressive treatment of all cardiovascular risk factors including hypertension and dyslipidemias is warranted in these patients given the increased risk of cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39352/abstract/8,40\">",
"     8,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=see_link&amp;anchor=H16#H16\">",
"     \"Hypertension after renal transplantation\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=see_link&amp;anchor=H10#H10\">",
"     \"Lipid abnormalities after renal transplantation\", section on 'Treatment of dyslipidemias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 10 to 30 percent of patients with proliferative lupus nephritis progress to end-stage renal disease (ESRD). Overall prognosis has improved in recent decades, perhaps due to the use of combined immunosuppression. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of ESRD is often though not always, associated with gradual complete or partial resolution of the extrarenal manifestations of lupus, although the underlying mechanism is unclear. (See",
"      <a class=\"local\" href=\"#H9521747\">",
"       'Lupus activity in ESRD patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient survival with either hemodialysis or continuous ambulatory peritoneal dialysis appears to be similar to that in the general population of patients with end-stage renal disease (ESRD), although there is an increased risk of death during the first three months of dialysis, due to sepsis and other complications of high-dose glucocorticoid therapy. There is an increased risk of peritonitis and non-catheter-related infection among peritoneal dialysis patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis in dialysis patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transplantation is a suitable option for patients with lupus nephritis. Overall 5- and 10-year graft survival rates are similar among patients with lupus compared with those among patients with other diseases. Patients with ESRD due to lupus nephritis should be dialyzed for at least three to six months and be on less than 10 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      per day prior to transplantation to allow for a possible reduction in lupus activity and a return in renal function. Lupus patients should be screened for the presence of antiphospholipid antibodies prior to renal transplant, as renal transplant recipients with underlying lupus who have antiphospholipid antibodies may be at increased risk for thrombotic events. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Issues related to renal transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lupus nephritis is reported to recur in the transplanted kidney in 2 to 11 percent of patients. Patients with recurrence generally present with an increased serum creatinine above their usual baseline, new onset proteinuria of a variable degree and new onset hematuria. Most episodes of recurrence occur in the first 10 years. Recurrent lupus nephritis is often more mild than the original disease was in the native kidney and has a good prognosis. The incidence of graft loss is less than 2 to 4 percent. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Recurrent lupus nephritis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of recurrent lupus nephritis is suspected among patients who develop proteinuria, hematuria or an increased serum creatinine. The diagnosis is made by biopsy. Prior to performing a biopsy, among all transplant recipients who present with an elated serum creatinine we first ensure adequate hydration, measure a serum calcineurin concentration and obtain a renal ultrasound with evaluation for renal artery stenosis. In addition, among transplant recipients who have a history of lupus nephritis, we perform a renal biopsy in the setting of abnormal protein excretion or hematuria. (See",
"      <a class=\"local\" href=\"#H21086538\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of recurrent lupus nephritis depends on the clinical presentation and the histology. Among all patients who have recurrent disease and proteinuria &gt;500",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      we suggest treating with either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H587480215\">",
"       'Nonimmunosuppressive treatment of recurrent nephritis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Selected patients may require modification of the immunosuppressive regimen. We suggest that patients who have a histologic diagnosis of recurrent lupus nephritis and a rapid deterioration of estimated GFR, or proteinuria &gt;500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      accompanied by severe proliferative lesions on biopsy be treated with immunosuppressive agents targeted to treat lupus nephritis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Options for immunosuppressive modification include using one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increase the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil to 2 to 3",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      Administer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and discontinue the current antimetabolite (usually",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ). The cyclophosphamide dose is generally selected based upon ancestry. In African-Americans, Afro-Caribbeans, and Hispanics, we use a longer (higher-dose) course of cyclophosphamide (0.5 to 1",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      intravenous pulses monthly for six or seven months). In whites, we use a shorter (lower-dose) course of cyclophosphamide (six 500 mg intravenous pulses every two weeks), as was used in Euro-Lupus.",
"      <br/>",
"      <br/>",
"      Subsequent cyclophosphamide doses are selected based upon the leukocyte nadir. If the leukocyte nadir after the first pulse of cyclophosphamide (usually 10 to 14 days post-infusion) is less than",
"      <span class=\"nowrap\">",
"       4000/microL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the absolute neutrophil count is less than",
"      <span class=\"nowrap\">",
"       1500/microL,",
"      </span>",
"      the dose at the next infusion should be reduced by 0.25",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      body surface area or even transiently withheld if the counts are very low. If, on the other hand, the total white cell nadir is greater than",
"      <span class=\"nowrap\">",
"       4000/microL,",
"      </span>",
"      the absolute neutrophil count is greater than",
"      <span class=\"nowrap\">",
"       1500/microL,",
"      </span>",
"      and the patient has not improved, the cyclophosphamide dose at the next infusion may be increased by 0.25",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      body surface area. The maximum dose is 1",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      body surface area.",
"     </li>",
"     <li>",
"      Patients that are treated with an increase in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      dose or with the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      should also be treated with glucocorticoids. We generally give",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      7",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      for three days followed by a tapering oral steroid regimen. (See",
"      <a class=\"local\" href=\"#H587480222\">",
"       'Immunosuppressive treatment of recurrent nephritis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/1\">",
"      Appel GB, Cohen DJ, Pirani CL, et al. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987; 83:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/2\">",
"      Ortega LM, Schultz DR, Lenz O, et al. Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010; 19:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/3\">",
"      Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009; 36:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/4\">",
"      Costenbader KH, Desai A, Alarc&oacute;n GS, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011; 63:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/5\">",
"      Mojcik CF, Klippel JH. End-stage renal disease and systemic lupus erythematosus. Am J Med 1996; 101:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/6\">",
"      Cheigh JS, Stenzel KH. End-stage renal disease in systemic lupus erythematosus. Am J Kidney Dis 1993; 21:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/7\">",
"      Nossent HC, Swaak TJ, Berden JH. Systemic lupus erythematosus after renal transplantation: patient and graft survival and disease activity. The Dutch Working Party on Systemic Lupus Erythematosus. Ann Intern Med 1991; 114:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/8\">",
"      Ponticelli C, Moroni G. Renal transplantation in lupus nephritis. Lupus 2005; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/9\">",
"      Moroni G, Tantardini F, Ponticelli C. Renal replacement therapy in lupus nephritis. J Nephrol 2003; 16:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/10\">",
"      Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/11\">",
"      Krane NK, Burjak K, Archie M, O'donovan R. Persistent lupus activity in end-stage renal disease. Am J Kidney Dis 1999; 33:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/12\">",
"      Huang JW, Hung KY, Yen CJ, et al. Systemic lupus erythematosus and peritoneal dialysis: outcomes and infectious complications. Perit Dial Int 2001; 21:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/13\">",
"      Siu YP, Leung KT, Tong MK, et al. Clinical outcomes of systemic lupus erythematosus patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2005; 20:2797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/14\">",
"      Lochhead KM, Pirsch JD, D'Alessandro AM, et al. Risk factors for renal allograft loss in patients with systemic lupus erythematosus. Kidney Int 1996; 49:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/15\">",
"      Grimbert P, Frappier J, Bedrossian J, et al. Long-term outcome of kidney transplantation in patients with systemic lupus erythematosus: a multicenter study. Groupe Cooperatif de Transplantation d'&icirc;le de France. Transplantation 1998; 66:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/16\">",
"      Ward MM. Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis. Kidney Int 2000; 57:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/17\">",
"      Bartosh SM, Fine RN, Sullivan EK. Outcome after transplantation of young patients with systemic lupus erythematosus: a report of the North American pediatric renal transplant cooperative study. Transplantation 2001; 72:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/18\">",
"      Moroni G, Tantardini F, Gallelli B, et al. The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis 2005; 45:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/19\">",
"      Bunnapradist S, Chung P, Peng A, et al. Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network database. Transplantation 2006; 82:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/20\">",
"      Norby GE, Leivestad T, Mj&oslash;en G, et al. Premature cardiovascular disease in patients with systemic lupus erythematosus influences survival after renal transplantation. Arthritis Rheum 2011; 63:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/21\">",
"      Contreras G, Mattiazzi A, Guerra G, et al. Recurrence of lupus nephritis after kidney transplantation. J Am Soc Nephrol 2010; 21:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/22\">",
"      Stone JH, Amend WJ, Criswell LA. Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls. Arthritis Rheum 1998; 41:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/23\">",
"      Lionaki S, Kapitsinou PP, Iniotaki A, et al. Kidney transplantation in lupus patients: a case-control study from a single centre. Lupus 2008; 17:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/24\">",
"      Bumgardner GL, Mauer SM, Payne W, et al. Single-center 1-15-year results of renal transplantation in patients with systemic lupus erythematosus. Transplantation 1988; 46:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/25\">",
"      Stone JH, Amend WJ, Criswell LA. Outcome of renal transplantation in systemic lupus erythematosus. Semin Arthritis Rheum 1997; 27:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/26\">",
"      Stone JH, Millward CL, Olson JL, et al. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era. Arthritis Rheum 1998; 41:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/27\">",
"      Weng F, Goral S. Recurrence of lupus nephritis after renal transplantation: if we look for it, will we find it? Nat Clin Pract Nephrol 2005; 1:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/28\">",
"      Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/29\">",
"      Burgos PI, Perkins EL, Pons-Estel GJ, et al. Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution. Arthritis Rheum 2009; 60:2757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/30\">",
"      Norby GE, Str&oslash;m EH, Midtvedt K, et al. Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study. Ann Rheum Dis 2010; 69:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/31\">",
"      Goral S, Ynares C, Shappell SB, et al. Recurrent lupus nephritis in renal transplant recipients revisited: it is not rare. Transplantation 2003; 75:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/32\">",
"      Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7:2350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/33\">",
"      Ibrahim HN, Jackson S, Connaire J, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol 2013; 24:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/34\">",
"      KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/35\">",
"      Ponticelli C, Moroni G, Glassock RJ. Recurrence of secondary glomerular disease after renal transplantation. Clin J Am Soc Nephrol 2011; 6:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/36\">",
"      Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/37\">",
"      Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/38\">",
"      Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/39\">",
"      Brennan DC, Glassock RJ, Bleyer AJ. American Society of Nephrology Quiz and Questionnaire 2012: Transplantation. Clin J Am Soc Nephrol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39352/abstract/40\">",
"      Clark WF, Jevnikar AM. Renal transplantation for end-stage renal disease caused by systemic lupus erythematosus nephritis. Semin Nephrol 1999; 19:77.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3066 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39352=[""].join("\n");
var outline_f38_27_39352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9521747\">",
"      LUPUS ACTIVITY IN ESRD PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS IN DIALYSIS PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ISSUES RELATED TO RENAL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29563535\">",
"      Allograft survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H257989415\">",
"      Timing of transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H257989422\">",
"      Evaluation for antiphospholipid antibodies prior to transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H475340\">",
"      Immunosuppressive therapy for antirejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Recurrent lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H480100821\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H480100944\">",
"      - Clinical presentation and biopsy findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9521341\">",
"      - Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21086538\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87545593\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H587480215\">",
"      Nonimmunosuppressive treatment of recurrent nephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H587480222\">",
"      Immunosuppressive treatment of recurrent nephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21086407\">",
"      - Renal prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antiphospholipid antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=related_link\">",
"      Antiphospholipid syndrome and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=related_link\">",
"      Clinical features and therapy of membranous lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=related_link\">",
"      Coronary heart disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2072?source=related_link\">",
"      Differential diagnosis of renal allograft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/23/16761?source=related_link\">",
"      Hypertension after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=related_link\">",
"      Induction immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=related_link\">",
"      Lipid abnormalities after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15258?source=related_link\">",
"      Overview of care of the adult kidney transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=related_link\">",
"      Risk factors for graft failure in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=related_link\">",
"      Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_27_39353="Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis";
var content_f38_27_39353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/27/39353/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39353/contributors\">",
"     David R Schwartz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39353/contributors\">",
"     Atul Malhotra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39353/contributors\">",
"     Steven E Weinberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/27/39353/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39353/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39353/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39353/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/27/39353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/27/39353/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/27/39353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy and the puerperium are well-established risk factors for venous thromboembolism (VTE), with estimates of the age-adjusted incidence of VTE ranging from 4 to 50 times higher in pregnant versus non-pregnant women, with an absolute incidence rate of 1 in 500 to 2000 pregnancies (0.025 to 0.10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deep venous thrombosis (DVT) and pulmonary embolism (PE), considered manifestations of the same disease, are often preventable and usually treatable. Nevertheless, VTE remains a substantial problem despite the dramatic decline in pregnancy-related mortality in industrialized countries over the past century. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite a 66 percent decrease in absolute PE-related mortality in Massachusetts between the 1950s and the 1980s, pulmonary embolism accounted for a larger proportion of maternal deaths in the latter period, surpassing pregnancy-induced hypertension and infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In pooled data from the Center for Disease Control's National Pregnancy Mortality Surveillance System from 1991 to 1999, pulmonary embolism was the most common cause of pregnancy-related death when both live births and all pregnancy outcomes were considered. Pulmonary embolism accounted for 20 percent of the maternal mortality, higher than both maternal hemorrhage (17 percent) and pregnancy-associated hypertension (16 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, and diagnosis of VTE during pregnancy will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Anticoagulation during pregnancy and general issues related to the prevention and treatment of DVT and PE in pregnancy and in nonpregnant patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thromboembolism (VTE) complicates between 1 in 500 and 1 in 2000 pregnancies and is more common postpartum than antepartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/1,2,5,12-18\">",
"     1,2,5,12-18",
"    </a>",
"    ]. This is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective cohort and case-control study, 395,335 women with pregnancies reaching 24 weeks of gestation were followed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/16\">",
"       16",
"      </a>",
"      ]. The incidence of VTE was 85 per 100,000 maternities. There were nearly twice as many postpartum than antepartum events. Postnatal risk factors included cesarean section, premature delivery, or history of cardiac disease. Multiple births were an antenatal risk factor.",
"     </li>",
"     <li>",
"      Using 30 years of data, a population-based inception cohort study detected an overall incidence of VTE of 200 per 100,000 woman-years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/5\">",
"       5",
"      </a>",
"      ]. DVT was three times more common than pulmonary embolism and VTE was five times more likely in the postpartum period than during the pregnancy. This was particularly evident with pulmonary embolism, which was 15 times more likely to occur in the postpartum period than during the pregnancy.",
"     </li>",
"     <li>",
"      A large prospective database in Great Britain found the risks of VTE in the antepartum and postpartum periods to be 3.5 and 11.9 times, respectively, greater than in non-pregnant women. The risk was highest during the first six weeks postpartum, approximately 22 times higher than in the non-pregnant state [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, one large retrospective cohort study found that 94 of 127 (74.8 percent) pregnant women with documented deep venous thrombosis (DVT) developed their clot during the antepartum period; in contrast, 60 percent of the cases of pulmonary embolism occurred in the postpartum period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most, but not all, reports the incidence of antepartum VTE appeared to be roughly equally distributed across trimesters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/1,2,12-17\">",
"     1,2,12-17",
"    </a>",
"    ]. Other studies have not been in agreement, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 268,525 deliveries there were 95 cases of objectively documented antepartum VTE; 50 percent of these occurred before 15 weeks and 29 percent after 20 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Conversely, in a second study of pregnancies in 972,683 women, the antepartum rates of VTE (episodes of a first VTE per 100,000 person-years) were highest in the third trimester, and were 20, 30, 40, and 114 for the following four time periods: outside of pregnancy, first, second, and third trimesters, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of deep vein thrombosis (DVT) is approximately twice as high after cesarean delivery than vaginal birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In addition, DVT is far more common in the left than the right leg. In one study of 60 pregnant women with a first episode of VTE, there were 58 isolated left lower extremity DVTs, 2 bilateral DVTs, and no isolated right lower extremity DVTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/12\">",
"     12",
"    </a>",
"    ]. This striking distribution has been attributed to increased venous stasis in the left leg related to compression of the left iliac vein by the right iliac artery, coupled with compression of the inferior vena cava by the gravid uterus itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/12,20,21\">",
"     12,20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the causes of venous thrombosis\", section on 'May-Thurner syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pelvic vein DVT is felt to be more likely in pregnancy, perhaps making the diagnosis more difficult. In an analysis of the DVT-Free Registry enrolling 5451 consecutive patients with ultrasound-confirmed DVT, only 1 percent of all patients had DVT confined to the pelvis, while 12 percent of pregnant and 11 percent of post-partum women had isolated pelvic DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of the literature commented on the site of DVT in 124 pregnant women with a diagnosis of DVT. Observations included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Involvement of the left leg was reported in 88 percent of the 96 patients for which the affected side was known.",
"     </li>",
"     <li>",
"      71 percent of the thromboses were restricted to the proximal veins without involvement of the calf veins.",
"     </li>",
"     <li>",
"      Among the 87 cases with proximal DVT, 64 percent were restricted to the iliac",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      femoral vein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy and the postpartum period may be marked by the presence of all three components of Virchow's triad: venous stasis, endothelial injury, and a hypercoagulable state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/2\">",
"     2",
"    </a>",
"    ]. Inherited or acquired thrombophilias unrelated to pregnancy increase thromboembolic risk and influence the approach to thromboprophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Stasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous stasis of the lower extremities occurs because of two factors: pregnancy-associated changes in venous capacitance and compression of large veins by the gravid uterus. The lower extremity veins of pregnant patients appear subject to increased stasis even before the uterus has enlarged substantially. Although blood volume and total venous return are supranormal in pregnancy, the linear flow velocity in the lower extremity veins is decreased, probably due to hormonally induced dilation of capacitance veins, which leads to venous pooling and valvular incompetence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These early changes are amplified by inferior vena caval compression by the gravid uterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. One study that assessed 24 pregnant women with monthly Doppler ultrasound examinations found progressive dilation of the deep veins of the legs during gestation. This corresponded to a decreased flow velocity in the left common femoral vein and inferior vena cava that was most severe in the supine position. Assuming the left lateral decubitus position significantly increased the velocity in both lower extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Endothelial injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery is associated with vascular injury and changes at the uteroplacental surface, which probably accounts for the frequency of VTE in the immediate postpartum period. Forceps, vacuum extraction, or surgical delivery can exaggerate vascular intimal injury and amplify this phenomenon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypercoagulability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is a hypercoagulable state associated with progressive increases in several coagulation factors, such as factors I, II, VII, VIII, IX, and X, along with a decrease in protein S [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/1,27-29\">",
"     1,27-29",
"    </a>",
"    ]. A progressive increase in resistance to activated protein C is normally observed in the second and third trimesters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/30\">",
"     30",
"    </a>",
"    ], and high resistance to activated protein C was shown in one study to be associated with an increased risk for pregnancy-related venous thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/31\">",
"     31",
"    </a>",
"    ]. Activity of the fibrinolytic inhibitors PAI-1 and PAI-2 is increased during pregnancy, although total fibrinolytic activity may not be impaired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of VTE is further magnified in pregnant women who have inherited thrombophilias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/4,27,34-38\">",
"     4,27,34-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .) The range of findings can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 60 women with an inherited deficiency of a naturally occurring anticoagulant (antithrombin, protein C, or protein S), the risk of venous thrombosis during pregnancy or the postpartum period was increased eightfold (4.1 versus 0.5 percent in nondeficient women) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The thrombotic risk for a woman with factor V Leiden during pregnancy or the puerperium has been estimated at approximately 1 in 400 to 500 compared with 1 in 1400 in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Two case-control studies looked for a genetic cause of thrombophilia in 42 and 119 women, respectively, with venous thromboembolism during pregnancy or the postpartum period and over 200 controls without a history of thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/35,37\">",
"       35,37",
"      </a>",
"      ]. Mutations, primarily factor V Leiden and the prothrombin gene mutation, were present in 60 percent of the women with thrombosis, an odds ratio of 5.2 compared with controls. Simultaneous mutations in both factor V Leiden and the prothrombin gene were present in 9 percent of the women with thrombosis and none of the controls, for an odds ratio of 107, and a projected incidence of thrombosis of 1 in 22 for this group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of antiphospholipid antibodies also predisposes women to thrombosis, especially during pregnancy or with use of oral contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. As an example, in one historic cohort study, 24 percent of thrombotic events in women occurred in association with pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/40\">",
"     40",
"    </a>",
"    ]. In another prospective study, the risk of thrombosis during pregnancy was 5 percent among women with known antiphospholipid syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of VTE during pregnancy can be complicated by physiologic changes associated with pregnancy and by reluctance of parents and clinicians to expose the fetus to even small amounts of ionizing radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of both DVT and PE is notoriously insensitive and nonspecific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. This problem is heightened in pregnant women since lower extremity swelling and discomfort are common in advanced pregnancy, and women with DVT may present with diffuse pain in the lower abdomen or leg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Dyspnea, the most frequent symptom of PE, occurs at some point in up to 70 percent of normal pregnancies, often stabilizing near term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=see_link\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39446?source=see_link\">",
"     \"Dyspnea during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American College of Chest Physicians Evidence-Based Clinical Practice Guidelines for the diagnosis, prevention, and treatment of VTE during pregnancy were published in early 2012 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American Thoracic Society (ATS) statement on the diagnostic approach to acute venous thromboembolism, as well as other ATS guidelines, can be accessed through the ATS web site at",
"      <a class=\"external\" href=\"file://www.thoracic.org/statements/\">",
"       www.thoracic.org/statements/",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      A clinical practice guideline for the evaluation of suspected PE in pregnancy, jointly issued by the ATS and the Society of Thoracic Radiology, was published in late 2011 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Predictive scoring systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commonly used clinical prediction rules for the diagnosis of VTE (eg, the Wells Scoring systems for PE and DVT) have not been validated in pregnancy.",
"   </p>",
"   <p>",
"    A cross-sectional study evaluated both subjective assessment as well as objective variables for predicting the presence of DVT in 194 unselected pregnant women with a suspected first episode of DVT. DVT was confirmed in 17 patients (8.8 percent) via diagnostic compression ultrasonography at initial or serial testing, or the presence of symptomatic VTE on follow-up. The following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians' subjective assessments categorized patients into low (two-thirds of patients) and non-low probability groups, with DVT prevalences of 1.5 and 25 percent, respectively.",
"     </li>",
"     <li>",
"      Three objective variables were highly predictive of DVT: symptoms in the left leg, calf circumference difference &ge;2 cm, and first trimester presentation. All 17 women with DVT had at least one of these variables. When a pregnant woman with suspected DVT presented with none, one or more, or two to three of these variables, DVT was diagnosed in zero, 16, and 58 percent of the cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings need to be prospectively validated in a larger number of patients before this prediction rule can be applied in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial blood gases are neither sensitive nor specific for the diagnosis of PE, and respiratory alkalosis is a very common feature of both pregnancy and PE. As in the non-pregnant population, a normal PO2, PCO2, or alveolar-arterial difference is common with PE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. As an example, one small retrospective study of arterial blood gases in pregnant women with documented PE found that 10 (59 percent) of 17 patients had a normal alveolar-arterial difference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assays for serum D-dimer, a breakdown product of cross-linked fibrin, have been extensively studied for use in the diagnosis of VTE. D-dimer levels are detectable by enzyme-linked immunosorbent assay (ELISA) in nearly all patients with PE at concentrations &gt;500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    of fibrinogen equivalent units. Although the D-dimer test has low specificity, its sensitivity is high. Thus, the negative predictive value of a normal D-dimer level for ruling out the presence of VTE is high, especially when combined with a low pretest probability of VTE. The usefulness of this test in the diagnosis of VTE is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\", section on 'D-dimer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis of acute pulmonary embolism\", section on 'D-dimer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the utility of this test in pregnancy is limited by the fact that elevations in D-dimer are found in uncomplicated pregnancy, increasing with gestational age and peaking at the time of delivery and in the early postpartum period. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 50 normal pregnant women, D-dimer levels increased with each trimester such that 22 percent of women in the second trimester and none (of 23) in the third trimester had a normal D-dimer concentration (ie, &lt;500",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study of 149 consecutive pregnant women presenting with suspected DVT, in whom this diagnosis was ruled out by compression ultrasonography, a SimpliRED assay for D-dimer was negative in 100, 76, and 49 percent of those in the first, second, or third trimester, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, the utility of a &ldquo;normal&rdquo; level of D-Dimer for helping to rule out VTE appears to fall progressively throughout the course of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17832?source=see_link&amp;anchor=H2#H2\">",
"     \"Abnormalities of coagulation and platelet function in preeclampsia\", section on 'Changes in hemostasis during normal pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiographic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;While invasive, uncomfortable,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation-requiring examinations should be avoided whenever possible in pregnant patients, greater harm to the patient and the fetus may result from the failure to detect VTE because indicated examinations are not obtained. The limited utility of signs, symptoms, and laboratory tests, the potential deleterious consequences of over- or under-treatment of VTE, and the implications of the diagnosis on future pregnancies necessitate a definitive diagnostic approach. Thus, there are no systematic differences in the diagnostic strategies for deep venous thrombosis and pulmonary embolism in the pregnant and the non-pregnant patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=see_link\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive tests for DVT of the lower extremities are readily available and relatively inexpensive. Their accuracy in the general population approaches that of venography, with the caveat that they are less sensitive for calf vein thrombosis (which is less common in the pregnant population) and pelvic vein thrombosis. Large, direct prospective comparisons between individual diagnostic modalities have not been performed specifically in pregnant patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Doppler ultrasound",
"      </strong>",
"      is the most commonly employed study in this setting; lack of compressibility of a thigh vein with the ultrasound probe is highly sensitive (95 percent) and specific (&gt;95 percent) for symptomatic proximal vein thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/57\">",
"       57",
"      </a>",
"      ]. The addition of Doppler analysis of flow variation with respiration in the left lateral decubitus position assists in diagnosing isolated iliac vein thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/26\">",
"       26",
"      </a>",
"      ]. The safety of withholding therapy in patients with single versus serial negative examinations has not been prospectively examined in this population. One small retrospective study from France evaluated 162 pregnant or postpartum women who had Doppler ultrasound performed for DVT suspicion. Forty-two patients had positive scans. Three-month follow-up by questionnaire of the available patients with negative examinations revealed zero thromboembolic events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Magnetic resonance imaging (MRI)",
"      </strong>",
"      is a modality that may find increasing use in the pregnant population. It can detect both thigh and pelvic vein DVT with a sensitivity that approaches 100 percent in the nonpregnant population. Although no comparison studies have been performed in pregnancy, one case series documented the usefulness of MRI, permitting diagnosis of pelvic vein thrombosis or the presence of a patent but extrinsically compressed inferior vena cava in situations where noninvasive examinations were equivocal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/59\">",
"       59",
"      </a>",
"      ]. The safety of MRI during pregnancy has not been proven, although no adverse effects have been documented to date [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/60\">",
"       60",
"      </a>",
"      ]. It is prudent, however, to inform pregnant patients that, although there have been no demonstrated untoward effects of MRI in pregnancy, its safety remains unproven [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Ascending contrast venography",
"      </strong>",
"      is considered the gold standard for the diagnosis of lower extremity DVT in both the pregnant and the non-pregnant populations. However, venography is rarely performed because the test requires ionizing radiation and percutaneous cannulation of lower extremity veins, and because noninvasive tests approach venography in sensitivity and specificity. Although the delivered radiation to the fetus is small (&lt;500 mcGy) when venography is performed with abdominal-pelvic shielding, shielding renders the test relatively insensitive to isolated iliofemoral thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/1,44,57,62\">",
"       1,44,57,62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We and others recommend compression venous color Doppler ultrasound as the initial test in pregnant women with suspected DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/46\">",
"     46",
"    </a>",
"    ]. The test should be performed in advanced pregnancy with the patient in the left lateral decubitus position. All tests positive for proximal DVT should prompt immediate treatment. When strong clinical suspicion exists for pelvic vein thrombosis, MRI should be performed, although Doppler ultrasound of the iliac vein or venography are acceptable alternatives. With increasing experience and availability of MRI, it may displace venography as the gold standard for the diagnosis of pregnancy-associated DVT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on institutional or personal bias, the level of activity, and individual patient characteristics, signs, symptoms, or preferences, a clinician may choose to evaluate the lower extremities with Doppler ultrasound as the initial test in the workup of pulmonary embolism. Because the treatments for DVT and submassive PE are identical, documentation of a DVT is sufficient to terminate the diagnostic evaluation and institute therapy. However, negative examinations for DVT are not definitive because fewer than 30 percent of unselected patients with PE have radiographic evidence of DVT at the time of presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More often, however, a patient who presents with respiratory and without lower extremity symptoms first undergoes an imaging study to identify clot within the lungs. The primary options are either helical (spiral) CT scanning using intravenous contrast (CT angiography) or lung scintigraphy (ventilation-perfusion or",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    lung scanning).",
"   </p>",
"   <p>",
"    CT angiography is the non-invasive study of choice for the diagnosis of pulmonary embolism in the non-pregnant population. In the PIOPED 2 study of 824 patients validating CT angiography, showing sensitivity of 83 percent and specificity of 96 percent for pulmonary embolism diagnosis, pregnancy was an exclusion criterion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/64\">",
"     64",
"    </a>",
"    ]. Specific advantages and drawbacks of this diagnostic modality are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef81416 \" href=\"mobipreview.htm?22/22/22892\">",
"     table 1",
"    </a>",
"    ). The estimated mean radiation dose to the fetus is 3 to 131 mcGy across pregnancy; these values are less than those calculated for",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of CT angiography versus",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scanning in the pregnant patient is currently controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/48,66,67\">",
"     48,66,67",
"    </a>",
"    ]. Despite shortcomings in the general population, particularly in patients with abnormal chest radiographs or underlying pulmonary disease,",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    lung scanning remains a useful test in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/66,68\">",
"     66,68",
"    </a>",
"    ]. As in the general population,",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scan results need to be interpreted in the context of pretest probability; only normal scans, low probability scans in the context of a low pretest probability, and high probability scans in the context of a high pretest probability are generally considered diagnostic (",
"    <a class=\"graphic graphic_table graphicRef78592 \" href=\"mobipreview.htm?16/12/16587\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the majority of scans in the general population are non-diagnostic, far more",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scans are diagnostic in younger, healthier pregnant women, who have a lower frequency of cardiac or respiratory diseases than the general population. In a study of 120 consecutive pregnant patients presenting with suspected pulmonary embolism, 75 percent of",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scan were diagnostic, with 73.5 percent being normal and 1.8 percent being high probability scans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of comparisons of spiral CT with",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scanning for pregnant patients with suspected pulmonary embolism (PE) indicate that when the chest X-ray (CXR) is normal,",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scanning is more accurate. In a retrospective cohort study, Cahill and colleagues evaluated 304 consecutive women who were either pregnant or within six weeks postpartum, with a clinical suspicion of PE of whom 108 (35.1 percent) underwent initial CTPA and 196 (64.9 percent) initial",
"    <span class=\"nowrap\">",
"     V/Q/",
"    </span>",
"    scanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/70\">",
"     70",
"    </a>",
"    ]. Among women with a normal CXR, CTPA was significantly more often nondiagnostic than",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scanning even after adjusting for confounding effects (30.0 versus 5.6 percent. Adjusted OR 5.4; 95% CI: 1.4-20.1).",
"   </p>",
"   <p>",
"    Another study compared diagnostic accuracy of CTPA and",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scans for PE in 28 and 25 pregnant patients, respectively, and noted that CTPA was significantly less reliable than",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scanning (inadequate diagnosis rate of 35.7 percent for CTPA versus 4 percent for",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scans) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/71\">",
"     71",
"    </a>",
"    ]. The authors also compared the relative accuracy of CTPA in pregnant versus nonpregnant women and reported that CTPA had a significantly higher diagnostic inadequacy rate among pregnant compared with nonpregnant women (35.7 versus 2.1 percent). Similar findings have been noted by multiple other investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. This was ascribed to more frequent interruption of contrast material by unopacified blood from the inferior vena cava in pregnancy, likely due to increased plasma volume. Several other studies have also demonstrated that the quality of CTPA is lower in pregnancy. In contrast, a French study reported a retrospective analysis of images from 46 CT angiographic examinations and 91",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    examinations in pregnant women; the two techniques were thought to have comparable performance for the diagnosis of PE during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/66\">",
"     66",
"    </a>",
"    ]. While interobserver agreement was better for CT angiography, and also enabled alternative diagnosis of unsuspected disease (eg, pneumonia), it also delivered a higher maternal dose than lung scintigraphy (7.3 versus 0.9 mSv).",
"   </p>",
"   <p>",
"    On balance, these studies suggest that",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    is the preferred test in pregnant women with suspected PE when the CXR is normal and that CTPA should be reserved for at risk pregnant women with abnormal CXRs (",
"    <a class=\"graphic graphic_algorithm graphicRef54668 \" href=\"mobipreview.htm?41/0/41997\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/11,48,75\">",
"     11,48,75",
"    </a>",
"    ]. Moreover, in addition to its higher diagnostic accuracy,",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scanning also results in substantially (150-fold) lower breast and lung irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/9\">",
"     9",
"    </a>",
"    ]. By contrast, CTPA generates only slightly less fetal irradiation than",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scanning. One study calculated a maximal fetal irradiation attributable to CTPA compared with",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scans of 131 mcGy versus 370 mcGy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/65\">",
"     65",
"    </a>",
"    ]. One caveat with the use of",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scanning in this setting are the results of a 1998 survey of 1000 clinician-directors of nuclear medicine facilities, which found that only 67 percent of respondents reported that they perform",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scans in pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnostic imaging procedures during pregnancy\", section on 'Ventilation-perfusion and helical CT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The estimated fetal radiation exposure from the",
"    <strong>",
"     combination",
"    </strong>",
"    of a chest radiograph,",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scanning, and pulmonary arteriography is less than 0.5 mSv (50 mrad) (",
"    <a class=\"graphic graphic_table graphicRef75594 \" href=\"mobipreview.htm?23/2/23596\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/1,56,76\">",
"     1,56,76",
"    </a>",
"    ]. This is 100 to 200 times less than the dose thought to produce a significant risk of fetal anomalies. However, a few studies have suggested a possible small increase in the risk of childhood leukemia from 1 in 2800 (baseline risk) to 1 in 2000 among children exposed to low dose ionizing radiation in utero [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. This degree of risk to the fetus is minimal in comparison with the 15 percent risk of maternal mortality if pulmonary embolism is not diagnosed and treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following measures can reduce fetal radiation exposure from",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scanning:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The dose of the perfusion agent can be reduced by up to one-half in patients who can tolerate the longer imaging times required for quality scans.",
"     </li>",
"     <li>",
"      A normal perfusion scan (performed first) requires no further testing.",
"     </li>",
"     <li>",
"      The patient should be hydrated and encouraged to void frequently in order to minimize radiation due to pooling of radionuclide in the maternal bladder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ultimately, some patients may require pulmonary arteriography to definitively establish or exclude the presence of PE. MRI may also be considered in specialized centers; however, the sensitivity and specificity of this test for diagnosis of PE are unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/81\">",
"     81",
"    </a>",
"    ], and large clinical studies comparing MRI with pulmonary arteriography are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/27/39353/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy and the puerperium are well-established risk factors for venous thromboembolism (VTE), with estimates of the incidence of VTE ranging from 4 to 50 times higher in pregnant versus non-pregnant women. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increased incidence of VTE may be related to venous stasis (due to pregnancy-associated changes in venous capacitance and compression of large veins by the gravid uterus), endothelial injury (due to changes at the uteroplacental surface and vascular injury during delivery), and a hypercoagulable state (pregnancy is associated with progressive increases in several coagulation factors, a decrease in protein S, and a progressive increase in resistance to activated protein C). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of VTE during pregnancy can be complicated by physiologic changes associated with pregnancy and reluctance to expose the fetus to even small amounts of ionizing radiation. While every effort should be made to avoid exposing the fetus to unnecessary radiation, such concerns should not prevent the appropriate diagnostic evaluation (",
"      <a class=\"graphic graphic_algorithm graphicRef54668 \" href=\"mobipreview.htm?41/0/41997\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with suspected pulmonary embolism and signs and symptoms of deep vein thrombosis, we suggest that the first radiologic procedure should be the performance of bilateral venous compression ultrasound of the lower extremities rather than chest radiography, computed tomographic pulmonary angiography (CTPA), or digital subtraction angiography (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Because of the superior accuracy of lung scintigraphy",
"      <span class=\"nowrap\">",
"       (V/Q",
"      </span>",
"      scanning) along with lower maternal breast irradiation, we recommend the use of lung scintigraphy, rather than CTPA, as the diagnostic test of choice in the workup of pulmonary embolism in pregnancy in women with a negative chest X-ray (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In those patients with an abnormal chest X-ray, we suggest the use of CTPA over lung scintigraphy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/1\">",
"      Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008; 359:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/2\">",
"      Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/3\">",
"      Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. JAMA 1986; 256:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/4\">",
"      Kujovich JL. Hormones and pregnancy: thromboembolic risks for women. Br J Haematol 2004; 126:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/5\">",
"      Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/6\">",
"      Morris JM, Algert CS, Roberts CL. Incidence and risk factors for pulmonary embolism in the postpartum period. J Thromb Haemost 2010; 8:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/7\">",
"      Sachs BP, Brown DA, Driscoll SG, et al. Maternal mortality in Massachusetts. Trends and prevention. N Engl J Med 1987; 316:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/8\">",
"      Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance--United States, 1991--1999. MMWR Surveill Summ 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/9\">",
"      Bourjeily G, Paidas M, Khalil H, et al. Pulmonary embolism in pregnancy. Lancet 2010; 375:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/10\">",
"      Brown HL, Hiett AK. Deep vein thrombosis and pulmonary embolism in pregnancy: diagnosis, complications, and management. Clin Obstet Gynecol 2010; 53:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/11\">",
"      Arya R. How I manage venous thromboembolism in pregnancy. Br J Haematol 2011; 153:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/12\">",
"      Ginsberg JS, Brill-Edwards P, Burrows RF, et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992; 67:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/13\">",
"      Rutherford S, Montoro M, McGehee W, Strong T. Thromboembolic disease associated with pregnancy: an 11-year review. Am J Obstet Gynecol 1991; 164(Suppl):286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/14\">",
"      Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynecol Scand 1983; 62:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/15\">",
"      Treffers PE, Huidekoper BL, Weenink GH, Kloosterman GJ. Epidemiological observations of thrombo-embolic disease during pregnancy and in the puerperium, in 56,022 women. Int J Gynaecol Obstet 1983; 21:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/16\">",
"      Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD. Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG 2001; 108:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/17\">",
"      Stein PD, Hull RD, Kayali F, et al. Venous thromboembolism in pregnancy: 21-year trends. Am J Med 2004; 117:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/18\">",
"      Sultan AA, West J, Tata LJ, et al. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol 2012; 156:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/19\">",
"      Gherman RB, Goodwin TM, Leung B, et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 1999; 94:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/20\">",
"      Cockett FB, Thomas ML, Negus D. Iliac vein compression.--Its relation to iliofemoral thrombosis and the post-thrombotic syndrome. Br Med J 1967; 2:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/21\">",
"      Hull RD, Raskob GE, Carter CJ. Serial impedance plethysmography in pregnant patients with clinically suspected deep-vein thrombosis. Clinical validity of negative findings. Ann Intern Med 1990; 112:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/22\">",
"      James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/23\">",
"      Chan WS, Spencer FA, Ginsberg JS. Anatomic distribution of deep vein thrombosis in pregnancy. CMAJ 2010; 182:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/24\">",
"      GOODRICH SM, WOOD JE. PERIPHERAL VENOUS DISTENSIBILITY AND VELOCITY OF VENOUS BLOOD FLOW DURING PREGNANCY OR DURING ORAL CONTRACEPTIVE THERAPY. Am J Obstet Gynecol 1964; 90:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/25\">",
"      Wright H, Osborn S, Edmunds D. Changes in the rate of flow of venous blood in the leg during pregnancy, measured with radioactive sodium. Surg Gynecol Obstet 1950; 90:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/26\">",
"      Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol 1997; 104:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/27\">",
"      McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/28\">",
"      Hellgren M, Blomb&auml;ck M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. Gynecol Obstet Invest 1981; 12:141.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Thromboembolism in pregnancy. ACOG Practice Bulletin 19. ACOG 2000; Washington, DC.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/30\">",
"      Walker MC, Garner PR, Keely EJ, et al. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 1997; 177:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/31\">",
"      Bergrem A, Dahm AE, Jacobsen AF, et al. Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism. Br J Haematol 2011; 154:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/32\">",
"      Kruithof EK, Tran-Thang C, Gudinchet A, et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/33\">",
"      Gerbasi FR, Bottoms S, Farag A, Mammen E. Increased intravascular coagulation associated with pregnancy. Obstet Gynecol 1990; 75:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/34\">",
"      Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/35\">",
"      Grandone E, Margaglione M, Colaizzo D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998; 179:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/36\">",
"      Dizon-Townson DS, Nelson LM, Jang H, et al. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol 1997; 176:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/37\">",
"      Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/38\">",
"      Bergrem A, Dahm AE, Jacobsen AF, et al. Differential haemostatic risk factors for pregnancy-related deep-vein thrombosis and pulmonary embolism: a population-based case-control study. Thromb Haemost 2012; 108:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/39\">",
"      Branch DW, Silver RM, Blackwell JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/40\">",
"      Silver RM, Draper ML, Scott JR, et al. Clinical consequences of antiphospholipid antibodies: an historic cohort study. Obstet Gynecol 1994; 83:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/41\">",
"      Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. JAMA 1990; 263:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/42\">",
"      Goldhaber SZ. Pulmonary embolism. N Engl J Med 1998; 339:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/43\">",
"      Lee RV, McComb LE, Mezzadri FC. Pregnant patients, painful legs: the obstetrician's dilemma. Obstet Gynecol Surv 1990; 45:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/44\">",
"      Bergqvist A, Bergqvist D, Hallb&ouml;&ouml;k T. Deep vein thrombosis during pregnancy. A prospective study. Acta Obstet Gynecol Scand 1983; 62:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/45\">",
"      Weinberger SE, Weiss ST, Cohen WR, et al. Pregnancy and the lung. Am Rev Respir Dis 1980; 121:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/46\">",
"      Bates SM, Jaeschke R, Stevens SM, et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e351S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/47\">",
"      Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/48\">",
"      Leung AN, Bull TM, Jaeschke R, et al. An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy. Am J Respir Crit Care Med 2011; 184:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/49\">",
"      Chan WS, Lee A, Spencer FA, et al. Predicting deep venous thrombosis in pregnancy: out in \"LEFt\" field? Ann Intern Med 2009; 151:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/50\">",
"      Stein PD, Goldhaber SZ, Henry JW. Alveolar-arterial oxygen gradient in the assessment of acute pulmonary embolism. Chest 1995; 107:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/51\">",
"      Stein PD, Goldhaber SZ, Henry JW, Miller AC. Arterial blood gas analysis in the assessment of suspected acute pulmonary embolism. Chest 1996; 109:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/52\">",
"      Powrie RO, Larson L, Rosene-Montella K, et al. Alveolar-arterial oxygen gradient in acute pulmonary embolism in pregnancy. Am J Obstet Gynecol 1998; 178:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/53\">",
"      Kline JA, Williams GW, Hernandez-Nino J. D-dimer concentrations in normal pregnancy: new diagnostic thresholds are needed. Clin Chem 2005; 51:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/54\">",
"      Chan WS, Chunilal S, Lee A, et al. A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med 2007; 147:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/55\">",
"      Chan WS, Lee A, Spencer FA, et al. D-dimer testing in pregnant patients: towards determining the next 'level' in the diagnosis of deep vein thrombosis. J Thromb Haemost 2010; 8:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/56\">",
"      Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/57\">",
"      Polak JF, Wilkinson DL. Ultrasonographic diagnosis of symptomatic deep venous thrombosis in pregnancy. Am J Obstet Gynecol 1991; 165:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/58\">",
"      Le Gal G, Prins AM, Righini M, et al. Diagnostic value of a negative single complete compression ultrasound of the lower limbs to exclude the diagnosis of deep venous thrombosis in pregnant or postpartum women: a retrospective hospital-based study. Thromb Res 2006; 118:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/59\">",
"      Spritzer CE, Evans AC, Kay HH. Magnetic resonance imaging of deep venous thrombosis in pregnant women with lower extremity edema. Obstet Gynecol 1995; 85:603.",
"     </a>",
"    </li>",
"    <li>",
"     ACR 1998 Standards, 1998, p.457.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/61\">",
"      Shellock FG, Kanal E. Policies, guidelines, and recommendations for MR imaging safety and patient management. SMRI Safety Committee. J Magn Reson Imaging 1991; 1:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/62\">",
"      Stein PD, Hull RD, Saltzman HA, Pineo G. Strategy for diagnosis of patients with suspected acute pulmonary embolism. Chest 1993; 103:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/63\">",
"      Turkstra F, Kuijer PM, van Beek EJ, et al. Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med 1997; 126:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/64\">",
"      Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med 2006; 354:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/65\">",
"      Winer-Muram HT, Boone JM, Brown HL, et al. Pulmonary embolism in pregnant patients: fetal radiation dose with helical CT. Radiology 2002; 224:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/66\">",
"      Revel MP, Cohen S, Sanchez O, et al. Pulmonary embolism during pregnancy: diagnosis with lung scintigraphy or CT angiography? Radiology 2011; 258:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/67\">",
"      Shahir K, Goodman LR, Tali A, et al. Pulmonary embolism in pregnancy: CT pulmonary angiography versus perfusion scanning. AJR Am J Roentgenol 2010; 195:W214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/68\">",
"      Balan KK, Critchley M, Vedavathy KK, et al. The value of ventilation-perfusion imaging in pregnancy. Br J Radiol 1997; 70:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/69\">",
"      Chan WS, Ray JG, Murray S, et al. Suspected pulmonary embolism in pregnancy: clinical presentation, results of lung scanning, and subsequent maternal and pediatric outcomes. Arch Intern Med 2002; 162:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/70\">",
"      Cahill AG, Stout MJ, Macones GA, Bhalla S. Diagnosing pulmonary embolism in pregnancy using computed-tomographic angiography or ventilation-perfusion. Obstet Gynecol 2009; 114:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/71\">",
"      Ridge CA, McDermott S, Freyne BJ, et al. Pulmonary embolism in pregnancy: comparison of pulmonary CT angiography and lung scintigraphy. AJR Am J Roentgenol 2009; 193:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/72\">",
"      U-King-Im JM, Freeman SJ, Boylan T, Cheow HK. Quality of CT pulmonary angiography for suspected pulmonary embolus in pregnancy. Eur Radiol 2008; 18:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/73\">",
"      Andreou AK, Curtin JJ, Wilde S, Clark A. Does pregnancy affect vascular enhancement in patients undergoing CT pulmonary angiography? Eur Radiol 2008; 18:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/74\">",
"      Litmanovich D, Boiselle PM, Bankier AA, et al. Dose reduction in computed tomographic angiography of pregnant patients with suspected acute pulmonary embolism. J Comput Assist Tomogr 2009; 33:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/75\">",
"      Leung AN, Bull TM, Jaeschke R, et al. American Thoracic Society documents: an official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline--Evaluation of Suspected Pulmonary Embolism in Pregnancy. Radiology 2012; 262:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/76\">",
"      Boiselle PM, Reddy SS, Villas PA, et al. Pulmonary embolus in pregnant patients: survey of ventilation-perfusion imaging policies and practices. Radiology 1998; 207:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/77\">",
"      Harvey EB, Boice JD Jr, Honeyman M, Flannery JT. Prenatal x-ray exposure and childhood cancer in twins. N Engl J Med 1985; 312:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/78\">",
"      Brent RL. The effects of embryonic and fetal exposure to x-ray, microwaves, and ultrasound. Clin Perinatol 1986; 13:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/79\">",
"      Mole RH. Childhood cancer after prenatal exposure to diagnostic X-ray examinations in Britain. Br J Cancer 1990; 62:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/80\">",
"      Wessler S. Medical management of venous thrombosis. Annu Rev Med 1976; 27:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/81\">",
"      Stein PD, Chenevert TL, Fowler SE, et al. Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med 2010; 152:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/27/39353/abstract/82\">",
"      Meaney JF, Weg JG, Chenevert TL, et al. Diagnosis of pulmonary embolism with magnetic resonance angiography. N Engl J Med 1997; 336:1422.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1349 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-122.72.76.133-B89E15691A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39353=[""].join("\n");
var outline_f38_27_39353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Stasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Endothelial injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypercoagulability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Predictive scoring systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiographic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1349\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1349|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?41/0/41997\" title=\"algorithm 1\">",
"      Suspected PE in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1349|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/22/22892\" title=\"table 1\">",
"      Pros and cons of spiral CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/12/16587\" title=\"table 2\">",
"      PIOPED diagnosis of PE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/2/23596\" title=\"table 3\">",
"      Fetal radiation exposure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17832?source=related_link\">",
"      Abnormalities of coagulation and platelet function in preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3351?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39446?source=related_link\">",
"      Dyspnea during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_27_39354="Pemphigus foliaceous face";
var content_f38_27_39354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87796%7EDERM%2F87795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87796%7EDERM%2F87795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Pemphigus foliaceous",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scales and crusts on a diffuse erythematous base with bacterial superinfection in a patient with pemphigus foliaceous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Pemphigus foliaceous",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The skin is erythrodermic and covered with large scales and crusts in this patient with pemphigus foliaceous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39354=[""].join("\n");
var outline_f38_27_39354=null;
var title_f38_27_39355="Lansky performance scale";
var content_f38_27_39355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lansky performance scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        100",
"       </td>",
"       <td>",
"        Fully active; normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"1\">",
"        90",
"       </td>",
"       <td>",
"        Minor restrictions in physically strenuous activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"1\">",
"        80",
"       </td>",
"       <td>",
"        Active, but tires more quickly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"1\">",
"        70",
"       </td>",
"       <td>",
"        Both greater restriction of and less time spent in play",
"activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"1\">",
"        60",
"       </td>",
"       <td>",
"        Up and around, but minimal active play; keeps busy with",
"quieter activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"1\">",
"        50",
"       </td>",
"       <td>",
"        Gets dressed but lies around much of the day; no active",
"play; able to participate in all quiet play and activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"1\">",
"        40",
"       </td>",
"       <td>",
"        Mostly in bed; participates in quiet activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        30",
"       </td>",
"       <td>",
"        In bed;",
"needs assistance even for quiet play",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        20",
"       </td>",
"       <td>",
"        Often sleeping; play entirely",
"limited to very passive activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        10",
"       </td>",
"       <td>",
"        No play; does not get out of bed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        0",
"       </td>",
"       <td>",
"        Unresponsive",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shakila P Khan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39355=[""].join("\n");
var outline_f38_27_39355=null;
var title_f38_27_39356="Dyspareunia differential dx2";
var content_f38_27_39356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnoses for physical causes of dyspareunia (cont.)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Location affected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Important history",
"       </td>",
"       <td class=\"subtitle1\">",
"        Source of dyspareunia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments and Caveats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"10\">",
"        Vestibule and vagina",
"       </td>",
"       <td>",
"        Atrophy: low or absent estrogen",
"       </td>",
"       <td>",
"        Dryness, irritation, hx breast feeding, oligo/amenorrhea, low",
"estrogen/high androgenic OCP, Depo-Provera, anorexia, exercise,",
"premenopausal tamoxifen, chemotherapy, radiation, BSO, aromatase",
"inhibitors",
"       </td>",
"       <td>",
"        Reduction in labial size, mucosal color and textural change, fissures; elevated vaginal pH, atrophic wet prep",
"       </td>",
"       <td>",
"        Can occur at any age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvovaginitis: Candida albicans",
"       </td>",
"       <td>",
"        Antibiotics, steroids, estrogen, immunosuppression",
"       </td>",
"       <td>",
"        Itching, erythema, edema, discharge, fissures; or few sx",
"       </td>",
"       <td>",
"        Look for superimposed vestibulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desquamative inflammatory",
"       </td>",
"       <td>",
"        Irritative sx, profuse discharge",
"       </td>",
"       <td>",
"        Erythema, sheets of wbc, parabasals, no lactobacilli",
"       </td>",
"       <td>",
"        Atypical pap. Look for vestibulodynia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vulvovaginitis: Trichomonas",
"       </td>",
"       <td>",
"        Itching, discharge, or few sx",
"       </td>",
"       <td>",
"        Mobile trichomonads; positive culture",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bartholin cyst or abscess",
"       </td>",
"       <td>",
"        Swelling and pain",
"       </td>",
"       <td>",
"        Cystic mass at base of vestibule",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seminal plasma allergy",
"       </td>",
"       <td>",
"        Itching on entry or ejaculation",
"       </td>",
"       <td>",
"        Edema and erythema post coitus",
"       </td>",
"       <td>",
"        Trial of condom helps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatosis: lichen sclerosus",
"       </td>",
"       <td>",
"        Itching or no symptoms",
"       </td>",
"       <td>",
"        Fissures, scaring around introitus",
"       </td>",
"       <td>",
"        Candida, vulvodynia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatosis: lichen planus",
"       </td>",
"       <td>",
"        Itching, burning, discharge",
"       </td>",
"       <td>",
"        Erosions, ulceration, scarring",
"       </td>",
"       <td>",
"        As above, atypical Pap smear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inadequate lubrication, dryness",
"       </td>",
"       <td>",
"        Poor sexual technique, sexual dysfunction, Sjogren's, OCP, medications, vestibulodynia",
"       </td>",
"       <td>",
"        Dryness, tenderness",
"       </td>",
"       <td>",
"        No good test; hard to judge on exam; history important",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation",
"       </td>",
"       <td>",
"        History of gyn or urinary tumor",
"       </td>",
"       <td>",
"        Pallor, loss of elasticity, scarring",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OCP: oral contraceptive pills; BSO: bilateral salpingo-oophorectomy; hx: history; sx: symptoms.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Elizabeth Gunther Stewart, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39356=[""].join("\n");
var outline_f38_27_39356=null;
var title_f38_27_39357="High and standard dose HEMO";
var content_f38_27_39357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival curves for high and standard dialysis doses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 269px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Graph showing that mortality in the high and standard dialysis dose groups were the same in the HEMO study. There was a nonsignificant 4 percent lower mortality in the high dose group compared with the standard dose group.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Eknoyan, G, Beck, GJ, Cheung, AK, et al. N Engl J Med 2002; 347:2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39357=[""].join("\n");
var outline_f38_27_39357=null;
var title_f38_27_39358="Orofacial mask";
var content_f38_27_39358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Orofacial mask",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mirage Quattro&trade; orofacial mask for use with noninvasive positive pressure ventilation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; ResMed 2012. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39358=[""].join("\n");
var outline_f38_27_39358=null;
var title_f38_27_39359="Grade IV HTN retinopathy I";
var content_f38_27_39359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grade IV hypertensive retinopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retinal examination in a patient with papilledema due to malignant hypertension. There is blurring of the margins of the optic disc, distension of the retinal veins, two cotton wool spots inferior to the disc, and a flame-shaped hemorrhage at a venous bifurcation (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced by permission from: Gallasch G, Ritz E, Nephrol Dial Transplant 1997; 12:1518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_27_39359=[""].join("\n");
var outline_f38_27_39359=null;
